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General Introduction
The Trachea
The trachea is a pipe-shaped conduit for the passage of air and secretions between 
the larynx and the lungs 1, hence the term "windpipe” that is used in popular speech 
(Figure 1). The length of the trachea in the adult male ranges from 10 to 13 cm from 
the lower border of the cricoid cartilage superiorly to the top of the carina caudally, 
fortified with about two C-shaped cartilage rings every centimeter 2 The trachea runs 
through both the neck and the chest. The upper part of the trachea is almost 
subcutaneously located anterior in the midline of the neck 1 in close relationship to 
the thyroid gland anteriorly and the pharyngo-esophageal junction posteriorly. The 
lower part of the trachea is located in the upper mediastinum behind the superior 
part of the sternum and adjacent to the esophagus posteriorly.
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Figure 1. The adult trachea. Printed with permission from McGraw-Hill
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When it comes to surgical procedures of the trachea, this dual localization makes the 
trachea part of the work fields of both thoracic surgeons and head and neck 
surgeons. Which specialty takes care of the trachea is mostly center dependent. In 
some centers, the thoracic surgeon is experienced with both intrathoracic tracheal 
and higher laryngotracheal resections, in other centers the head and neck surgeon 
does not evade mediastinal tracheal resections, and in some centers the thoracic 
surgeon and head and neck surgeon cooperatively perform tracheal surgery. An 
example of a cooperative surgical relationship is the Radboud University Medical 
Centre St Radboud in Nijmegen, the Netherlands. In this centre, patients with 
trachea-related disease are managed by a multidisciplinary team consisting of a 
pulmonologist, radiologist, radiotherapist, thoracic surgeon and head and neck 
surgeon.
Primary Tracheal Tumors
One of the most important and difficult conditions managed by this multidisciplinary 
team is cancer of the trachea. Usually, this is either a primary carcinoma of the 
trachea or a thyroid carcinoma growing directly into the trachea.
Although the trachea is lined with respiratory epithelium like the larynx and the 
bronchi and shares smoking as an important risk factor 3-5, tracheal cancer is very 
rare and occurs 40 times less frequent than laryngeal cancer and 400 times less 
frequent than bronchial cancer 3,5-7 This distinct difference in incidence is mainly 
attributed to the laminar airflow in the trachea, as a result of which less carcinogens 
might be deposited in the tracheal mucosa compared with the mucosa of the larynx 
and bronchi 8
Tracheal Surgery
The first tracheal resection and reconstruction was done by Küster in 1886 9 This 
was however a limited resection of a short segment of benign stenosis of cervical 
trachea.
Before single-staged tracheal resection and reconstruction became a feasible 
operation in a wider category of diseases, patients were mostly offered a permanent 
tracheostomy or airway tube. In some cases, staged procedures were employed to 
reconstruct the trachea using a wide variety of materials; foreign materials, nonviable 
tissue, autogeneous tissue, tissue engineering and allogeneous transplantation 10. 
Most of these techniques were technically difficult, had a high rate of complications 
and were successful in few selected cases only. It was not until the fifties and sixties 
of the twentieth century that single-staged tracheal resection and reconstruction 
really took off. Grillo (Figure 2) and co-workers 2 and Salassa and associates 11 
described the blood supply to the trachea. The surgical technique was adapted so 
that the lateral blood supply was not impeded while dissecting around the trachea.
12
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Grillo and Pearson and their co-workers further 
developed techniques of mobilization by which up to 
around 50% of tracheal length could be resected 
without excessive anastomotic tension 212-16. Since, 
segmental tracheal resection is a safe airway- 
preserving surgical technique with good results and 
low morbidity and mortality 17,18.
Figure 2.
Hermes C. Grillo, M.D.
Thyroid Carcinoma w ith Tracheal Involvem ent
Thyroid carcinoma is a relatively common tumor, occurring in approximately 3 per 
100,000 persons in the Netherlands 19 and 14 per 100,000 persons in the United 
States 20 In the United States, thyroid carcinoma was the sixth leading site of new 
cancer cases in 2008 20. Although death in thyroid carcinoma is uncommon, more
than half of all deaths in well and poorly differentiated thyroid carcinoma is caused
21by airway obstruction or bleeding .
Thyroid carcinoma is usually treated with surgical resection in combination with non- 
surgical management. The invasion of larynx or trachea occurs in approximately 6% 
of all patients with thyroid carcinoma. It is however very unusual to find tracheal 
involvement preoperatively, and thus the operative planning is often not aimed at 
airway surgery. In more than 80% of cases, adherence or invasion of the trachea or 
larynx is found intra-operatively by the surgeon performing thyroidectomy 22 
Controversy exists on how the surgeon should deal with this finding. One of the 
methods to remove the disease is to scrape or "shave” off the thyroid carcinoma 
attached to the airway 22-25, while some authors state that this procedure violates 
oncologic principles 26,27, favoring en bloc resection of the thyroid carcinoma in 
conjunction with the involved airway segment 21,28-31.
A im s and Scope o f th is  Thesis
This thesis aims to describe the treatment of patients with tracheal cancer and the 
outcome on a population-based level. The epidemiology, histology, presentation, 
diagnosis, and management of primary tracheal cancer will be discussed in more 
detail in Chapter 2. Despite the very low incidence of malignant tumors of the 
trachea, two large patient series were investigated at the Massachusetts General 
Hospital (Boston, MA), affiliated with Harvard Medical School (Cambridge, MA). This 
center is one of the world’s leading institutes with the largest experience in tracheal
13
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surgery available. The results from these series attribute to the knowledge of and 
clinical decision making in the two most common histologic types of primary tracheal 
carcinoma (Chapters 3.1 and 3.2).
As shown in Chapter 2, there is an important discrepancy in the treatment of primary 
tracheal cancer between population-based studies 4,5,32 and surgical series 33,34 In 
this thesis, we try to elucidate the cause for this discrepancy. In Chapter 4.1, the 
situation regarding the treatment of tracheal cancer in the Netherlands is mapped 
and the nationwide results of all applied treatment modalities are given for a 14-year 
period. Next, Chapter 4.2 describes a uniquely designed nationwide audit by a 
multidisciplinary team of experts that was undertaken in the Netherlands to answer 
the question what proportion of patients with primary tracheal carcinoma can be 
candidates for surgical resection. Both studies were performed in collaboration with 
the Netherlands Cancer Registry.
An extensive overview of the controversy in the literature on thyroid carcinoma 
invading the airway, supplemented with a review of the epidemiology, 
characteristics, presentation, diagnosis and staging of thyroid carcinoma invading 
the larynx or trachea is given in Chapter 5.1. In Chapter 5.2, the operative results 
and long-term survival and disease-free survival results in patients with thyroid 
carcinoma invading the airway treated with segmental airway resection are 
discussed, and an analysis is made of the difference in outcome between patients 
managed with limited "shave” resection versus patients undergoing en bloc resection 
including tracheal resection.
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ABSTRACT
Objective: Primary tracheal tumors pose a diagnostic and therapeutic 
challenge for the physician when confronted with this mostly malignant tumor. 
Diagnosis is often delayed for months or years due to its aspecific and asthma- 
mimicking symptoms. Knowledge from retrospective series is limited and few 
clinicians have gained experience with this tumor. The available literature on 
the diagnosis and management of this group of tumors is reviewed to 
summarize the available knowledge about these uncommon tumors. New 
diagnostic, staging and treatment guidelines are proposed.
Methods: PubMed was searched for English publications from 1960. 
The available literature was reviewed and summarized.
Results: Surgical resection and primary reconstruction is the best 
curative treatment modality available at present. In centers of experience, 
more than half of all patients with tracheal cancer may be candidates for 
surgical resection, although in population-based studies this treatment is 
applied in only 10-25% of patients.
Conclusions: Selecting patients that are candidates for surgical 
treatment is important in the workup of patients with tracheal cancer. Toward 
this goal, centralization of care concerning tracheal tumors is advised. 
Centralization may increase long-term survival and decrease operative 
morbidity and mortality even further.
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Introduction
Most tracheal tumors are malignant 1, and thus threaten the patient’s life not only by 
airway obstruction, but by locoregional invasion and progression to distant disease. 
As a rule, the delay in diagnosis measures months and years 2, and symptoms of 
airway obstruction are erroneously attributed to adult onset asthma 3. The time point 
of diagnosis determines the prognosis of the disease, and unresectable tumors are 
associated with prolonged symptom duration 2 The physician is faced with a 
challenge of finding an uncommon diagnosis for common symptoms. Population- 
based studies suggest that few patients undergo surgical resection, the treatment 
affording the best long-term prognosis 3-5. Finding resection rates for tracheal tumors 
as low as 10% in Denmark, Licht and associates assumed a lack of knowledge as 
the cause and accused physicians of therapeutic nihilism 3 A Multidisciplinary audit 
of 50 cases of tracheal cancer in the Netherlands found that a majority of patients 
with potentially resectable disease was treated with other modalities than curative 
surgery 6 We review the available literature on the epidemiology, diagnosis and 
management of this group of tumors to summarize the available knowledge about 
these uncommon tumors.
Materials and Methods
We searched PubMed using the MeSH-term ‘Tracheal Neoplasms’ with 
subheadings, including only English language publications of primary tracheal 
malignancies in humans between January 1960 and July 2009. Of the 1469 search 
results, 66 articles reporting on series of ten or more patients with true primary 
tracheal cancer were included in this review. More than 40 additional references 
were acquired from the bibliographies of the selected articles.
Epidem iology
Ninety percent of all tracheal tumors in adults are malignant 7, in contrast to 
approximately 30% in children 8 The incidence of primary tracheal cancer is 
approximately 0.1 in every 100.000 persons per year 4,9 These tumors make up 
approximately 0.2% of all tumors of the respiratory tract and account for 0.02 -
0.04% of all registered malignancies 3,9,10 Cancers of the larynx and bronchi occur 
approximately 40 and 400 times more frequent than cancer of the trachea, 
respectively.
Squamous cell tracheal carcinoma usually develops in the sixth or seventh decade 
and is more common in men and smokers 9 In contrast, adenoid cystic carcinoma 
tends to occur in younger patients, is not smoking-related and equally distributed 
among the sexes 11-13 The relatively low incidence of squamous cell carcinoma of 
the trachea when compared with laryngeal and bronchial cancer is attributed to the
chapter
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laminar airflow in the trachea 14, which might prevent the deposition of carcinogens in 
the tracheal mucosa.
Table 1. Histologic Types of Tracheal Cancer Found in Epidemiologic Studies
Author Year Period Type* Cases Histology % n
Kurien 41 1981 1957-1974 R 97 Squamous cell carcinoma 46.4% 45
Adenoid cystic carcinoma 3.1% 3
Small cell carcinoma 5.1% 5
Adenocarcinoma 6.2% 6
Other1" 39.2% 38
Manninen 9 1991 1967-1985 N 95 Squamous cell carcinoma 71.6% 68
Adenoid cystic carcinoma 6.3% 6
Small cell carcinoma 7.4% 7
Adenocarcinoma 12.6% 12
Other 2.1% 2
Gelder 1 1993 20 years P 321 Squamous cell carcinoma 52.4% 174
Adenoid cystic carcinoma 10.6% 34
Small cell carcinoma 5.0% 16
Adenocarcinoma 4.0% 13
Large cell carcinoma 5.9% 19
Other* 20.2% 65
Yang 104 1997 1979-1994 S 67 Squamous cell carcinoma 52.2% 35
Adenoid cystic carcinoma 7.5% 5
Small cell carcinoma 6.0% 4
Adenocarcinoma 14.9% 10
Other 19.4% 13
Licht 3 2001 1978-1995 N 109 Squamous cell carcinoma 63.3% 69
Adenoid cystic carcinoma 7.3% 8
Small cell carcinoma 7.3% 8
Adenocarcinoma 10.1% 11
Large cell carcinoma 1.8% 2
Other 10.1% 11
Honings 4 2007 1989-2002 N 308 Squamous cell carcinoma 52.9% 163
Adenoid cystic carcinoma 7.1% 22
Small cell carcinoma 11.0% 34
Adenocarcinoma 6.2% 19
Large cell carcinoma 7.5% 23
Other 15.3% 47
Total 997 Squamous cell carcinoma 55.6% 554
Adenoid cystic carcinoma 7.8% 78
Small cell carcinoma 7.4% 74
Adenocarcinoma 7.3% 73
Large cell carcinoma 4.4% 44
Other 17.5% 174
* N = national registration, S = single institution, P = nationwide postal survey, R = regional 
registration
T Study includes 25 cases with unknown histologic type
* Study includes 44 cases with unknown histologic type
20
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Histology
The two most common tracheal carcinomas are squamous cell carcinoma and 
adenoid cystic carcinoma 215-19, occurring in 36 -  45% and 31 -  40% of tracheal 
tumors 17,20 respectively. Even a majority of the remaining tumor types is malignant 
21, including non-squamous bronchogenic carcinoma, mucoepidermoid carcinoma, 
carcinoid tumors, sarcomas, melanomas and lymphomas. Benign tumors are found 
in 11 -  13% 17,20 These data are derived from clinical studies, since population- 
based studies do not contain either pathologic or radiologic review and are therefore 
unreliable 6 The high proportion of adenocarcinoma and small cell carcinoma, for
example, in national studies suggests a contamination with lymph node metastases
22from lung and mediastinal tumors Where a radiologic review has been part of 
epidemiologic data, the low incidence of non-squamous bronchogenic carcinoma 
has been confirmed 6.
Squamous cell carcinoma makes up more than half of all carcinomas in population- 
based series 3,4,9 (Table 1), and yet their more rapid natural history and progression 
of disease leads to a lack of referral for curative therapy. In contrast, adenoid cystic 
carcinoma grows far more slowly but is amenable to surgical resection for a longer 
period of time 23 Complete resection, however, is hard to achieve due to extensive 
submucosal growth 23 Although prognosis is better than in squamous cell 
carcinoma, adenoid cystic carcinoma is known for its tendency to develop late local 
and distant recurrences, which can occur up to 30 years after treatment 24
Presentation and D iagnostic Evaluation
Tracheal tumors are most commonly misdiagnosed as adult onset asthma. 
Symptoms usually include dyspnea (58%), cough (54%), hemoptysis (45%), wheeze 
(36%) and stridor (24%) 2. These symptoms develop over months and years 2,25 and 
may be treated with inhaled medications or even oral steroids 26-28 Airway 
obstruction is often advanced and life-threatening at the time of diagnosis 29. Patients 
will develop symptoms like dyspnea on exertion, dyspnea in rest and stridor when 
the tracheal lumen is progressively obstructed. Stridor and dyspnea at rest will 
predominantly develop when the tumor is located at the cranial part of the trachea 
and the remaining surface of the lumen is severely compromised 29-32.
Continuous progression or new onset of adult asthma requires radiographic 
evaluation. Also, hemoptysis or hoarseness should alert the physician to the 
possibility of malignant upper airway pathology. Conventional chest roentgenograms 
can be used to exclude other forms of pathology, but are rarely diagnostic for 
tracheal neoplasms. According to studies by Manninen and co-workers and Honings 
and associates, chest X-ray identified a tracheal tumor in only 8 of 44 (18%) and in
14 of 50 (28%) patients with tracheal cancer, respectively 6,33
chapter
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Pulmonary function testing is an accessible and non-invasive tool that can easily be 
performed and may offer important clues for the diagnosis of tracheal tumors (Figure 
1). The effect of anatomical lesions on maximal airflow depends on the site of 
obstruction, the type of lesion (variable or fixed) and the extent of anatomical 
obstruction. In patients with an extra-thoracic obstruction, the maximum inspiratory 
flow is decreased. A fixed obstruction will result in a decreased inspiratory and peak 
expiratory flow (PEF). Also, the maximum inspiratory flow at 50% of the forced vital 
capacity (MIF50) will be decreased and approximately equal to the maximal 
expiratory flow at 50% of the vital capacity (MEF50). This will therefore result in a 
MIF50/MEF50 ratio of approximately 1. In contrast, a variable extra-thoracic 
obstruction will result in a decreased MIF50 but a normal or decreased PEF, and 
consequently a reduced MIF50/MEF50 ratio of usually less than 1.
In patients with an intra-thoracic tracheal tumor located below the thoracic inlet, a 
fixed or variable obstruction airflow pattern as described above can be seen. Intra- 
thoracic airway obstruction is characterized by a decreased PEF, a normal or 
decreased MIF50 and consequently a MIF50/MEF50 ratio of 1 or more 34 However, 
when central airway pathology is suspected, endoscopic inspection of the 
tracheobronchial tree is warranted, even in the absence of a spirometric pattern 
suspect for central airway obstruction.
Flow [L /s ]
F/V ex
Vol [L]
1 2 4 5
F/V in
Figure 1. This flow volume curve shows severe inspiratory and expiratory airway obstruction caused by 
an intratracheal tumor. Straight line indicates predicted expiratory curve
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The most useful test in diagnosing 
tracheal cancer is bronchoscopy (see 
Figure 2). Bronchoscopy provides an 
accurate evaluation of the nature and 
the extent of the tumor. Location and 
length can be related to anatomic 
landmarks such as the carina and the 
cricoid cartilage and tumor 
dimensions can be related to the 
airway diameter. Furthermore, a 
tumor biopsy can be taken for 
pathologic evaluation. Flexible 
tracheobronchoscopy however can 
provoke cough, edema and bleeding 
of the airway, which in turn could 
aggravate the obstruction of the 
airway. In patients with acute 
respiratory distress, the use of rigid 
bronchoscopy is advised.
Together with tracheobronchoscopy, chest and neck computed tomography (CT)
35scans form the mainstays for diagnosing and staging of primary tracheal tumors 
CT scans are helpful to assess the depth of invasion, possible involvement of 
adjacent structures and to search for lymphogenic and distant metastasis or 
synchronous primary tumors (Figure 3A). Diagnostic recommendations based on this 
study are summarized in Table 2. Currently, novel imaging techniques for the 
evaluation of the upper airway are under study, including three-dimensional virtual 
tracheoscopy, super-high resolution computed tomography scanning and 
endoscopic ultrasound 36 Esophagoscopy may provide information about 
esophageal invasion.
Figure 2. This endoscopic view shows high 
grade narrowing of the trachea caused by an 
adenoid cystic carcinoma at the time of 
diagnosis. Endoscopic debridement may 
precede definitive treatment to prevent acute 
airway obstruction
Figures 3A and 3B. Axial imaging of the trachea by either CT scan (panel A) or MRI (panel B, T1 
weighted) demonstrate degree of obstruction and show here the absence of extratracheal invasion. Note 
that neither study may rule out esophageal invasion. Arrow indicates tumor arising from membranous 
portion
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Staging o f Tracheal Cancer
At this moment, there is no TNM staging system available for malignancies of the 
trachea 37 The definition of lymph node involvement used in the TNM-classification 
for bronchial carcinoma cannot be applied to tracheal carcinomas 38,39 
Efforts to create a staging system for tracheal cancer are impeded by the low 
incidence of this tumor. Bhattacharyya suggested a tumor and lymph node 
dependent staging system in 2004 40 In 23 patients with mixed histology (squamous 
cell carcinoma; 11, adenoid cystic carcinoma; 9, other; 3) the system as proposed by 
Bhattacharyya proved a significant predictor of survival, although groups were small 
and both surgery and radiotherapy were used in unknown proportion in each stage
19 41Recently, a new staging system was proposed by Macchiarini . This system is 
based upon a TNM classification in combination with tumor localization in the 
trachea (upper, middle and lower). The suitability of both systems and their 
therapeutic and prognostic implications are not yet clarified and should be subject of 
further investigation.
Table 2. Diagnostic Recommendations for Malignant Tracheal Tumors
Chest X-ray and/or chest CT for:
Dyspnea, stridor or wheezing unresponsive to bronchodilators 
Upper airway obstruction at spirometry, unresponsive to bronchodilators 
New cough for more than three weeks
Bronchoscopy:
No abnormalities, explanatory for symptoms 
Tracheal mass, compression or deviation
Chest CT and bronchoscopy:
Hemoptysis 
Persistent hoarseness
CT = computed tomography
Apart from staging, assessment of local resectability is essential in the work-up of 
patients. Based on the experience of a center for airway surgery with selected 
referral, Gaissert and colleagues stated that locoregional, and not distant, disease 
determines resectability in most patients 2 In the presence of a localized tracheal 
carcinoma, every patient should undergo an evaluation to determine resectability 
and the histologic diagnosis consisting of radiographic and bronchoscopic 
examination with computed tomography of the neck and chest. Magnetic resonance
imaging can also be used (Figure 3B), but provides no advantage over computed 
tomography. When clinically indicated, workup can be expanded with various
investigative modalities. Positron emission tomography (PET) scanning can be used 
to assess local lymph node involvement and distant metastases, endo-esophageal 
ultrasound or esophagoscopy can be performed to investigate ingrowth in the 
esophagus, computed tomography or ultrasound of the abdomen, bone scintigraphy
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and magnetic resonance imaging of the cerebrum can be used to detect distant 
metastases. The recommended steps in the workup of biopsy proven tracheal 
carcinoma (after bronchoscopy) are shown in Table 3.
Table 3. Workup for Biopsy Proven Primary Tracheal Cancer
When acute intervention is necessary to maintain airway 
Salvage endoscopic debulking
Do not perform procedures which prohibit surgical resection (such 
as stents or tracheostomy)
Always perform 
CT of the neck 
CT of the chest
When tracheoscopy or neck CT shows possible invasion of esophagus 
Esophagoscopy and/or endo-esophageal ultrasound
When clinically indicated 
PET scan
CT or ultrasound of the abdomen
Bone scintigraphy
CT or MRI of the cerebrum
CT = computed tomography, PET = positron emission tomography, MRI 
= magnetic resonance imaging
Treatment
In the management of primary tracheal cancer, it is necessary to be familiar with the 
full range of available treatment modalities. Only when the multidisciplinary team has 
sufficient knowledge and experience with these techniques can a good decision be 
made on the appropriate management in a specific patient.
Since resection is the treatment with the greatest potential to change the natural 
history of disease, a focus on selecting candidates for resection is important. Other 
forms of treatment serve as adjuvant after or palliative treatment in place of surgical 
resection 242.
Management o f Acute Airway Obstruction
Acute airway obstruction with imminent suffocation requires urgent relief of 
symptoms using rigid bronchoscopy 29 During this procedure it is possible to 
improve airway patency by endotracheal tumor debulking. Temporary enlargement 
of the airway provides time to complete the assessment of resectability and prepare 
the patient for elective surgery. We advise against airway stenting, tracheostomy and 
pre-operative radiotherapy in the acute setting, as these procedures may impair the 
results of definitive surgical treatment 43
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Surgery
Airway obstruction caused by tracheal cancer is immediately relieved with surgical 
resection of the involved tracheal segment. This approach, with or without post­
operative radiotherapy, offers long-term survival in many and cure of disease in 
some patients 7 Webb and associates advocate standard application of adjuvant 
radiotherapy in all patients operated for tracheal cancer 44
Tracheal resection is a well established technique with predictable success. Salassa 
and colleagues described the vascular anatomy of the trachea and Grillo and 
Pearson and their co-workers developed surgical mobilization techniques by which 
up to 50% of the tracheal length may be removed with subsequent primary 
reconstruction, without compromising anastomotic healing 45-53. This technique was
54 55further developed for resection and reconstruction of the carina 5455. Even in some 
proximally located tracheal tumors with extension into the subglottic larynx, radical 
resection can be achieved by cricotracheal resection and primary reconstruction, 
without jeopardizing the function of voice 56 Concurrently with these developments 
and the growing experience in tracheal surgery, operative mortality has declined at 
centers of experience to approximately 3% in the past decade 2 
Surgery is contra-indicated when complete tumor resection would result in excessive 
tension at the anastomosis, often when tumor length exceeds 50% of the trachea, 
when vital organs (aorta, heart) are involved by tumor, the mediastinum has received 
high-dose irradiation therapy, or massive lymph node invasion is present 2,7,57 The 
latter condition precludes radical surgery, because the lateral arterial blood supply to 
the trachea would be seriously compromised after radical lymphadenectomy 7. 
Because adenoid cystic carcinomas usually progress slowly, even in the presence of 
distant metastasis, surgical resection may be beneficial to the patient 58. This is in 
contrast to squamous cell carcinoma, where distant metastases are more common. 
Through the decades, various techniques have been evaluated to replace trachea 
with foreign materials, nonviable tissue, autogeneous tissue and allo- and 
xenotransplantation 59 Recently, Wurtz and associates reported the successful use 
of aortic allografts enforced with silicone stents in two patients, who had good 
respiratory function after 18 months of follow-up 60 An international group with 
Macchiarini and Birchall reported a case in which the left mainstem bronchus was 
replaced with a de-cellularized and de-antigenized donor tracheal transplant 
colonized by the recipients epithelial cells and chondrogenic mesenchymal cells 61. 
Enforced free cutaneous flaps have also been used with success 59,62-64. Long-term 
outcome of these techniques is still unknown. Further research and refinement of 
these techniques are required. Nonetheless, they might hold some promise for the 
future of tracheal surgery.
Radiotherapy
Radiotherapy in tracheal carcinoma is applied either as adjuvant therapy after 
resection or as primary therapy in unresectable or inoperable patients. Postoperative 
radiotherapy can be applied to improve survival by reducing the chance of local
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recurrence 26,65. The results of primary radiotherapy are inferior compared to those of 
surgery 1,5,20,65-71
Because of the rarity of the disease, many studies included patients treated several 
decades ago, even in the 1950’s and 60’s. At that time radiotherapy equipment and 
radiation techniques had their limitations and often suboptimal doses and 
fractionation schedules were used. Also, several studies combine tumors of different 
histology. Adenoid cystic carcinomas are generally considered to be less 
radiosensitive than squamous cell carcinomas.
Some more recent studies indicate that better results can be obtained with higher 
radiation doses 68,71-73 Bittner and associates recently reported a 5-year survival of 
89.4% in 19 patients with unresectable adenoid cystic carcinoma treated with fast 
neutron radiotherapy in combination with endobronchial brachytherapy in 6, although 
the 5-year disease free survival was only 28% and 6 of 12 failures occurred locally, 
all within the field of treatment 74 Although the general outlook remains poor for 
patients with advanced and unresectable tumors, 5-year survival rates of 25-30% 
can be obtained with adequately dosed radiotherapy indicating that there is a 
subgroup of patients that can be cured 72,73 Using higher doses, the risk of 
complications is increased. Modern techniques such as conformal radiotherapy and 
intensity-modulated radiotherapy (IMRT) may incrementally reduce the risk of higher 
doses by lowering the exposed tissue volume. When external beam radiotherapy is 
used in a curative setting, a dose of at least 60 Gy and, if possible, up to 70 Gy in 
daily fractions of 1.8 -  2.0 Gy is recommended 41,69,71,72 a  dose of 60 Gy is 
recommended for microscopic residual disease in an adjuvant situation 41. Adequate 
dose delivery requires at least CT-based planning and three dimensional conformal 
treatment techniques with position verification. Another approach is to deliver the 
boost dose through intraluminal brachytherapy 71,73,75-79 To this end, the use of a 
special applicator which secures central positioning of the source within the tracheal 
lumen is mandatory. Central positioning of the brachytherapy catheter in the lumen 
enables a homogeneous dose distribution and prevents high contact doses delivered 
to the tracheal mucosa.
Thus, primary radiotherapy should be considered as a curative option for patients 
with advanced unresectable disease in good general condition and for patients with 
resectable disease but not sufficiently fit for surgery. In other cases radiotherapy can 
provide palliation with good symptomatic relief. Amelioration of hemoptysis and 
obstruction was reported in three-quarters of the patients and reduction of dyspnea 
and cough in approximately half 67
Endotracheal Treatment
Various endotracheal techniques are available which all aim to dilate the airway 
obstruction or debulk tumor mass in the trachea in order to provide a patent airway
29 These procedures are performed during rigid bronchoscopy under general 
anesthesia. With the rigid tracheobronchoscope it is possible to maintain ventilation 
during the procedures. Endotracheal techniques can be used in two clinical settings: 
acute relief of airway obstruction, which might be prior to definitive surgical
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treatment, and palliation in patients with unresectable disease. In both settings, 
endoscopic debridement is a minimally invasive procedure, which immediately 
relieves symptoms 31. Tumor mass may be removed with mechanical core out 80,81, 
electrocoagulation, neodymium-doped yttrium aluminum garnet (Nd:YAG) laser 82-87, 
carbon dioxide laser 88-90 or argon beam 91,92 coagulation, cryotherapy 93-95 or 
photodynamic therapy 96-98
As stated before, long term airway stenting should be prevented as much as 
possible in patients who might be candidate for airway resection 32 However, when 
patients suffer from unresectable disease, airway stenting, in some patients 
preceded by tumor debulking, may effectively secure the airway and improve quality 
of life even in the long term 32,99-103.
Systemic Therapy
In the absence of prospective trials, the value of systemic chemotherapy in patients 
with unresectable tracheal cancer or as adjuvant therapy in combination with surgery 
or radiotherapy remains uncertain.
Outcome and Prognosis
Prognosis of patients with tracheal cancer is dismal. Population-based studies from 
Europe have shown that the 5- and 10-year survival rates of all types of tracheal 
carcinoma are 5-15% and 6-7%, respectively 3,4,42 In these studies, it is emphasized 
that patients treated with surgical resection have better prognosis, the 5- and 10-year 
survival rates being 50% and 35-50%, respectively 3,4 Several reports from surgical 
clinics have shown similar outcomes: airway resection yields improved survival 20 In 
a Russian study by Perelman and colleagues 104, resection was performed for 
malignant tracheal tumors in 120 patients, of which 55% had adenoid cystic 
carcinoma. 5- and 10-year survival rates were 36% and 27%, respectively 104 In a 
French multicentre study by Regnard and associates, the 5-year survival rate after 
surgery for adenoid cystic carcinoma was 73% (n=63) and 47% for tracheal 
carcinomas other than adenoid cystic carcinoma (n=94) 17. In 29 patients with 
adenoid cystic carcinoma reported by Maziak and colleagues, 5-year survival was 
79%, although three operative deaths were excluded from survival analysis 24 A 
Japanese study by Hazama and associates reported a 5-year survival rate of 53% in 
nine cases of resected squamous cell carcinoma and even 100% in seven cases of 
resected adenoid cystic carcinoma 15 Gaissert and colleagues found that the 5-year 
survival rates in resected patients were 39% in squamous cell carcinoma (n=90) and 
52% in adenoid cystic carcinoma (n=101) 2 In 2006, the same group showed that, 
also in patients with uncommon primary tracheal neoplasms, such as carcinoid and 
sarcoma, airway resection leads to long-term survival and is superior to local 
endoscopic tumor destruction 21. In a recently published Chinese study, the reported 
5-year survival was 40% in 35 cases of ACC, of which 28 underwent resection and 7 
only received radiotherapy 105 These data are summarized in Table 4.
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Table 4. Results after Segmental Tracheal Resection for Primary Tracheal Cancer
Author Year Country Period Cases
Survival (%) 
5-year 10-year
Squamous cell carcinoma
Gaissert 2 2004 USA 1962-2002 90 39 18
Hazama 15 2003 Japan 1979-2000 9 53 53
Regnard 17 1996 France 1970-1993 65 73 51
Adenoid cystic carcinoma
Zhengjaiang 103 * 2008 China 1981-2002 35 40
Honings 4 2007 Netherlands 1989-2002 18 77 41
2Gaissert 2004 USA 1962-2002 101 52 29
Hazama 15 2003 Japan 1979-2000 7 100 100
Maziak 23 1996 Canada 1963-1995 32 39 51
Various histologic types
Honings T 2007 Netherlands 1989-2002 34 51 35
Perelman 102 * 1996 Russia 1963-1995 120 36 27
* Of 35 cases, 28 underwent resection and 7 received primary radiotherapy
T Histologic types: 53% squamous cell carcinoma, 32% adenoid cystic carcinoma, 15% 
other
* Histologic types: 55% adenoid cystic carcinoma, 18% squamous cell carcinoma, 17% 
carcinoid, 10% other
The most important prognostic factors in primary tracheal carcinoma are histology 
and treatment: adenoid cystic carcinoma and mucoepidermoid carcinoma have a 
better prognosis than other histologic types 106-108 and survival in resected patients is 
better than in non-resected patients, particularly when resection is histologicly
3 5complete This is not only the case in small and locally confined tumors. In 
patients even with advanced tumors, surgery yields the best survival and chances of 
cure of disease. In adenoid cystic carcinoma, because of its slowly progressing 
character and adjuvant radiotherapy, tension-free anastomosis is more important 
than tumor free resection margins 17,109
Another factor that needs to be addressed is lymph node involvement. The role of 
positive lymph nodes in tracheal cancer is still unclear. Macchiarini suggested a 
staging system based upon tumor size, infiltration depth, involved organs, lymph 
node spread and presence of distant metastasis. The correlation with survival yet 
remains to be investigated 41. Bhattacharyya advocated a tumor and node-based 
staging system, where stage IV would include both T4 and patients with any T-status 
and one or more positive lymph nodes 40. After correction for histologic type, survival 
in stage III (T3N0) and IV was identical. Further, each stage comprised a 
heterogeneous group including patients treated with surgery with or without 
radiotherapy, radiotherapy alone and patients with unknown treatment. Regnard and 
associates did not find a decrease in survival in patients with positive lymph nodes 
17 This finding was iterated by Gaissert and colleagues, who commented that this 
might be due to the small sample size 2.
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Figure 4. Proposed treatment algorithm for primary tracheal malignancy
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The influence of nodal metastases in tracheal cancer needs to be elucidated. In view 
of this and in the absence of retrospective or prospective proof we are not able to 
recommend any staging system.
Most important in improving the survival of patients with primary tracheal 
malignancies seems to be selecting the patients who are amenable for definitive 
surgery. The treatment algorithm depicted in Figure 4 is primarily focused on this 
aspect and may contribute to a situation in which more patients with tracheal cancer 
are treated with curative intent. The judgment whether distant metastasis form a 
contra-indication should be precisely made for each individual patient, especially in 
the case of adenoid cystic carcinoma 58 Such considerations and the delivery of 
definitive surgical care can best be done in tertiary centers specialized in tracheal 
surgery. In Europe, only 10% of patients with tracheal cancer is treated with airway 
resection 1,3-5,42 though in principle this is feasible in more than half of all patients 
15,43 This statement is further reinforced by a recent audit in the Netherlands 6 By 
implementing a centralized care system, more patients might be treated with airway 
resection. Also, morbidity and mortality from airway surgery are lower in the hands of 
experienced airway surgeons 2,17,58
Conclusion
Primary malignancies of the trachea are rare and diagnosis is often delayed due to 
its aspecific symptoms. Several studies have suggested a lack of knowledge and 
expertise in clinicians facing patients with tracheal tumors, ultimately leading to a 
relative undertreatment of this challenging disease. Surgical resection, in the vast 
majority followed by primary reconstruction and postoperative radiotherapy in case of 
microscopic residual disease, is the best curative treatment modality available at 
present. Currently, no validated staging system exists, for which future prospective 
research is warranted. However, we feel that most important in the workup of 
patients with tracheal cancer is selecting patients who might be amenable for 
surgical resection, which is expected be the case in more than 50% of patients. 
Radiotherapy should only be used as adjuvant therapy after airway resection and in 
patients with unresectable disease or in patients who are inoperable. Centralizing the 
care for patients with tracheal malignancies could lead to an increase in long-term 
survival and a decrease in operative morbidity and mortality.
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ABSTRACT
Background: While squamous cell carcinoma (SCC) is the most 
common tracheal malignancy, few reports describe the pathologic 
considerations that may guide intraoperative decisions and prognostic 
assessment.
Methods: We reviewed 59 tracheal SCC treated between 1985 and 
2008 by segmental resection of the trachea, including resection of the carina in 
24% and inferior larynx in 14%. We classified these tumors by grading 
histologic differentiation and microscopic features used in SCC of other sites.
Results: Of 59 tumors, 24% (14/59) were well differentiated, 49% 
(29/59) were moderately differentiated, and 27% (16/59) were poorly 
differentiated. Unfavorable prognostic factors were tumor extension into the 
thyroid gland (all of 5 so afflicted patients died of tumor progression within 3 
years) and lymphatic invasion (mean survival 4.6 versus 7.6 years). 
Keratinization, dyskeratosis, acantholysis, necrosis, and tumor thickness, did 
not predict prognosis.
Conclusion: As surgical resection is the only curative treatment, the 
surgeon should establish clean lines of resection, using as appropriate 
intraoperative frozen section. The pathologist can provide additional important 
prognostic information, including tumor differentiation and extent, invasion of 
surgical margins, and extension into the thyroid.
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Introduction
Although squamous cell carcinoma (SCC) accounts for more than half of all tracheal 
tumors 1, the pathologic features in resection specimens and the impact of these 
features on survival have only been described in small series 2 At least two staging 
systems have been proposed for tracheal malignancies; one, a cross-sectional 
analysis of a national cancer database by Bhattacharyya, is based on retrospective 
TNM documentation correlated with survival statistics in 41 squamous cell 
carcinomas, 19 adenoid cystic carcinomas and 32 tumors of other histology 3, 
although a TNM staging system validated by clinical and pathologic evidence for this 
disease does not exist. The other, by Macchiarini, is a non-validated TNM- 
classification 4 Both classifications are intended to be applied to all histologic types 
of tracheal cancer.
We describe specific pathologic features of primary tracheal SCC in a large series of 
surgical specimens from a single institution to identify prognostic predictors of 
survival.
Materials and Methods
A retrospective analysis was conducted of consecutive patients who underwent 
resection for primary SCC of the trachea from 1985 to 2008 at Massachusetts 
General Hospital (MGH) and for whom pathology slides or blocks were available. All 
except 4 patients were included in a previous report describing the surgical results 5 
We included one patient in whom a second resection at MGH completed tumor 
excision after a first resection elsewhere. One patient underwent 3 resections, but 
only the first, for tumor resection, was included in this study. Pathology reports, 
operative reports, and hospital charts were reviewed to exclude laryngeal cancer and 
tumors of the lung that extended to the carina. The MGH institutional review board 
approved the most recent protocol (No. 2008-P-000113) in January 2008.
Types of Resection
The surgical technique has been detailed previously 6 For standard tracheal 
resection, a sleeve of trachea was removed with end-to-end reconstruction, resulting 
in 2 airway margins and a radial soft tissue margin. When tracheal resection was 
combined with laryngectomy, cervical or mediastinal end-tracheostomy was 
required. For laryngotracheal resection, the tumor was removed with a portion of 
infraglottic larynx while preserving at least one recurrent laryngeal nerve not involved 
with tumor. Reconstruction was achieved by shaping the remaining trachea to 
conform to the laryngeal defect. Carinal resection was performed with or without 
concomitant lung resection resulting in either 2 or 3 airway margins, respectively. 
Systematic lymph node dissection is assumed to interfere with the tracheal blood 
supply and was therefore not performed. Regional lymph nodes were often not 
included in the specimen if not grossly enlarged. Absence of tumor at the airway
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margins was confirmed by frozen section unless the limits of resection had been 
reached and no additional trachea could be removed.
E.
Figure 1. A. Cross section of trachea with exophitic tumor attached to anterior wall; B. Lymphatic 
invasion in peritracheal adventitia; C. Squamous cell carcinoma in situ, with full thickness replacement 
of epithelium by cells with hyperchromatic nuclei and lack of surface maturation; D. Cancerization of 
mucus ducts and glands by malignant squamous cells but no invasion beyond basement membrane; E. 
Squamous cell carcinoma invading from surface epithelium into lamina propria and eliciting 
inflammation and fibrosis but not as far as tracheal cartilage (bottom)
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Pathologic Review and Tumor Data
In all reviewed cases, photographs of the resected specimen (Figure 1A) and slides 
stained with hematoxylin and eosin were retrieved. Slides were recut from stored 
blocks if necessary. Pathologic review of two or more slides per case was done in 
each case by a senior pulmonary pathologist (E.J.M.), on average 4 to 6 slides of the 
tumor itself and additional slides of resection margins and lymph nodes. The 
following histologic features were scored: degree of differentiation based on degree 
and extent of nuclear pleomorphism, using the criteria for well, moderately, or poorly 
differentiated subtypes in the AFIP Atlas of Tumor Pathology 7; tumor thickness, 
defined as the distance from the luminal tumor surface to the farthest extent of 
invasion; keratinization; necrosis; dyskeratosis; acantholysis; and lymphatic invasion 
(Figure 1B). Since no TNM-based staging system currently exists for tracheal 
carcinoma, depth of tumor invasion into the tracheal wall was scored according to a 
system devised for the study as shown in Figure 2, with both squamous cell 
carcinoma in situ (Figure 1C) and invasion of carcinoma into tracheal mucus glands 
and ducts (so-called cancerization, Figure 1D) considered level 0 and superficially 
invasive (Figure 1E) as grade 1.
Further, operative and pathology reports were reviewed for length of resection in the 
long axis of the airway and the presence of tumor metastasis in lymph nodes. Since 
lymph node excision in tracheal resection occurs merely sporadic, we combined 
cases with positive lymph node biopsy and cases with lymphatic invasion on 
histologic examination, in order to provide a meaningful, albeit restricted analysis.
Adjuvant Radiotherapy
Postoperative radiotherapy was usually recommended at a dose of 54 Gy 6 to 8 
weeks after resection and often administered outside Massachusetts General 
Hospital.
Follow-Up
Patients and the MGH cancer registry were contacted for follow-up information. The 
Social Security Death Index was searched. Patients were determined to have died if 
name, date of birth, and social security number matched. The survival period began 
on the day of operation and was concluded by death.
Statistical Analysis
Overall survival after airway resection was calculated using the Kaplan-Meier 
procedure with the log rank test implemented in the SPSS 14.0 statistical software 
program (SPSS Inc, Chicago, IL), in contrast to the earlier report that used an 
actuarial method 5. Categorical variables were compared with the Chi-Square test 
and covariate analysis was done with Pearson’s bivariate analysis.
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Figure 2. Depth of invasion in tracheal squamous cell carcinoma ranked by levels. Tumor invaded 
between cartilage plates and not through the cartilage
Level Definition
0 Carcinoma in situ
1 Infiltrating lamina propia
2a Abutting or extending between cartilage
2b Invading beyond cartilage
3a Invading peritracheal fibroadipose tissue
3b Abutting soft tissue resection margin
4 Invading into thyroid gland
42
Pathologic Characteristics in Tracheal Squamous Cell Carcinoma
Results
Since 1985, 75 patients have undergone surgical resection for tracheal SCC at 
Massachusetts General Hospital. There were no operative deaths. Slides or blocks 
were retrieved in 64 cases, of which 5 were excluded: there was no viable tumor 
after radiotherapy in 3 patients, a cutaneous SCC occurred at a tracheostomy site in
1, and two separate SCC were present in 1 other patient, of which only one was 
resected. Thus, the study included 59 cases.
Overall Characteristics
There were 44 men (75%) and 15 women (25%) with a mean age of 61.9 years 
(range 29 to 79 years). Prior locoregional or pre-operative radiotherapy was 
administered in 24% (14/59). Resection involved trachea only in 63% (37/59), 
trachea and carina in 24% (14/59) and trachea and larynx in 14% (8/59) of cases. 
Mean length of resected airway was 3.2 cm (range 1 to 6 cm). Pathologic 
characteristics are listed in Table 1. Postoperative radiation was documented in 
42.4% of patients (25/59). We know of no patient who received postoperative 
chemotherapy.
Follow-up and Overall Survival
Mean follow-up in 59 cases was 5.5 years (range 1 month to 18.3 years). Survival 
information was complete in 90% of patients (53/59). Mean survival was 6.5 years 
and the 5- and 10-year survivals were 46% and 27%, respectively. Table 1 shows 
the survival calculated for each subgroup.
Differentiation
A majority of tumors had moderate differentiation, while close to half were equally 
distributed between well and poorly differentiated. Survival was longer in well 
differentiated tumors, though this difference was not significant (Figure 3A). Survival 
in well differentiated carcinomas was 8.8 years versus 5.8 years in the group of 
moderately and poorly differentiated carcinomas combined (P = 0.117).
Keratinization, Necrosis, Dyskeratosis and Acantholysis
Two thirds of tumors (39/59) showed keratinization. Focal or extensive necrosis was 
present in 48% (28/59) and 20% (12/59), respectively. Necrosis was present 
significantly more frequently in moderately and poorly differentiated tumors (82%, 
37/45) compared to well differentiated tumors (21%, 3/14; P < 0.001). Dyskeratosis 
was seen in 59% and acantholysis in 27%.
Survival was not significantly correlated with the presence or absence of 
keratinization, necrosis, dyskeratosis or acantholysis.
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Table 1. Survival According to Pathologic Subgroups
Pathologic subgroup No. No. (%)
Mean survival 
(years) P -value
Survival (%) 
5-year 10-year
Tumor differentiation
Well differentiated 14 23.7 8.8 73 55
Moderately differentiated 29 49.2 6.3 0.164 44 25
Poorly differentiated 16 27.1 4.5 29 10
Keratinization
Yes 39 66.1 6.5 0.719 50 28
No 20 33.9 6.6 39 26
Necrosis
Extensive 12 20.3 7.2 46 27
Focal 28 47.5 6.1 0.726 45 26
No 19 32.2 6.2 47 30
Dyskeratosis
Yes 35 59.3 6.7 0.942 51 34
No 24 40.7 6.3 39 20
Acantholysis
Yes 16 27.1 5.6 0.307 47 31
No 43 72.9 6.9 46 26
Lymphatic invasion
Yes 22 37.3 4.6 0.049 24 24
No 37 62.7 7.6 60 31
Depth of invasion
Level 0 2 3.4 n.a. 100 100
Level 1 5 8.5 7.6 75 25
Level 2a 14 23.7 6.0 50 25
Level 2b 11 18.6 7.1 0.001 50 38
Level 3a 16 27.1 7.7 53 31
Level 3b 
Level 4
6
5
10.2
8.5
2.1
1.4 0
Tumor thickness
0.1 - 1.0 cm 29 49.2 6.8 48 32
1.1 - 2.0 cm 21 35.6 6.8 0.650 56 26
> 2.0 cm 9 15.3 4.1 13 13
Overall 59 100.0 6.5 46 27
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Lymphatic Invasion
In 22 cases (37%), there was tumor in peritracheal lymphatics on histologic 
examination (7 cases), a tumor-positive lymph node biopsy was present (9), or both 
(6). In the other 36 cases (61%), neither lymphatic invasion nor lymph node 
metastasis was demonstrated. Lymphatic invasion was correlated with the degree of 
differentiation: histologic lymphatic invasion or tumor positive lymph node biopsies 
were present in 1 of 14 well differentiated (7%), 13 of 29 moderately differentiated 
(49%) and 9 of 16 poorly differentiated (56%) tumors (P = 0.015). Survival in 
patients without lymphatic invasion was higher than when lymphatic invasion was 
present (P = 0.049, Figure 3B). There was no difference in survival between patients 
who had lymphatic invasion only versus patients with positive lymph nodes only, 
versus both (P = 0.382).
Depth of Invasion (Table 2 and Figure 3C)
Carcinomas in situ (level 0) were uncommon, while tumor invaded peritracheal 
fibroadipose tissue (level 3a) in 16 cases (27%), extended to the soft tissue resection 
margin (level 3b) in 6 cases (10%), and invaded the thyroid gland (level 4) in 5 cases 
(8%). While both patients with carcinoma in situ were alive without disease 9.6 and
15 years after resection, there was no difference in survival between levels 1, 2 (a 
and b) and 3a (Table 1 and Figure 3C). Incomplete resection and involvement of the 
thyroid gland were both negative prognostic markers: mean survival was 2.1 years in 
patients with tumor at the soft tissue resection margin (level 3b), and 1.4 years when 
tumor invaded the thyroid gland (level 4), both significantly lower than in other levels 
of invasion (P = 0.025 and P < 0.001, respectively). Lesser levels of invasion were 
associated with a higher incidence of well differentiated histology (P = 0.018) and a 
lower incidence of lymphatic invasion (P = 0.002).
Table 2. Pathologic Characteristics According to Depth of Invasion
Well
Differentiated
Lymphatic
Invasion
Tumor thickness 
> 2 cm
Depth of invasion N % N % N % N %
Level 0 2 3.4 2 100.0 0 0.0 0 0.0
Level 1 5 8.5 2 40.0 0 0.0 0 0.0
Level 2a 14 23.7 5 35.7 1 7.1 0 0.0
Level 2 b 11 18.6 4 36.4 5 45.5 2 18.2
Level 3a 16 27.1 1 6.3 7 43.8 6 37.5
Level 3 b 6 10.2 0 0.0 4 66.7 1 16.7
Level 4 5 8.5 0 0.0 5 100.0 0 0.0
Overall 59 100.0 14 23.7 22 37.3 9 15.3
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Tumor Thickness
Mean tumor thickness was 1.3 cm (median 1.1 cm, range 0.1 -  5.5 cm). Tumors 
were 2 cm or smaller in 85%. Within this range, tumor thickness had no significant 
impact on survival (P = 0.650). Tumors of greater thickness were associated with 
resections of greater (> 3 cm) length (P = 0.008), although there were two resections 
of 2.0 and 2.5 cm in length of trachea with a tumor of 3 and 5 cm in thickness, 
respectively (Figure 4, correlation coefficient 0.364). Tumors > 2 cm in thickness 
had no different survival than tumors of 2 cm or less (P = 0.353). Tumors > 2 cm in 
thickness more frequently invaded peritracheal fibroadipose tissue (6 of 9, 67%) than 
smaller tumors (10 of 50, 20%) (P = 0.004), but were not associated with level 3b or 
level 4 (Table 2).
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Discussion
In this pathologic review of primary tracheal squamous cell carcinoma, the largest 
series to date, we show that completeness of resection, involvement of the thyroid 
gland, and lymphatic invasion are histopathologic features with important prognostic 
value. Increasing depth of invasion into the tracheal wall is associated with a loss of 
histologic differentiation and lymphatic invasion. Although survival in well 
differentiated carcinomas is higher, this difference is not significant and may be 
attributed to the higher incidence of lymphatic invasion in moderately and poorly 
differentiated carcinomas. Further, we observed that resected tracheal SCCs are 
mostly small tumors (median thickness 1.1 cm) and that tumor thickness within this 
range did not significantly affect prognosis. A possible explanation for this finding is 
that thickness may result from the exophitic portion of the tumor and thus is not 
conditioned on deeper invasion into the tracheal wall. A higher proportion of larger 
tumors, however, exhibit lymphatic invasion, a significant predictor of survival.
Surgical resection may lead to excellent survival even when the tumor violates the 
boundaries of the trachea and invades peritracheal fibroadipose tissue. To provide 
the best chances of survival, it is however important for the surgeon to achieve 
negative soft tissue resection margins. When faced with a tracheal SCC growing 
into the thyroid gland, our findings indicate that surgical resection should be applied 
to carefully selected patients and palliative therapy may be considered when 
complete resection is otherwise compromised. Further, the pathologist reviewing
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SCC of the trachea should be aware of the importance of lymphatic invasion and 
specifically investigate the tumor for the presence of this feature.
There are some limitations to our study. We retrospectively analyzed large 
pathologic specimens of tracheal SCC, and only resected cases were included. 
Tumors growing into vital organs such as the heart or the great vessels and tumors 
involving long segments of airway judged unresectable were treated at the 
Massachusetts General Hospital but are not included in our study. We might have 
underestimated or misjudged the histologic characteristics, as only a limited number 
of representative slides for each case were available during histologic review; 
further, there were only 5 cases with invasion of the thyroid gland.
Tracheal SCC is a rare tumor, and few centers acquire proficiency in its surgical 
treatment. The dissemination of whatever prognostic information is available 
assumes therefore a greater importance. We confirm that lymphatic invasion 
predicts prognosis, while depth of invasion could not be correlated with survival, 
except for a marked decline when tumor was present at the resection margin or 
invaded the thyroid gland. We therefore conclude that even in cases where tumor 
invades peritracheal fibroadipose tissue, excellent survival can be achieved provided 
the patient undergoes surgical resection and the resection is complete. Positive 
resection margins in turn predict treatment failure. Our previous report showed that 
outcome in patients with unresected tumors is worse than in patients that underwent 
resection 5, a finding supported here by the poor prognosis in patients with 
incomplete resection. Thus, tumor resectability, usually dictated by tumor length in 
the long axis of the airway and invasion of vital organs, may possibly be the single 
most important prognostic factor in this very distinct type of cancer.
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ABSTRACT
Purpose: We wished to investigate the influence of tumor and resection 
characteristics on survival in adenoid cystic carcinoma (ACC) of the trachea.
Methods: A retrospective study of 12 laryngotracheal, 58 tracheal, and 
38 carinal resections for primary ACC in 108 consecutive operative survivors 
between 1962 and 2007 was conducted. Postoperative radiotherapy was 
administered to 82% of patients (89/108). Depth of invasion, extramural extent, 
organ invasion, perineural growth, margin status, and lymph node involvement 
were described.
Results: Tumor was intramural in 15% (16/108), extramural in 85% 
(92/108), and invaded adjacent organs in 20% (22/108). Airway margins were 
grossly positive in 9 (8%), microscopically positive in 59 (55%) and negative in 
40 (37%) of 108 resections. Adventitial (radial) margins of transmural sections 
were grossly positive in 3 (3%), microscopically positive in 95 (88%) and 
negative in 10 (9%). Perineural growth was present in 37 (34%), absent in 12 
(11%) and not observed in 59 (55%). Lymph nodes were positive in 16 (15%), 
negative in 45 (42%) and not sampled in 47 (44%). Median overall (OS) and 
disease-free survival (DFS) for the entire group were 17.7 and 10.2 years. OS 
was longer after resection with negative airway margins (20.4 vs. 13.3 years, P 
= 0.028), negative radial margins (21.7 vs. 13.3 years, P = 0.050) and absence 
of extramural disease (21.7 vs. 13.3 years, P = 0.007), perineural growth (22.8 
vs. 7.5 years, P = 0.011), or lymph node metastases (16.8 vs. 6.1 years, P = 
0.017). DFS was longer after resection with negative airway margins (16.6 vs. 
9.3, P = 0.005) and absence of extramural disease (17.9 vs. 9.3 years, P = 
0.008), perineural growth (17.9 vs. 6.6 years, P = 0.033), or lymph node 
metastases (10.2 vs. 3.0 years, P = 0.005).
Conclusions: After tracheal resection for ACC, limited tumor extent and 
complete resection are associated with longer overall and disease-free 
survival. Long-term survival (> 10 years), however, is also observed after 
tracheal resection of locally advanced ACC.
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Introduction
Adenoid cystic carcinoma (ACC), the second most common tracheal tumor, is a 
malignant gland tumor known for its distinct epidemiologic, clinical, pathologic and 
oncologic characteristics. ACC is not related to smoking, equally distributed among 
sexes and mean age at presentation is lower than in bronchogenic carcinoma 1. 
While patients with ACC of the trachea are usually excellent operative candidates, 
their tumors often exhibit extensive submucosal and perineural spread. Tumor-free 
resection margins may therefore be difficult to achieve without excessive 
anastomotic tension.
Due to insidious growth, prolonged survival may be observed even following 
palliative treatment. Consequently, long-term follow-up (> 15 years) is important for 
survival and recurrence analysis.
Complete surgical resection of ACC is associated with long survival 2,3 The impact of 
lead-time bias and the role of microscopic tumor at the resection margins or in lymph 
nodes, however, are less clear than for bronchogenic carcinoma. Regnard and 
associates 4 described 62 patients with ACC, in whom survival in patients with 
complete resection was better than in patients with incomplete resection, although 
this difference was not statistically significant. In the most recent review of MGH 
data, tumor-positive lymph nodes significantly lowered survival in patients with 
squamous cell carcinoma, but had no effect on survival in patients with ACC 2. To 
further elucidate the impact of pathologic factors on overall and disease-free survival 
and to assess the role of resection margins and lymph node metastases, a 
retrospective review of patients with primary ACC of the trachea that underwent 
resection at our institution was conducted.
Patients and Methods
Patient Selection
A retrospective analysis of all patients with resection for primary ACC of the trachea 
since 1962 was conducted at Massachusetts General Hospital (MGH). Medical 
records, Department of Pathology databases and the thoracic surgical database 
were searched to identify tracheal tumors. Patients who underwent their first 
resection elsewhere were included if the purpose of the second procedure at MGH 
was complete tumor excision. Pathology reports, operative reports, and hospital 
charts were reviewed to exclude laryngeal cancer and tumors of the lung extending 
to the carina. Because this study aims to investigate disease-specific survival rather 
than procedure-specific survival, patients who died prior to discharge (operative 
deaths) were also excluded. The MGH institutional review board approved previous 
retrospective studies and the most recent protocol (No. 2006-P-002009/3) in March 
2008. Consent was received from patients before obtaining follow-up information.
chapter
3 2
53
Chapter 3.2
Types of Resection
The surgical technique has been detailed previously 5 Resections were grouped by 
anatomic region and extent. The trachea was divided into three parts from the cricoid 
to the carina. The location was recorded as proximal when tumor occupied the 
distance from cricoid to 3 centimeters below the cricoid and distal from the carina to 
3 centimeters above the carina, while tumors located between proximal and distal 
were labeled middle. Designations of tumor location made by the airway surgeon 
were followed when applicable.
For standard tracheal resection, a sleeve of trachea was removed with end-to-end 
reconstruction. When tracheal resection was combined with laryngectomy, cervical 
or mediastinal end-tracheostomy was required. For laryngotracheal resection, the 
tumor was removed with a portion of infraglottic larynx while preserving at least one 
recurrent laryngeal nerve not involved with tumor. Reconstruction was achieved by 
shaping the remaining trachea to conform to the laryngeal defect. Carinal resection 
was performed with or without concomitant lung resection. Carcinomas involving the 
carina by extension from the lung or a mainstem bronchus were excluded from 
analysis. Systematic lymph node dissection was assumed to interfere with the 
tracheal blood supply and was therefore not performed. Regional lymph nodes were 
often not included in the specimen if not grossly enlarged. Absence of tumor at the 
airway margins was confirmed by frozen section unless the limits of resection had 
been reached and no additional trachea could be removed.
Tumor Data
Operative and pathology reports were reviewed for the assessment of airway and 
adventitial margins of transmural sections (radial margin). Resection margins were 
regarded as grossly positive when visible tumor was noted by surgeon or 
pathologist. Tumor dimension in the long axis of the airway, extramural invasion, 
perineural growth, lymph node metastases and the presence of microscopic tumor at 
airway and radial resection margins were recorded as noted in the pathology report. 
Microscopically positive airway margins indicated true residual tumor by pathologic 
evaluation. In contrast, the radial margins were interpreted as microscopically 
positive when tumor was within 1 mm of the margin, usually indicating that only a 
thin layer of connective tissue covered the outside of the tumor. Extension through 
the tracheal adventitia was recorded as extramural invasion.
Adjuvant Radiotherapy
Adjuvant postoperative radiotherapy was introduced for malignant tumors during the 
second decade of this experience for close or tumor-bearing margins. After 
bronchoscopic assessment of anastomotic healing, a recommended dose of 54 Gy 
was administered 6 to 8 weeks after resection. Most patients received radiation 
treatment outside Massachusetts General Hospital.
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Follow-Up
Patients and their physicians were contacted for follow-up information. The Social 
Security Death Index was searched. Patients were determined to have died if name, 
date of birth, and social security number matched. Patients were judged to have 
recurrent disease when proven by biopsy or clinically suspect recurrence was 
present. The survival period began on the day of operation. Recurrent disease or 
death concluded the disease-free survival.
Statistical Analysis
In contrast to the earlier report that used an actuarial method 2, median overall and 
disease-free survival after airway resection were calculated using the Kaplan-Meier 
procedure with the log rank test implemented in the SPSS 14.0 statistical software 
program (SPSS Inc, Chicago, IL). Categorical variables were compared with the Chi- 
Square test.
Results
Between 1962 and March 2008, 117 patients with primary adenoid cystic carcinoma 
of the trachea underwent surgical resection. Nine operative deaths, six of these after 
carinal resection, were excluded. The cause of death was related to the anastomosis 
in 5 patients and to respiratory failure in the other 4.
Table 1. Tumor Localization and Types of Operation
n %
Tumor localization in trachea
Proximal 23 21
Middle 27 25
Distal 58 54
Type of operation
Laryngotracheal 12 11
Tracheal 51 47
Tracheal with permanent tracheostomy 7 6
Carinal without pulmonary resection 26 24
Carinal with pulmonary resection 12 11
Total 108 100
chapter
3 2
55
Chapter 3.2
Table 2. Pathologic Characteristics in 108 Cases of 
Adenoid Cystic Carcinoma
n %
Airway resection margins
Grossly positive 9 8
Microscopically positive 59 55
Negative 40 37
Radial resection margins
Grossly positive 3 3
Microscopically positive 95 88
True positive 78 72
Within 1 mm 17 16
Negative 10 9
Extramural extent
Yes 92 85
No 16 15
Invading adjacent organ(s)
Yes 22 20
Esophageal muscle layer 16 15
Thyroid gland 10 9
Recurrent laryngeal nerve 7 6
Strap muscles 4 4
Great vessels 1 1
Pericardium 1 1
No 86 80
Perineural growth
Yes 37 34
No 12 11
Not noted in pathology report 59 55
Lymph node invasion
Yes 16 15
No 45 42
No lymph nodes sampled 47 44
Total 108 100
Overall Characteristics
There were 46 men (43%) and 62 women (57%) with a mean age of 48 years 
(range, 24 to 80 years). Tumor localization and type of operative treatment are 
shown in Table 1. More than half of all tumors were localized in the distal part of the 
trachea, requiring carinal resection in two-thirds. Laryngotracheal resection for ACC 
was performed in 11% (12/108) of cases. In only 7 cases (6%), a permanent 
tracheostomy resulted from resection (laryngectomy in 4, cervical exenteration in 2 
and tracheal resection with permanent tracheostomy in 1). Mean length of resected 
airway was 4.1 cm (range, 1.5 to 8.0 cm).
Postoperative radiation was confirmed in 82% of patients (89/108). Seventeen of 19 
patients who did not undergo postoperative radiation had microscopically positive
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radial margins, while 6 of the 17 had also microscopically positive airway margins 
and 1 a grossly positive airway margin. Between patients with and without 
postoperative radiation, median survival (17.7 vs. 16.8 years, P = 0.81) and disease- 
free survival (10.3 vs. 4.3 years, P = 0.68) did not differ significantly.
Overall Survival and Disease-Free Survival
Mean follow-up in 108 cases was 8.6 years (range, 0 months to 32.5 years). Survival 
follow-up was complete in 59% of patients (64/108), and disease-free survival follow- 
up in 66% (71/108). Median survival was 17.7 years and 5-, 10-, 15- and 20-year 
survival were 78%, 65%, 53% and 43%, respectively. Median disease-free survival 
was 10.2 years and 5-, 10-, 15- and 20-year disease-free survival were 67%, 53%, 
38% and 26%, respectively.
Information derived from pathology reports is detailed in Table 2. Survival and 
disease-free survival data in all pathologic subgroups are shown in Table 3 and 
Figures 1 (A -  E) and 2 (A -  C).
Airway resection margins
Grossly positive airway margins occurred in less than 10% of cases. Survival was 
significantly lower in patients with gross positive airway margins (P = 0.026). In 
patients with negative gross airway margins, pathologic examination of the airway 
resection margins revealed microscopic tumor presence in a little more than half of 
cases.
As depicted in Figure 3A, the presence of gross or microscopic tumor at the airway 
resection margins was related to length of resection, although not in a linear manner. 
After resection of up to 4.6 cm in length, margins were either grossly or 
microscopically positive in 56% (44/78), compared to 80% (24/30) in resections of 
greater length (P = 0.023).
Grossly positive tracheal margins had a marked early negative impact on overall 
survival (Table 3), while the survival of patients with microscopic positive airway 
resection margins decreased and separated from the group with microscopic 
negative airway margins only beyond 15 years (Figure 1A). A distinct advantage in 
disease-free survival was found in favor of tumors with negative airway resection 
margins compared to positive gross and microscopic airway margins, clearly 
separating after 10 years (Figure 2A).
Radial resection margins
Negative gross radial margins were obtained in all but 3 patients and in these, airway 
margins were also grossly positive. However, radial resection margins were 
microscopically close in nearly 90% of cases.
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Table 3. Overall and Disease-Free Survival According to Pathologic Subgroups
Pathologic subgroup
Median
survival
(years) 95% Cl
Survival (%) Median
DFS
5-yr 10-yr 15-yr 20-yr (years) 95% Cl
Disease-Free Survival (%)
5-yr 10-yr 15-yr 20-yr
Airway resection margins
Grossly positive 9 6.1 (2.1-10.1) 56 28 28 28 2.6 (1.2-4.0) 31 31 31 31
Microscopically positive 59 13.3 (6.7-20.0) 75 65 46 33 9.7 (7.8-11.5) t 66 48 24 7
Negative 40 20.4 (15.4-25.4) 86 71 64 57 16.6 (6.7-26.5) 76 63 56 50
Radial resection margins
Grossly positive 3 2.5 (na)
Microscopically positive 95 13.3(7.5-19.2)
Negative 10 21.7(20.1-23.2)
Extramural extent
Yes 92 13.3 (8.9-17.6)
No 16 21.7 (na)
Invading adjacent organ(s)
Yes 22 10.3 (4.1-16.5)
No 86 19.0 (13.4-24.8)
Perineural growth
0.050
0.007
0.257
50
77
100
74
100
69
81
62
100
60
93
52
68
47
100
44
93
31
57
36
100
35
80
31
46
2.3 (na)
9.7 (7.3-12.1)
17.9 (15.2-20.7)
9.3 (7.1-11.4)
17.9 (11.1-24.7)
3.0 (0.0-6.4) 
11.2 (7.2-15.2)
0.090
0.008
0.167
50
64
100
61
100
44
73
50
86
47
93
44
55
33
86
29
85
33
39
25
43
22
49
16
29
Yes 37 1^ cn (4.6-10.4) n m 1 62 40 23 23
CDCD (2.3-10.9) n cm 51 33 27 13
No 12 22.8 (na)
U .U  I I
91 91 91 78 17.9 (16.1-19.8)
u .  u o o
92 80 80 32
Not noted in report 59 19.0 (12.6-25.4) 86 73 58 46 11.9 (8.0-15.8) 72 58 35 31
Lymph node invasion
Yes 16 6.1 (1.4-10.8)
n  n i 7
54 32 16 16 3.0 (2.1-3.9)
n  n n ^
34 7
No 45 16.8 (10.7-22.8)
U .U  I /
76 66 54 38 10.2 (6.7-13.7)
U. UUvJ
63 56 33 20
No lymph nodes sampled 47 21.6 (10.2-33.0) 91 80 71 71 18.4 (10.8-26.0) 86 71 62 47
Overall 108 17.7 (12.0-23.3) 78 65 53 43 10.2 (7.4-12.9) 67 53 38 26
‘ Negative versus positive (n=68), P 
compared (Figure 1A), P = 0.017 
f Negative versus positive (n=68), P 
compared (Figure 2A), P = 0.010
: 0.028. Gross positive versus gross negative (n=99), P = 0.026. Microscopic positive versus negative, P = 0.069. All three 
0.005. Gross positive versus gross negative (n=99), P = 0.074. Microscopic positive versus negative, P = 0.012. All three
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Figure 1. Survival in resected adenoid cystic carcinoma by A. Airway margins; B. Radial margins; C. 
Extramural extent; D. Perineural growth; E. Lymph node invasion
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Figure 2. Disease-free survival in resected adenoid cystic carcinoma by A. Airway margins; B. Radial 
margins; C. Lymph node invasion
The length of resected airway correlated with the presence of tumor at the radial 
margins (Figure 3B). In resections less than 4.6 cm in length, radial margins were 
either grossly or microscopically positive in 88% (69/78), compared to 97% (29/30) in 
resections of greater length (P = 0.19).
Median overall survival in patients with negative radial resection margins, with tumor 
contained by tracheal adventitia, was higher than in patients with microscopically 
positive resection margins (21.7 vs. 13.3 years, P = 0.050, Figure 1B). Disease-free 
survival in patients with negative radial margins was also higher (P = 0.090, Figure 
2B). The small sample size did not allow comparisons with gross radial resection 
margins. Within the subgroup of cases with microscopically positive radial resection 
margins, there were no differences in survival (P = 0.38) or disease-free survival (P =
0.19) between true positive margins (n = 78) and tumor within 1 mm of the radial 
resection margin (n = 17).
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Figure 3. Resection margins by length of resection. A. Airway resection margins; B. Radial resection 
margins
Extramural Extent
More than 80% of tumors grew through the tracheal wall beyond the adventitia. 
Since radial margins are limited by the presence of essential adjacent organs, 
extramural tumor presence was almost always accompanied by exceedingly close, 
or positive, radial resection margins. Invasion through the adventitia was a significant 
prognostic factor for both overall survival (Figure 1C) and disease-free survival. 
Mean overall survival and disease-free survival in 20 tumors without extramural 
extent exceeded 20 years, and their 20-year survival was 72%.
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Invasion of Adjacent Organs
In most cases of organ invasion, more than one organ was invaded, typically a 
combination of thyroid gland and esophageal muscle coat. Organ invasion did not 
impact overall (P = 0.26) or disease-free survival (P = 0.17) if all gross tumor was 
removed.
Perineural Growth
The pathology report included a statement on the presence or absence of perineural 
growth in 46% (49/108), and in 37 of these (76%), there was perineural growth. 
Absence of perineural invasion was specifically observed in only 11% of pathology 
reports (12/108). The presence of perineural growth decreased both overall survival 
(Figure 1D) and disease-free survival. In cases where the absence of perineural 
growth was recorded, survival (P = 0.18) and disease-free survival (P = 0.11) were 
similar to cases in which no statement on perineural growth was included in the 
pathology report.
Lymph Node Invasion
Lymph nodes were sampled in 57% of resected tumors (61/108) and found to be 
positive in 26% (16/61). The lymph node stations in these 16 cases were 
paratracheal in 9, paratracheal and hilar in 3, subcarinal in 2, and hilar only in 2. 
Overall survival (Figure 1E) and disease-free survival (Figure 2C) were significantly 
lower in patients with lymphatic invasion. No significant survival differences existed 
between patients with negative and without sampled lymph nodes.
Discussion
This study describes the influence of pathologic characteristics on long-term survival 
in a consecutive series of patients undergoing surgical treatment for primary tracheal 
ACC. Our most recent review included analysis of prognostic value of lymph node 
status in 96 cases of ACC and airway resection margins in 82 cases using an 
actuarial survival analysis 2 In the current review, new cases were added, follow-up 
was updated and operative deaths were excluded. We analyzed survival and 
disease-free survival in 108 cases of resected ACC using the Kaplan-Meier method 
according to detailed review of airway and radial resection margins, extramural 
extent, invasion of adjacent organs, perineural growth and lymph node status.
Airway and radial resection margins were important prognostic factors for both 
survival and disease-free survival. Patients with grossly positive airway margins had 
significantly worse survival than patients with grossly negative resection margins. 
Microscopically positive airway margins, present in nearly half of all patients, were 
associated with lower survival and correlated with poorer disease-free survival. Due 
to the high rate of extramural extent, microscopically positive radial resection 
margins occurred in 88% of patients. Positive microscopic radial margins, probably a 
surrogate for larger tumor mass in this study, led to a significant decline in both
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survival and disease-free survival. Invasion of adjacent organs did not seem to affect 
survival. En bloc resection of invaded organs, such as the thyroid or the esophageal 
muscle coat, resulted in acceptable long-term survival, as long as negative radial 
margins can be obtained. In the multi-institutional study by the French Society of 
Thoracic and Cardiovascular Surgery 4, 5-year survival was 82% in 36 patients with 
complete resection for ACC, and 63% in 26 patients with incomplete resection. This 
and another study of 29 cases of resected ACC 6 document the difficulties of 
establishing statistically significant observations in this rare tumor. The limited follow- 
up period may have been inadequate to demonstrate meaningful differences in 
survival.
Regnard and associates reported that there was no correlation between survival and 
lymph node status in either tracheal ACC or non-ACC tracheal cancer 4 In our 
previous report 2, lymph node-positive SCC had a markedly lower survival than 
tumors without nodal metastasis, while in ACC, no such difference was observed. In 
the current series, to assess the impact of lymph node status on survival, only 
lymph-node biopsied patients were compared. Patients with lymph node metastasis 
had a markedly lower overall and disease-free survival than patients with negative 
lymph node biopsies. As demonstrated in Table 3, survival of patients who did not 
have any lymph nodes sampled was comparable to that of patients with negative 
sampled lymph nodes. A lack of difference here may be explained by the limited 
information gained from non-systematic lymph node sampling alone: both groups of 
patients may contain similar proportions of undisclosed lymph node disease.
Another important prognostic factor was perineural growth. Although widely reported 
as predictor of tumor aggressiveness and survival in head and neck and bronchial 
carcinoma, the impact of perineural invasion has not previously been described for 
tracheal carcinoma. The presence or absence of perineural growth was not noted in 
the pathology report in 55% (59/108) of patients. Most likely, in cases where 
perineural growth was present, the pathology report included a statement on this 
feature. The absence of this growth characteristic, however, was probably lacking in 
around half of all cases. This is supported by the distinct difference in survival 
between cases where perineural invasion was present and those where either no 
statement on perineural invasion was present in the pathology report or perineural 
growth was absent. In these latter two groups, overall and disease-free survival was 
similar in length. Given its importance, we recommend to always include a statement 
regarding perineural growth in the pathology reports describing all specimens of 
tracheal tumors.
Since both perineural growth and extramural extension through the tracheal 
adventitia were important prognostic factors, these should likely be incorporated in 
any staging system of tracheal ACC. Both currently proposed non-validated staging 
guidelines for tracheal cancer are however TNM-based 78, leading to greater 
emphasis on lymph nodes although systematic lymph node sampling should not be 
part of resection to preserve tracheal blood supply. In the absence of systematic
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lymph node sampling, it is important for the surgeon to resect visibly enlarged lymph 
nodes and for the pathologist to thoroughly examine the paratracheal tissue of the 
resected tracheal segment for the presence of lymph node tissue and lymphatic 
spread.
When frozen section reveals microscopic tumor at the tracheal margin, complete 
resection would demand further shortening of the trachea in order to reach tumor­
free tracheal wall as long as anastomotic tension is modest. Since failure of the 
anastomosis may lead to dehiscence, if not death, in patients with a slow-growing 
malignancy, a microscopically positive resection margin may have to be accepted. 
The survival analysis in this study has shown that patients undergoing tracheal 
resection for ACC with negative and microscopically positive airway margins have a 
good long-term prognosis, while survival is short when residual gross tumor remains. 
Thus, surgical resection of the tumor remains the treatment of choice in this rare 
airway tumor.
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ABSTRACT
Background: The aim of this study was to assess the incidence, 
characteristics, treatment and survival of patients with tracheal malignancies in 
the Netherlands.
Methods: All cases of tracheal cancer entered into the database of the 
Netherlands Cancer Registry in the period 1989-2002 were selected. Data on 
histologic type, age at time of diagnosis, treatment and survival were analyzed 
retrospectively.
Results: The annual incidence was 0.142 per 100,000 inhabitants (308 
cases, of which 15 were found incidentally at autopsy). Of these, 72% were 
men. In 52.9% the histologic type was squamous cell carcinoma and in only 
7.1% adenoid cystic carcinoma (ACC). Mean age at time of diagnosis was 
64.3 years. Of the 293 patients diagnosed while alive, 34 patients underwent 
surgical resection (11.6%), 156 patients received radiotherapy (53.2%), and 
103 patients neither (35.4%). Median survival of all 293 patients was 10 
months (mean 28 months) with 1-year, 5-year and 10-year survival rates of 
43%, 15% and 6%, respectively. The prognosis of patients with ACC was 
significantly better. The 5-year survival rate in patients who underwent surgical 
resection was 51 % and the 10-year survival rate in these patients was 33%.
Conclusion: The prognosis of patients with a tracheal malignancy is 
usually poor. Surgical treatment, however, can lead to good survival rates; still, 
this is currently only used in selected patients, even though it would seem to 
be possible in more cases in view of the technical advances in the field of 
tracheal surgery. Centralizing the care and treatment of tracheal cancers and 
implementing a more assertive attitude towards this disease could make 
surgery accessible to a larger number of patients. Data from the literature 
show that this would lead to a better survival in patients with a tracheal 
malignancy.
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Introduction
Primary tracheal cancer is rare and its incidence is very low compared with laryngeal 
or bronchial cancer. The annual incidence of tracheal cancer is approximately 0.1 
per 100,000 persons 12, accounting for only 0.2% of malignant neoplasms of the 
respiratory tract 3,4 and only 0.02-0.04% of all reported malignancies 1,5 Because of 
its low incidence, knowledge of the epidemiology, etiology, prognostic factors and 
methods of treatment is limited. Tracheal cancer is more common in men and 
patients with a history of smoking, the latter group making up 77-86% of all patients 
with tracheal cancer. Median age at the time of diagnosis is 67 years 5,6 The 
prognosis of patients diagnosed with tracheal cancer is poor, the 5-year survival rate
being 5-35% 2,5-8.
Surgery with or without irradiation is considered to be the treatment of choice 2,6,9-12 
for two histologic types of primary tracheal carcinoma, with different characteristics: 
squamous cell carcinoma (SCC) and adenoid cystic carcinoma (ACC) 67,10,11,13. Licht 
et al. (2001) concluded that a nihilistic attitude exists, based on ignorance of the 
surgical treatment of tracheal cancers. In Denmark, less than 10% of all patients with 
tracheal cancer were treated surgically, whereas patients undergoing this type of 
treatment had better survival rates compared with patients undergoing other types of 
treatment 5 These findings are in line with those of Manninen et al. in 1993 6 If 
ignorance of surgical treatment is so widespread, the management of tracheal 
cancer could certainly be improved. A more aggressive approach towards tracheal 
cancer might lead to improved survival in patients diagnosed with this disease.
In the Netherlands, all hospitals are associated with one of the nine regional cancer 
registries (Comprehensive Cancer Centers), which submit their data to the national 
database of the Netherlands Cancer Registry (NCR), thus creating a systematic 
collection of data on all malignant neoplasms occurring in the Netherlands since 
1989. This provides the prerequisites for a reliable nationwide study on tracheal 
cancer. The goal of this study was to assess the incidence, characteristics, treatment 
modalities and treatment outcome of tracheal cancer in the Netherlands.
Materials and Methods
In the Netherlands, a population-based cancer registry exists. Nine regional cancer 
registries gather data on patient characteristics, topography, morphology, stage and 
treatment of cancer. The main source of notification is a national archive of 
pathology reports. This is completed with data from the National Hospital Discharge 
Registry. After notification, specially trained registrars collect data from the patient 
files in the hospitals.
For the current study, all cases of primary tracheal cancer reported in the files of the 
Netherlands Cancer Registry (NCR) between 1989 and 2002 were selected. The 
regional cancer registries provided data on patient characteristics, clinical
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information, pathologic data and treatments given with regard to the tracheal cancer, 
as well as the occurrence of other malignant tumors before or after the diagnosis of 
tracheal cancer. For these other tumors, the localization, histologic type and date of 
diagnosis were recorded. Furthermore, the date of death was recorded and, if not 
applicable, the date of the most recent follow-up. All data were stored in a database 
designed especially for the study.
The annual incidence as an average over the 14-year period was calculated using 
data from Statistics Netherlands (Centraal Bureau voor de Statistiek, CBS). During 
the period of the study, the number of inhabitants in the Netherlands increased from
14.8 million in 1989 to 16.1 million in 2002. The average size of the population in this 
period was 15.4 million. Survival was calculated from the time of diagnosis until the 
last follow-up and analyzed using the Kaplan-Meier procedure with the log-rank test 
to compare survival functions. Statistical analysis was performed using the statistical 
program SPSS 12.0.1.
Results
During the 14-year period between 1989 and 2002, 312 cases of tracheal cancer 
were reported in the files of the Netherlands Cancer Registry. After reviewing the 
tumor localization, four patients were excluded, of which two had a lymphoma, one a 
laryngeal carcinoma and one a bronchial carcinoma. Finally, 308 cases were 
regarded as true cases of primary tracheal cancer and included for further 
investigation. These cases accounted for 0.034% of all recorded malignancies in this 
period. The calculated annual incidence in this period is 0.142 per 100,000 
inhabitants.
Table 1. Histologic Types in 308 Tracheal Cancer Cases in the Netherlands
Histologic type n %
Squam ous cell carcinom a (SCC) 163 52.9
Small cell carcinom a 34 11.0
Epithelial large cell carcinom a 23 7.5
Adenoid cystic carcinom a (ACC) 22 7.1
Adenocarcinom a 19 6.2
Carcinoid 4 1.3
Papillary SCC 2 0.6
N euroendocrine carcinom a 2 0.6
M ucinous adenocarinom a 2 0.6
Adenosquam ous carcinom a 2 0.6
M alignant m elanoma 2 0.6
Carcinoma, not otherwise specified 24 7.8
O ther 9 2.9
Total 308 100.0
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Seventy-two percent of all tracheal cancers were diagnosed in men (n=223) and 
28% in women (n=85). The most common histologic type was SCC, which was 
observed in 52.9% of all patients (n=163). The distribution of all histologic types is 
shown in Table 1. In patients with ACC, the male/female ratio was 1:1 but all other 
histologic types of tracheal cancer were found predominantly in males.
Fifteen cases (4.9%) were found incidentally at autopsy and 293 were diagnosed 
while the patients were alive and confirmed by histopathologic examination. This 
latter group was used for a more detailed analysis and investigation of the age 
characteristics, treatment modalities and survival outcome.
The mean age at diagnosis was 64.3 years (range 30-95 years). An analysis of the 
relationship between histologic type and age revealed a lower age at diagnosis for 
ACC (mean 59.5 years) compared to patients with SCC (mean 64.7 years, Table 2); 
this difference was almost significant (p=0.054).
Table 2. Age According To Gender And Histologic Type
n
Mean age 
(in years) Range
Overall 293 64.3 30 - 95
Sex
Male 213 64.5 30 - 95
Female 80 63.8 35 - 89
Histologic type*
SCC 156 64.7 35 - 95
Small cell carcinoma 32 65.9 43 - 87
Epithelial large cell carcinoma 23 62.5 45 - 79
ACC 21 59.5 38 - 93
Adenocarcinoma 19 61.4 31 - 88
Other 42 66.2 30 - 89
* P -value 0.054
SCC = squamous cell carcinoma; ACC = adenoid cystic carcinoma
Thirty-four (11.6%) of the 293 patients underwent surgical resection as the primary 
treatment; of these, 23 received additional radiotherapy. One of these 23 cases also 
underwent endobronchial laser therapy. Radiotherapy as the primary treatment was 
given to 156 (53.2%). Additionally, 12 of these 156 patients received some form of 
endobronchial treatment, focused mainly on tumor reduction, and another 12 
patients received chemotherapy. Of the remaining 103 patients (35.2%) who did not 
receive either radiotherapy or surgery, 20 patients were treated with chemotherapy 
and 10 received endobronchial treatments such as laser therapy with palliative 
intent.
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Table 3. Localizations of Prior, Concurrent 
and Second Primary Tumors (N=85)
Localization n %
Bronchus/lung 46 45.5
Head & neck 17 16.8
Skin 11 10.9
Bladder 4 4.0
Esophagus 4 4.0
Breast 4 4.0
Thyroid gland 3 3.0
Trachea 2 2.0
Stomach 2 2.0
Other 8 7.9
Total 101 100.0
Eighty-five patients (29%) had a total of 101 
other primary malignancies (Table 3) before 
or after their tracheal cancer was diagnosed 
(a mean of 1.2 other primary malignancies 
per person). Of these tumors, 56% were 
SCC and 12% were adenocarcinoma. 
Seventy-three of these other primary 
tumors were found before the carcinoma in 
the trachea, 20 were diagnosed in the same 
year and eight were discovered after the 
diagnosis of tracheal cancer. More than half 
of these second primary tumors were 
located in the respiratory tract.
Table 4. Survival in Tracheal Cancer According to Histologic Type and Type of Treatment
Survival (months) Survival rates (%)
n Median Mean 1 -year 2-year 5-year 10-year
Histologic type* SCC 156 10 24 45 29 12 0
ACC 21 - * 107 95 89 61 61
Other types 116 7 18 32 17 9 3
Treatment* None / other 103 3 13 25 17 4 3
Radiotherapy 156 11 24 47 27 11 0
Surgery 34 82 79 79 69 51 35
Overall 293 10 28 44 29 15 6
* P -value < 0.0001
* More than 50% of patients with ACC are alive at date of follow-up 
SCC = squamous cell carcinoma; ACC = adenoid cystic carcinoma
The 10-year follow-up is complete in 223 of 293 patients (76.1%). The overall 
median survival (n=293) was 10 months (mean 28 months) with a 1-year survival 
rate of 43%, a 5-year survival rate of 14% and a 10-year survival rate of 6% (Table 4 
and Figure 1). Surprisingly, the survival of patients who had one or more other 
primary tumors (n=85) was not significantly different from that of patients without 
other primary tumors (n=208): median survival times of 16 months (95% CI 9-23 
months) and 8 months (95% CI 5-11 months), respectively (p=0.0896). The survival 
following different methods of treatment did differ and was significantly better after 
surgery (p<0.0001, Table 4). For surgically treated patients without radiotherapy 
(n=11), the median survival was 91 months (mean 79 months). When surgery and 
radiotherapy were combined, median survival was 82 months (mean 80 months). 
Overall, for surgically treated patients (n=34), median survival was 82 months (mean 
79 months). Patients treated with radiotherapy alone had a median overall survival
70
Incidence and Treatment of Tracheal Cancer
chapter
4 1
Figure 3.
Months
Figure 4.
0 20 40 60 80
Months
Figures 1-4. Survival in months. 1. Overall survival of tracheal cancer in the Netherlands (n=293); 2. 
Survival by treatment; 3. Survival by histologic type; 4. Survival in patients with SCC (n=156) by 
treatment. SCC = squamous cell carcinoma; ACC = adenoid cystic carcinoma
time of 11 months (median 24 months). In the group of patients who did not receive 
either surgical treatment or radiotherapy the median survival time was 3 months 
(mean 13 months). The 5-year overall survival rates were 51% for patients who 
underwent surgical treatment, 11% for patients treated with radiotherapy alone and 
only 5% for patients who received neither surgery nor radiotherapy. In the latter 
group, there were no differences in survival between patients treated with 
chemotherapy, laser therapy or who received no treatment. Ten years after 
diagnosis, only three of the 260 patients who were not treated surgically were alive.
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The 10-year overall survival rate for patients treated surgically, with or without 
radiotherapy, is 33% (Figure 2).
Except for ACC, there were no significant differences in survival between the 
different histologic types. The survival of patients with ACC was significantly better 
than that for all other histologic types (p<0.0001, Table 4 and Figure 3). Eleven 
(52.4%) of 21 cases of ACC underwent surgery, which was combined with 
radiotherapy in eight. These 11 cases made up 32.4 % of all surgically treated 
patients. Other histologic types in this group included eighteen patients with SCC 
(52.9%), two epithelial large cell carcinomas (5.9%), one carcinoid (2.9%), one 
epithelial-myoepithelial carcinoma (2.9%) and one malignant melanoma (2.9%).
The differences in survival following different methods of treatment were also 
investigated in the histologically homogeneous group of patients with SCC who were 
alive at diagnosis (n=156). The survival time within this group in relation to method of 
treatment showed nearly the same outcome per treatment modality as the overall 
outcome (p<0.0001, Table 5 and Figure 4). Survival of patients treated with surgery 
only (n=5) and patients treated with surgery and radiotherapy (n=13) did not differ 
significantly (median 49 months and median 23 months respectively).
Table 5. Survival in Tracheal Squamous Cell Carcinoma By Type of Treatment (P<0.0001)
Treatment n
Survival (months) Survival rates (%)
Median Mean 1-year 5-year
None / other 49 2 11 23 3
Radiotherapy 89 13 24 50 11
Surgery 18 31 49 77 41
Total 156 10 24 45 12
Discussion
In this study, data from the Netherlands Cancer Registry (NCR) were used and 
reviewed retrospectively. Data collection and data management were carried out on 
a nationwide basis and related to the histologic diagnosis 14 We included all cases of 
tracheal cancer reported in the files of the NCR and found that four of 312 reported 
cases were misclassified (1.3%). In two other epidemiologic studies, the frequency of 
misclassification of tracheal tumors (16-29%) led to the conclusion that the incidence 
may be overestimated 1,5
According to the study of Licht et al., tracheal cancer in Denmark makes up 0.02% of 
all reported malignancies; in our study, this proportion was higher (0.034%). This 
might indicate that some of the 308 cases of tracheal cancer that we found were 
misclassified. However, the data on all cases were extracted from the patients’ 
medical records and checked individually by trained registration employees of the
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Comprehensive Cancer Centers before being entered into the NCR 14 For the 
coding of the data, national and international standards are used. Although 
registration errors will occur, it is unlikely that the difference between the results of 
Licht et al. and ours can be explained by misclassification.
Only a few other epidemiologic studies on tracheal cancer have been performed. In 
Finland, the annual incidence of tracheal cancer is 0.104 per 100,000 inhabitants, 
and the proportion of all malignancies accounted for by tracheal cancer (0.038%) 1. 
This is in accordance with the figures in the Netherlands, which are 0.142 per 
100,000 inhabitants and a proportion of 0.034% of all malignancies 
Licht et al. in Denmark found that 17% of all cases of tracheal carcinoma were found 
incidentally at autopsy 5, whereas in our study this was only 4.9%. This is probably 
due to the difference in the total number of autopsies per year: in Denmark, autopsy 
is performed in 27% of all deaths 5, while in the Netherlands it is only performed in 
7% 15.
Table 6. Treatment Modalities and Distribution of Histologic Types in 5 Epidemiologic Studies
Author Year Period Type* Cases Histology (n) Overall treatment'1' (n)
Licht** 2001 1978-1995 N 109 63% SCC (69) 
7% ACC (8) 
29% other (32)
7% surgery (6) 
46% RT (42) 
48% othertt (44)
Yang 1997 1979-1994 S 67 52% SCC (35) 
8% ACC (5) 
40% other (27)
18% surgery (12) 
73% RT (49)
9% other (6)
Manninen 1993 1967-1985 N 95 72% SCC (68) 
6% ACC (6) 
22% other (21)
6% surgery (6) 
63% RT (60) 
31% other (29)
Gelder 1993 20 years P 321 54% SCC (174) 
11% ACC (34) 
35% other (113)
10% surgery (31) 
62% RT (199) 
28% other (91)
Kurien 1981 1957-1974 R 97 46% SCC (45) 
3% ACC (3) 
51% other (49)
7% surgery (7) 
27% RT (26) 
66% other (64)
Present study** 2005 1989-2002 N 308 53% SCC (163) 
7% ACC (22) 
40% other (123)
12% surgery (34) 
53% RT (156) 
35% other (104)
Total 997 56% SCC (554) 
8% ACC (78) 
37% other (365)
10% surgery (96) 
55% RT (532) 
35% other (338)
* N = national registration, S = single institution, P = nationwide postal survey, R = regional 
registration
'  Primary treatment is stated. Surgery includes cases with adjuvant radiotherapy. ‘Other' therapy 
also includes none
** Cases found at autopsy were excluded from treatment analysis 
ft  Of which 24 patients underwent endoscopic local resection
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When one looks at the available literature on the distribution of the histologic types of 
tracheal cancer (Table 6), it is striking that in all epidemiologic studies, including 
ours, SCC accounts for 46-72% of all cancers while ACC makes up only 3-11% 25­
716. In contrast, in studies performed in surgical clinics, ACC is seen in 30-50% of all 
cases 11,17-20 In a study by Bhattacharyya, based on the U.S. SEER database, 19 of 
92 cases of tracheal cancer consisted of ACC (20.7%). However, patients with 
distant metastasis were excluded in this study 21. Gaissert suggests that this 
disparity in the distribution of histologic types of tracheal cancer could be explained 
by the absence of radiologic and pathologic review of cases in epidemiologic studies 
17 However, this is the third national epidemiologic study in which a lower 
percentage of ACC was found. All our cases were registered nationally only on the 
basis of a histologic diagnosis. Still, in all three of the national epidemiologic studies 
mentioned above, 47-80% of patients with ACC underwent surgical resection, while 
overall, only 6-18% received surgery. In a Danish national study, small cell and large 
cell carcinoma accounted for 7.3% and 1.8% of all cases respectively 5, while in our 
study these portions were 11.0% and 7.5% respectively. An explanation for these 
relatively high incidences could not be found, as pathology slides were not reviewed 
in this retrospective chart review. Gelder and Hetzel also observed an unexpected 
high incidence of small cell carcinoma (6%) 7.
In our patients, more than 50% of those with ACC received surgical treatment, 
compared to only 8.1% of the patients with other histologic types of primary tracheal 
carcinoma. More than 30% of all surgically treated patients had ACC. Moreover, it 
seems that patients with ACC are more often operable than patients with other 
histologic types 22 These results are suggestive of a selection bias in studies from 
surgical clinics, as a result of which ACC appears to be a common histologic type.
It was already known that most patients with tracheal cancer are male 1,23 ACC is 
associated with a more equal distribution between the sexes or may even be found 
predominantly in females 24 Another characteristic of ACC is that it is found in 
younger patients. Gelder and Hetzel found a mean age of 50 years in 34 patients 
with ACC 7 The 135 patients with ACC in the study of Gaissert et al. had a mean 
age of 49 years 9. In our study, this difference in age was less clear and in fact not 
significant (p=0.054). The mean age of patients with ACC was almost 60 years (with 
an equal distribution between males and females). Patients with ACC have by far the 
best prognosis of all histological types, regardless of treatment modality 616,19, which 
is also confirmed by our series (Table 4). In our study, patients with ACC had a 10- 
year survival rate of 61 %.
We also analyzed the impact of other primary tumors, prior to or after the diagnosis 
of tracheal cancer, on survival. However, no significant effect on survival was found. 
León et al. found that 16% of patients with malignancies of the head and neck 
developed other primary tumors, which led to a significant decrease in survival 25. 
The high incidence of other primary tumors is closely related to the abuse of tobacco 
and alcohol 26. It is known that the vast majority of patients with tracheal cancer are 
smokers. Of all patients with primary tracheal cancer, 77-86% smoke or have a
74
Incidence and Treatment of Tracheal Cancer
history of smoking 1,5,7 This predominance is even more explicit in patients with 
SCC, of which 89-92% are smokers, whereas ACC is distributed more equally 
between non-smokers and smokers, the latter group making up 45-60% of all 
patients with ACC 7,9,27
According to the studies listed in Table 6, 6-18% of all patients with tracheal cancer 
underwent surgery as their primary treatment, 27-73% were treated with 
radiotherapy and 9-66% had other types of treatment or best supportive care. These 
figures correspond to those for patients with tracheal cancer in the Netherlands 
during the period 1989-2002. When we look at the survival following different 
methods of treatment, it is clear that patients who underwent surgical resection of 
their tracheal cancer survived longer than patients who were treated otherwise 
(p<0.0001). One of the reasons for this difference is that ACC makes up 32.4% 
(n=11) of the group of operated patients (n=34). Nevertheless, when we looked at 
the patients with SCC separately, we found that in this histologically homogeneous 
group, patients treated with surgery had a 5-year survival of 41% compared to 11% 
in patients treated with radiotherapy (p<0.0001, Table 5). This indicates that, 
irrespective of histologic type, surgical treatment yields the best survival. The 
differences in outcome between surgery with and without adjuvant radiotherapy were 
not analyzed separately, since radiotherapy was used in patients selected by staging 
information and surgical margins. In a French multicenter study including 208 cases 
of tracheal tumors, Regnard et al. found that the 5-year survival rate after surgery 
was 62% 11. However, this may be too optimistic, since 11% of the included tumors 
were benign. Gaissert et al. included 270 cases of tracheal cancer, half SCC and 
half ACC, and achieved a 5-year survival rate of 56% in operated cases 9 A 
Japanese study even showed a 5-year survival rate of 72% in surgically treated 
patients, although this group consisted of only 16 patients, of which nine had SCC 
and seven had ACC 19 Given these good results, the available literature on tracheal 
cancer shows consensus regarding treatment: surgery is the only realistic treatment 
with curative intent and leads to the best survival rates 18,28 However, not all tumors 
in patients presenting with tracheal carcinoma are resectable due to locally 
advanced disease, metastatic disease or contraindicating co-morbidity 12,29 
Several other treatment modalities have been described. Endoscopic resection can 
be used to relieve airway obstruction but does not provide complete resection and 
the chances of a cure are therefore minimal 17 Radiotherapy can also be used as 
palliation or as adjuvant treatment after surgery 30,31. Webb et al. recommend 
adjuvant radiotherapy in patients treated with surgical excision 27. Very poor survival 
rates in patients treated with radiotherapy alone are seen in most studies. A French 
study by Mornex et al. reported a 5-year survival rate of 8% in 82 patients treated 
with radiotherapy 8, and Makarewicz reported a 5-year survival rate of 9% in 23 
cases in 1998 32 Our data show a 5-year survival rate of 11% in patients treated by 
primary radiotherapy. The application of endotracheal brachytherapy after external- 
beam irradiation has shown to improve local tumor control. This relatively new 
treatment modality is subject of future research to further optimize the management
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of tracheal tumors. Cisplatinum based chemotherapy is the treatment of choice for 
selected patients with disseminated and locally advanced disease. The intent of 
chemotherapy is usually palliative and chemotherapy can only be advised in patients 
with a good performance status. Small cell cancer of the trachea is very rare and is 
often part of a disseminated disease where chemotherapy can be successful but no 
large trials have been published 33 There is very little data available on the effect of 
adjuvant or neoadjuvant chemotherapy or concurrent chemoradiotherapy of non 
small cell tracheal carcinomas 34
It can be expected that only patients in the best clinical condition and with the most 
favorable tumor stage are offered surgery, thus affecting the survival rate. Still, 
Gaissert 17 and Macchiarini 12 state that, unless technically impossible, surgery 
should be the treatment of choice in patients with tracheal cancer. The 
implementation of this recommendation is impeded by the lack of a uniform staging 
system for tracheal cancer, because the classic TNM-staging cannot be applied. 
New staging systems for tracheal carcinomas have been suggested by 
Bhattacharyya 21 and Macchiarini 12 The value of these systems should be subject 
of future research projects.
Hazama et al. and Gaissert concluded that resection is indicated in even more than 
50% of all patients with tracheal cancer 17,20. This is in contrast to all the studies 
listed in Table 6, including our study, in which only 10% were treated surgically. The 
reason why surgery is considered in only a few cases may be that only few centers 
have gained experience in the management of tracheal malignancies because of 
their rarity 17. This is also supported by Gelder and Hetzel 7 Licht et al. also report a 
nihilistic attitude towards the management of tracheal cancer in Denmark 5. Based 
on our findings, this also seems to be the case in the Netherlands, although future 
research is needed to determine to what extent contra-indications to surgery play a 
role in the low amount of patients treated with surgical resection of their tracheal 
cancer.
Conclusion
Looking at the survival rates in our study, we can conclude that overall, the 
prognosis of patients with tracheal cancer is dismal. Surgery of patients with a 
tracheal carcinoma can lead to a significantly better survival, compared to 
radiotherapy. In our patients and in other epidemiologic studies, however, surgery 
was offered to only 10% of all patients. Several studies indicate that surgery would 
be applicable in at least 50% of all cases of tracheal cancer. Whether this 
discrepancy is based on a difference in patient population or unawareness among 
physicians about developing treatment possibilities needs to be investigated. 
Research should be conducted to develop a standard classification that can be used 
to determine resectability. Given the infrequent incidence of this disease, the 
management and treatment of these patients should be performed by
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multidisciplinary teams in centers equipped and experienced with the full range of 
treatment modalities (surgery, radiotherapy, chemotherapy and endobronchial 
treatment) in order to achieve more experience with this rare tumor within these 
teams. We believe that this centralization could lead to better palliative care and may 
improve survival in selected patients. Further studies are needed to evaluate the role 
of adjuvant chemotherapy and concurrent or sequential chemoradiotherapy to further 
improve survival.
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ABSTRACT
Background: National epidemiologic data were examined to determine 
the eligibility for curative therapy in tracheal carcinoma.
Methods: An expert audit of primary tracheal carcinomas registered from 
2000 to 2005 with the Netherlands Cancer Registry (NCR) included blinded 
patient data and radiographic review to assess diagnosis and resectability. 
Actual treatment was compared to the opinions of a multidisciplinary panel 
(Radboud panel) and a second reviewer.
Results: Of 101 NCR-registered primary tracheal carcinomas, the 
Radboud panel diagnosis was metastatic disease or local extension of 
adjacent tumors in 34. Seventeen cases were excluded for missing data. In 50 
cases confirmed by panel and second reviewer, actual treatment consisted of 
surgery in 24% (12/50), radiotherapy in 58% (29/50), endobronchial treatment 
in 12% (6/50), and observation in 6% (3/50). Both panel and second reviewer 
identified 16 additional surgical candidates, a total of 56% (28/50). Treatment 
recommendations of panel and second reviewer disagreed in 4 cases (8%).
Conclusions: One third of NCR-registered primary tracheal carcinomas 
were misclassified non-tracheal primaries involving the trachea. A majority of 
cases meeting audit criteria for diagnosis and surgical resection was treated 
with other modalities. Inter-reviewer disagreement was small. The audit of a 
national cancer registry suggests that incorrect diagnosis and undertreatment 
are common in rare airway tumors.
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Introduction
Primary malignancies of the trachea are rare and challenging tumors. Surgical 
resection of the involved tracheal segment is the treatment of choice 1 and long-term 
disease-free survival have been reported following tracheal resection 2,3 At least half 
of all patients with primary tracheal carcinoma are surgical candidates according to 
clinical series 4,5 The actual treatment of tracheal cancer in the Netherlands as 
reported for the period 1989 to 2002 consisted of resection in only 12% of cases 6 
Identical proportions were found in epidemiologic studies from Denmark and Finland
7,8 The discrepancy between reported ratios of surgical clinics and these 
epidemiologic studies may be in part based on patient selection. However, some 
authors suspected a lack of knowledge and a nihilistic attitude towards the treatment 
of tracheal malignancies 7,8
Previous epidemiologic studies contained database information 7, but no systematic 
review of radiographs, to explain the discrepancy between clinical and epidemiologic 
data. To determine the proportion of the Dutch cancer registry cases of tracheal 
cancer whose radiographic findings are consistent with the diagnosis and who are 
candidates for surgical resection, a nationwide audit of cases was conducted.
Methods and Materials
Patient Selection
In a six-year period from 2000 to 2005, all cases coded for primary tracheal 
carcinoma, labeled C33.9 according to the International Classification of Diseases 
for Oncology, 3rd Revision (ICD-O-3) 9 and reported to the Netherlands Cancer 
Registry (NCR), through all nine regional cancer registries, were selected. The main 
source of notification is the national archive of pathology reports (Pathologisch 
Anatomisch Landelijk Geautomatiseerd Archief, PALGA), complemented by data 
from the national hospital discharge registry with case summaries of all patients. The 
documentation of registered tumors is completed by reviewers at the regional 
registries who excerpt patient hospital charts. We received permission for this study 
from the national supervisory committee of the NCR. A waiver for patient consent 
was obtained with the provision that the primary care physician would agree to 
enrolment in the study.
Patient Data Collection
From the database of the NCR, name and address of the primary care physician 
concerning each patient were acquired. All physicians gave permission to include 
their patients into the study following a written request. Copies of patient charts 
detailing diagnosis and treatment of tracheal disease were gathered with additional 
documentation from referring physicians or specialists providing second opinions. 
Information on patient and clinical characteristics, diagnostic procedures, tumor 
pathology, and treatment were entered into a study database. The interval from first 
presentation to a specialist until a histologic diagnosis was obtained and termed
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diagnostic delay. Patient charts were searched for documentation of therapeutic 
decisions and potential contra-indications to surgical treatment. Thoracic or 
otolaryngologic consultation, where documented, was recorded. To protect 
confidentiality, data entered the audit anonymised and panel members or second 
reviewer had no access to patient records or identifiers.
The minimum diagnostic evaluation that was considered complete consisted of 
cross-sectional imaging by computed tomography (CT) or magnetic resonance 
imaging (MRI) and bronchoscopy. Cases were excluded if documentation of 
evaluation was unavailable or abnormal findings of either diagnostic modality were 
not explained or evaluated. Diagnostic images were obtained from radiological 
hospital archives for each case. From these images, tumor length and extension to 
other organs, lymph node enlargement, presence of metastatic disease, and 
evidence of potential comorbid conditions were recorded. Where radiological tumor 
length diverged from bronchoscopic descriptions, the longer length was recorded. 
Evaluation of liver and adrenal glands was assumed when a dedicated abdominal 
CT was obtained or both organs were shown on the chest study.
Audit Case Review
Cases were reviewed by a multidisciplinary panel of physicians treating tracheal 
cancer at Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands 
(Radboud panel). The panel consisted of one pulmonary physician (HH), one 
cardiothoracic surgeon (AV), one radiologist (LD), two radiation oncologists (JK and 
JB), and one surgical head & neck oncologist (HM). A second review, independent 
from the Radboud panel, was provided by a thoracic surgeon with experience in 
tracheal carcinoma (HG).
For each case, clinical summaries in combination with CT or MRI of the trachea and 
chest were reviewed. Auditors were given demographic and historic information 
including sex, age, co-morbidity, prior malignancy and treatment, complaints, and 
excerpts of available radiographic, endoscopic, pathology or staging reports. The 
team was blinded to the actual treatment.
Audit of the Diagnosis of Primary Tracheal Carcinoma
The audit consisted of two parts, both done by the Radboud panel and second 
reviewer. The first part reviewed the primary diagnosis. In the presence of enlarged 
mediastinal lymph nodes, the tumor was assumed to be primary tracheal carcinoma 
only when the main tumor mass was located in the trachea, the tracheal tumor was 
separate from mediastinal lymph nodes and no other radiographic finding indicated 
the presence of a primary carcinoma of the lung elsewhere. If the main tumor mass 
was centered either in a mainstem bronchus or in a different organ adjacent to the 
trachea, in the esophagus or the larynx, the tumor was assumed to be a local 
extension and not primary tracheal carcinoma.
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Audit of Treatment
For the second part of the audit, Radboud panel and second reviewer determined 
resectability and therapeutic options in each case. Tumors were assumed to be 
resectable when the tumor-bearing tracheal segment could be removed and 
reconstructed by primary anastomosis, taking into account age and body habitus of 
the patient (between 20 and 50% of the total tracheal length), absence of vital organ 
invasion such as the heart or great vessels and of mediastinal lymph node 
involvement. Previous high dose (>50 Gy) irradiation to the trachea was also 
regarded as a contraindication to resection.
Radboud panel findings regarding resectability and advised management were 
consensus-based, replicating every-day multidisciplinary oncology practice. The 
opinion of the second reviewer was compared with the panel assessment. The 
combined opinion of panel and second reviewer was compared with actual 
treatment, marking cases as surgical candidates only when decided independently 
by both reviews.
Statistical Analysis
Statistical testing was performed with SPSS 14.0 statistical software program (SPSS 
Inc, Chicago, IL). Continuous variables were compared with the One-Way ANOVA 
test and categorical variables were compared with the Chi-Square test.
Results
The Diagnosis of Tracheal Cancer
The results from the audit process are depicted in Figure 1. Excluding two cases in 
children and two found at autopsy, the NCR identified 104 tracheal carcinomas from 
51 hospitals in the period 2000 - 2005. Three cases for which imaging studies could 
not be located were excluded from analysis.
Of 101 cases reviewed in the initial audit, 34 carcinomas (33.7%) were judged to 
originate from sites other than the trachea and excluded from further analysis. In 
19.8% (20/101), a tracheal biopsy positive for carcinoma originated from a primary 
tumor elsewhere: the lung or mainstem bronchus with ingrowth into trachea in 14 
cases (squamous cell carcinoma (SCC) in 7, small cell carcinoma in 3, large cell 
carcinoma in 3, and adenocarcinoma in 1), the esophagus in 3 (all SCC), and the 
larynx in 3 (SCC in 2 and carcinoma in situ in 1). One of these laryngeal tumors had 
been surgically resected.
In the other 13.9% (14/101), mediastinal lymphadenopathy extended into the 
tracheal lumen or caused malignant stricture without detectable primary tumor. 
These cases were regarded as a metastatic malignant stricture.
Missing Information
Seventeen cases, none resected, were excluded due to insufficient clinical 
information. There was no staging for distant metastasis in 7 cases: in 3, the chest 
CT was incomplete and in 4, potential metastasis identified by CT was not evaluated.
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Table 1. Patient Characteristics and Referral Pattern
n % n %
Sex Referred to
Male 30 60 Pulmonologist 44 88
Female 20 40 Internist 3 6
Otolaryngologist 2 4
Co-morbidities Cardiologist 1 2
Alcohol use 15 30
Cardiovascular 10 20 Symptoms
COPD 8 16 Dyspnea 33 66
Hypertension 5 10 Cough 28 56
Diabetes 5 10 Hemoptysis 21 42
Prior stroke 2 4 Stridor 18 36
Pulmonary embolus 2 4 Weight loss 6 12
Deep vein thrombosis 1 2 Hoarseness 4 8
Asthma 1 2 Dysphagia 3 6
Obesity 1 2 Neck mass 3 6
Benign tracheal stenosis 1 2 Chest pain 2 4
Other 8 16 Fatigue 2 4
None 19 38 Other 3 6
None 1 2
Smoking history
Yes 37 74 Duration of symptoms*
No 7 14 < 1 week 2 4
Unknown 6 12 1 - 4 weeks 15 31
1 - 3 months 17 35
Prior airway cancer 3 - 6 months 9 18
Lung 11 22 6 - 12 months 2 4
Larynx 3 6 > 12 months 4 8
Oropharynx 1 2
Prior diagnosis*
Prior cancer, non-airway Bronchitis 7 14
Colon 3 6 Asthma 4 8
Prostate 1 2 Other 3 6
Breast 1 2 None 36 73
Thyroid 1 2
Uterine 1 2
* In 49 patients presenting with symptoms
Resectability could not be determined in 6 cases. Extent and length of an adenoid 
cystic carcinoma (ACC) was unclear in 2, and in the other cases bronchoscopy was 
not done or not documented, the extent of esophageal invasion was not evaluated, 
or enlarged mediastinal lymph nodes were not biopsied.
Operability was uncertain due to important cardiovascular disease in 2 cases and 
locally advanced synchronous bronchial carcinoma in 2 others.
Patient Characteristics and Presentation
Characteristics of the remaining 50 cases are shown in Table 1. Mean age was 63.7 
years (range 32 -  85 years). Two of 15 prior airway cancers were synchronous
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bronchial cancer. Two other cases had synchronous colon carcinoma and papillary 
thyroid carcinoma, respectively.
Cases of ACC were younger (mean 57.9 years versus 66.4 years, p = 0.047), more 
often female (61.5% versus 37.0%, NS), less often smokers (58.3% versus 91.7%, p 
= 0.017) and had fewer prior airway malignancies (0% versus 48.1%, p = 0.002) than 
those with SCC.
The four most common presenting symptoms were dyspnea, cough, hemoptysis, 
and stridor. In 94.0% (47/50), one or more, and in 72% (36/50), two or more of these 
symptoms were present. One tracheal carcinoma presented asymptomatic 
concomitant with bronchial cancer during workup of a nasal inverted papilloma. Ten 
cases were first seen at a tertiary centre. Referral to tertiary centres occurred in 9 
cases for treatment and in 18 for a second opinion, while 13 (26%) were not referred. 
Diagnostic delay measured 9 days (mean 24) and ranged from 0 to 285 days.
Diagnostic Procedures
Diagnostic tests and tumor histology are summarized in Tables 2 and 3. Endoscopic 
tumor and tracheal length was measured by the treating physician in 28% of cases 
(14/50). In six cases, cervical nodal invasion was found on CT and confirmed with 
biopsy. In five cases (10%), chest CT showed pulmonary metastases. Abdominal CT 
showed liver metastases in 1 case.
Table 2. Diagnostics and Dissemination Tests
n % n %
Seen on chest X-ray Localization
Yes 14 28 Proximal 19 38
No 36 72 Middle 11 22
Distal 20 40
Seen on chest / neck CT
Yes 42 84 Dissemination tests
No 8 16 CT liver and adrenal glands 29 58
PET scan 14 28
Endoscopic examination Scintigraphy 6 12
Flexible 17 34 Esophagoscopy 6 12
Rigid 5 10 US abdomen 5 10
Both flexible and rigid 28 56 Histology neck node 5 10
MRI of the chest 4 8
Seen at endoscopy US neck 4 8
Yes 50 100 CT or MRI brain 3 6
No 0 0 Endoesophageal US 3 6
Medistinoscopy 2 4
High resolution chest CT 2 4
Swallow X-ray 1 2
CT = computed tomography, PET = positron emission tomography, US = 
ultrasound, MRI = magnetic resonance imaging
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Table 3. Histologic Types Found in 50 Cases of Primary Tracheal Carcinoma
n %
Squamous cell carcinoma 27 54
Adenoid cystic carcinoma 13 26
Carcinoid 4 8
Large cell carcinoma 3 6
Adenocarcinoma 2 4
Small cell carcinoma 1 2
Actual Treatment
Primary treatment was radiotherapy in 58% (29/50) of cases, combined with 
endobronchial treatment in 8, chemotherapy in 3 and both endobronchial treatment 
and chemotherapy in 5. The radiation dose was less than 39 Gy in 6, between 39 
and 59 Gy in 4, above 59 Gy in 19 cases, and 70 Gy or more in 6 of these cases. 
Surgical resection was performed in 24% (12/50). Resection was preceded by 
endoscopic debulking in 4 cases. Postoperative adjuvant radiotherapy was 
administered using a dose of 39 to 59 Gy in 4 cases and more than 59 Gy in 5. In 
12% of cases (6/50), primary treatment consisted of endobronchial resection. In 6% 
of cases (3/50), only supportive care had been administered. Seven of 13 ACC 
cases underwent surgical airway resection (54%).
Radboud Panel Opinion
In 10 cases without distant metastases, the tracheal tumor was considered 
unresectable due to mediastinal invasion in 5, excessive length in 4, and 
dissemination during previous thyroidectomy in 1. The panel regarded 3 cases 
resectable but inoperable due to advanced age or local recurrence of a peripheral 
lung cancer. In 31 of 50 primary tracheal carcinoma (62%), the panel advised 
surgical tracheal resection with curative intent.
Opinion of Second Reviewer
In 4 of 50 cases (8%), the individual thoracic surgeon differed from the panel 
regarding tumor resectability. The second reviewer judged 3 cases considered 
resectable by the panel as unresectable because of prior cervicomediastinal 
radiation. The Radboud panel considered 1 case judged resectable by the second 
reviewer as unresectable due to lymphadenopathy. Thus, there were 28 candidates 
for resection as determined by both Radboud panel and second reviewer.
Potential Surgical Candidates
Of 28 potential surgical candidates, actual treatment in 16 cases (57%) consisted of 
other modalities: radiotherapy in 11, endobronchial therapy in 4, and supportive care 
in 1. Only 43% (12/28) of surgical candidates actually underwent surgical resection. 
Age, histologic types and tumor length in these groups are shown in Table 4. 
Contraindications to surgery as stated in the medical chart are listed in Table 5.
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Figure 1. Patient is noted as resectable only when indicated by both the review by the Radboud panel 
and the second reviewer. The actual treatment (dark balloons) is compared with the assessment of the 
audit (white balloons) in 50 patients with primary tracheal carcinoma (p = 0.005). Surface area of balloons 
represents the number of patients in each group.
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Table 4. Patient and Tumor Characteristics in Surgical and Non-Surgical Candidates
N
Mean age in 
years (range)
Histologic type (%)
Mean tumor length 
in cm (range)SCC ACC Cd Other
Surgical candidates 28 61.4a (32 - 80) 32.1 35.7 14.3 17.9 3.0b (1.0 - 5.5)
Resected 12 57.8c (37 - 75) 33.3 58.3 8.3 0 2.8d (1.5 - 5.5)
Not resected 16 64.3c (32 - 80) 31.3 18.8 18.8 31.3 3.3d (1.0 - 5.2)
Non-surgical candidates 22 66.5a (46 - 85) 81.8 13.6 0 4.5 5.5b (1.4 - 12.0)
Overall 50 63.7 (32 - 85) 54.0 26.0 8.0 12.0 4.2 (1.0 - 12.0)
SCC = squamous cell carcinoma, ACC = adenoid cystic carcinoma, Cd = carcinoid 
a P- value 0.165 
b P- value < 0.0001 
c P -value 0.190 
d P- value 0.358
Surgical consultation had been obtained in half (8/16) of surgical candidates who 
had not undergone resection.
If we assume that none of the 17 cases excluded from review due to insufficient 
clinical information would have been a candidate for tracheal resection, 42% (28/67) 
of cases would have been surgical candidates, as opposed to the actual resection 
rate of 18% (12/67; p = 0.003).
Table 5. Documented Reasons for Non-Surgical Management in 16 
Non-Resected Surgical Candidates
n %
Tracheal process unresectable 7 43.8
Segment too long 2 12.5
Possible ingrowth muscular esophagus 1 6.3
Long dysplastic area in trachea 1 6.3
Not documented 1 6.3
Carcinoid tumor 3 18.8
Patient's preference 1 6.3
Not documented 7 43.8
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Discussion
An audit review of the NCR finds metastases to the trachea in one third of cases 
registered, and therefore in our view misclassified, as primary tracheal carcinoma. 
Our study further finds that less than half of all cases with resectable tumors undergo 
surgical resection. These findings highlight the limited validity of epidemiologic data 
for this and other rare diseases that are reported to the registry without radiologic or 
histologic review. The audit more importantly points to problems in the clinical care of 
patients with uncommon tracheal tumors.
The concept of unsolicited panel and radiographic review of all registered cases of a 
certain type of tumor in one country in a designated period, is unique in its design, 
and, to our best knowledge, never described before. While external auditing of 
blinded and abstracted data by a panel of experts itself is subject to limitations, this 
method approximates the concept of multidisciplinary oncologic review by local 
experts adopted for common tumors in every-day practice. Treatment advice of our 
panel review is furthermore reproducible, as the inter-reviewer disagreement 
between the Radboud panel and a second reviewer was small (8%). In rare diseases 
such as tracheal tumors, however, the pool of experts is small and often not local. 
The emphasis on local surgical assessment and care may imply a potentially 
profound difference in the indications for surgical therapy and the outcome of 
individual patients.
The high proportion of misclassified tracheal carcinomas in the NCR suggests that 
the registration process for uncommon tumors may be improved. Errors in this 
classification consisted of a misattribution of tumors originating from adjacent organs 
or mediastinal lymphadenopathy with invasion of the airway wall to the trachea. Any 
biopsy of tumor from the trachea is reported to the NCR as tracheal cancer through 
the direct link with the national pathology database (PALGA). The final registration in 
the NCR database, however, involves a review of the patient medical chart. Some of 
the misdiagnoses may therefore have occurred when the tumor site of origin was 
misclassified in the report to the NCR. A retrospective review may correct the 
database error, but not the implications for patient care.
Three other epidemiologic studies of national cancer registry data also found 
misclassified tracheal carcinomas. A Finnish study found 36 metastatic tracheal 
lesions among 133 registered primary carcinomas (27.1%) 10, while a Danish audit 
excluded 16 misclassified tumors from 130 registered cases (12.3%) 7 In a review of 
the American Surveillance, Epidemiology, and End Results (SEER) database, 
Bhattacharyya disregarded cases with distant metastasis and excluded an additional 
7 of 99 cases (7.1%) with carcinoma in situ or unclear pathology 11. None of these 
studies, however, included a complete radiological review and thus may have 
underestimated the proportion of misclassified metastatic tumors. Misclassification, 
conversely, could also have occurred by labeling cases of primary tracheal cancer as 
metastatic bronchial, laryngeal, esophageal or thyroidal carcinoma. This error, 
however, is expected to occur less frequently since the registry is linked to the site of
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biopsy requiring active intervention by the responsible physician to change the tumor 
site.
A critical assessment of our previous study on incidence and treatment of tracheal 
carcinoma, also based on the files of the NCR but without review of radiographs 6, 
now suggests that the incidence of this disease in the Netherlands is overestimated 
and probably closer to 0.1 in every 100.000 persons per year. The high rate of small 
cell carcinoma in our previous study (11.0%), regarded as a marker of contamination 
with metastatic disease 12, was likely caused by the misclassification of peripheral 
bronchial carcinomas. We estimate that ACC accounts for approximately one quarter 
of tracheal cancers. In surgical series, ACC is encountered in 40 -  60% of cases 13­
15 The reported incidence of SCC lies fairly constant around 50% in both 
epidemiologic and surgical series 3,6,16-18 Future epidemiologic studies of tracheal 
carcinoma and other tumors of low incidence should therefore include an audit 
review of radiographic and, where feasible, also histologic images.
Our study had important limitations. A retrospective case review does not include 
patient contact, physical assessment, or endoscopic examination. The locoregional 
extent of disease, in the context of patient factors such as age, weight, and neck 
mobility, is the single most important factor determining resectability 2 Despite panel 
review of CT’s, endoscopy reports were usually brief and often non-descriptive. 
Endoscopic measurements of tracheal and tumor length were missing in 72% of 
patients. Thus, the actual resectability rate may be lower than our estimate. Still, 
tumor length in potential surgical candidates was well within the range of resectable 
disease 2 and differences of mean and range of tumor length between cases treated 
with resection and additional surgical candidates were small (mean 2.8 and 3.3 cm, 
respectively). A further potential source of error in our study was the determination of 
operability status based on available evidence in the patient’s medical chart. 
However, the Radboud panel excluded 4 cases in which the absence or presence of 
medical contra-indications to surgery could not be determined, even though patients 
are rarely declared unresectable due to medical contraindications 2. As depicted in 
Table 5, no medical contraindications were identified in any of the 16 additional 
surgical candidates who did not undergo surgical resection.
Our results provide additional evidence that half of all patients with primary tracheal 
cancer are surgical candidates 4,5 The balance is tipped furthest toward resection in 
ACC: the Radboud panel judged 10 of 13 cases (77%) to have resectable disease. 
As this national audit was preceded by epidemiologic studies in Denmark, Finland 
and the United Kingdom with comparable outcome with those in the Netherlands, 
these results are likely representative for the situation in most western European 
countries 6-8,16.
We believe that each patient diagnosed with a tracheal tumor should be referred to a 
tertiary oncology centre with multidisciplinary experience in the treatment of tracheal 
tumors. Given the rarity of the disease, to warrant sufficient exposure to malignant
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tracheal pathology and to maintain experience, one centre per each population of an 
estimated 10 - 20 million would be optimal. In the Dutch situation, this would mean 
one national centre. By centralizing the care for patients with this rare airway tumor, 
more patients may be selected for surgical resection, thus potentially improving 
outcome. As this improvement is inferred but untested, close evaluation would be 
needed once a centralized system is implemented to assess the exact benefit of this 
new strategy.
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ABSTRACT
Objective: To describe the controversies in the management of thyroid 
carcinoma invading the airway.
Study design: contemporary review of literature, level of evidence: 5.
Results: Invasion of the larynx or trachea by thyroid carcinoma is 
uncommon and often identified at the time of operation, when the surgeon 
must decide the extent of resection. Invasion of the airway is associated with 
loss of tumor differentiation and a reduction in long-term survival compared to 
tumors limited to the thyroid gland. Whether or not the invaded airway should 
be resected remains controversial. Tangential shave excision of tumor is 
commonly performed, despite a marked risk of local recurrence. 
Circumferential sleeve resection of the larynx and trachea is safe and lowers 
the risk of local recurrence. In recurrent disease, laryngotracheal resection 
provides effective palliation of airway obstruction and hemoptysis.
Conclusion: Long-term (>10-20 years) prospective studies are required 
to compare the outcome after shave excision with segmental airway resection 
for thyroid carcinoma. Based on the current literature and on our experience, 
we advocate circumferential tracheal resection in the setting of airway 
involvement.
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Introduction
Invasion of the larynx or trachea by thyroid cancer ranges from asymptomatic 
tracheal adherence to airway obstruction or bleeding from transmural invasion. Over 
half of all deaths from well- and poorly differentiated thyroid cancer are due to airway 
obstruction and bleeding 1, but death in thyroid cancer remains uncommon. 
Tracheal invasion by tumor is associated with loss of cellular differentiation and a 
reduction of long-term survival compared to tumors limited to the thyroid gland. 
Usually identified at the time of operation, airway invasion demands from the 
surgeon a decision on the extent of resection. Tracheal invasion at the time of 
thyroidectomy is often treated with tangential "shave” resection; the margins are 
difficult if not impossible to assess. Complete resection of local disease is assumed 
to be a prime objective in the surgical treatment of thyroid carcinoma, producing the 
best palliation and longest survival. A meta-analysis of all available surgical 
techniques is desirable but presently unachievable. The diversity of the reported 
experience with regards to primary and recurrent disease, degree of tumor 
differentiation, laryngeal or tracheal invasion, present or absent lymph node 
involvement, and type of resection, has not been summarized in a statistically 
meaningful manner. Kim and associates provided a careful tabulation of respiratory 
tract invasion in their review, but no statistical analysis 2 Any conclusions or 
recommendations regarding the extent of resection in patients with thyroid 
carcinoma invading the airway rest therefore on incomplete data The purpose of this 
review is to describe the clinical presentation and long-term outcome of 
laryngotracheal invasion, the methods of resection, and the clinical data supporting 
their use.
Incidence of Laryngotracheal Invasion
The argument for conservative surgical therapy of laryngotracheal invasion is based 
on the excellent prognosis of well-differentiated tumors of papillary and follicular 
histology, with over 90% of patients surviving 10 years after complete resection 3,4 
The proportion of patients with thyroid cancer involving the larynx and trachea 
depends on histology, disease severity, and the definition of invasion. Extrathyroidal 
invasion into the trachea or larynx was noted in 3.6% 5 to 22.9% 6 of all patients 
undergoing thyroidectomy, with the highest proportion in a tertiary referral center. 
Luminal tumor inside the trachea, the most advanced stage of invasion, was visible 
on endoscopy in only 0.5 to 1.5% of patients presenting for resection 7-9 The 
surgeon’s definition of invasion, ranging from any attachment of the gland to gross 
tumor transgression further influences this proportion. Tracheal or esophageal 
adherence was noted in 10.9% (45/412) of patients in a referral center 10, while Clark 
and associates found deep laryngeal invasion necessitating laryngectomy in 5 of 218 
(2.3%) patients undergoing thyroidectomy 11.
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Table 1. Occurrence of Laryngotracheal Invasion by Thyroid Carcinoma (Studies >50 Cases)
Author Year
Period
(years)
No. of Thyroid 
Carcinomas (N)
Airway Involvement
Well Differ­
entiated (%)No. %
All thyroid carcinomas
Schindel, J 15 1971 15 225 10 4.4 ns
Breaux, GP 16 1980 10 210 44 21.0 72.2
Segal, K 17 1984 25 500 29 5.8 65.5
Tsumori, T 18 1985 24 180 28 15.6 ns
McCarty, TM 19 1997 44 597 40 6.7 85
Koike, E 20 2001 0.5 171 16 9.4 93.8
Sywak, M 21 2003 2 97 7 7.2 100
Tsai, YF 22 2005 15 532 43 8.1 93.0
Randolph, GW 23 2006 - 135 21 15.6 ns
Well-differentiated thyroid carcinomas
Friedman, M 24 1982 30 190 13 6.8 100
McConahey, WM 12 1986 25 859 85 9.9 100
Nishida, T 6 1997 25 301 69 22.9 100
Hu, A 14 2007 38 576 13 2.3 100
Laryngectomy
Clark, RL 11 1966 19 218 5 2.3 ns
Radiologic evidence
Lawson, VGf 13 1983 - 100 35 35.0 ns
Invasion of aerodigestive tract
Melliere, DJ 10 1993 20 412 45 10.9 64.4
Ballantyne, AJ 25 1994 40 1098 46 4.2 65.2
Segal, K 26 2006 40 1200 49 4.1 100
Tracheal cartilage invasion only
Park, CS 5 1993 10 432 16 3.7 100
Tracheal luminal disease
Frazell, EL 9 1958 25 393 6 1.5 100
Britto, E 7 1990 20 1925 10 0.5 100
Total 10251 595 5.8
f The Cases Reported by Lawson are not Included in the Totals
ns = not stated
Two retrospective studies from the same institution noted widely different results 
depending on whether endoluminal disease (0.9% in 2000 patients 8) or external 
adherence to the wall (9.9% in 859 patients 12) determined invasion. Radiologic 
criteria such as compression or displacement by tumor, found in up to 35%, probably 
overestimate invasion 13 A recent study from Hu and colleagues reported 
macroscopic tracheal invasion in 13 of 531 patients (2.4%) with more than five years 
of follow-up 14 In a total of 20 studies (Table 1) 5-7,9-26, we found 10251 patients with
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thyroid cancer 595 (5.8%) of whom had airway invasion. In the absence of 
epidemiologic studies, this may be the best general estimate of laryngotracheal 
tumor adherence or invasion among all patients presenting for surgical resection.
Tumor Characteristics and Prognosis
Tracheal invasion is of interest to surgeons because it is a marker for more 
aggressive tumors and defines a patient population at greater risk of death from what 
is otherwise a comparably indolent tumor. Indeed, malignant airway obstruction from 
either a primary tumor or recurrent disease is the cause of death in half of all patients 
with thyroid carcinoma 1. Active local disease is further stated to be present in 
greater than 80% of patients who die of thyroid carcinoma 27. Among 18 cases of 
thyroid cancer infiltrating the trachea, Tsumori and associates found poor 
differentiation in 50% of papillary and follicular carcinoma compared to 11.4% when 
airway was not invaded 18 Within individual tumors, Tsumori found loss of 
differentiation along the axis from well-differentiated center of the gland to the poorly 
differentiated site of airway invasion, suggesting that invasion beyond the capsule 
and loss of differentiation are related phenomena. Depth of invasion appears to 
predict outcome, with shorter survival in patients with endoluminal tumor, as shown 
by Shin and colleagues 28 In Djalilian and associates’ study of 18 patients with 
intraluminal thyroid cancer, for example, 11 patients died of disease, 3 were alive 
with metastasis, and the longest survivor had lung metastasis 8 years after 
laryngectomy 8 Ten of these patients had thyroidectomy and 10 either laryngectomy 
or tracheal resection. Furthermore, among 292 patients with well-differentiated 
papillary carcinoma, the most commonly encountered histology and hence the group 
of greatest interest, Czaja and McCaffrey identified laryngotracheal invasion in 124 
patients (41%) as a significant independent predictor of death 29 In separate 
studies, both McCaffrey 30 and Ito and their associates 31 found that aerodigestive 
tract invasion was an important negative prognostic factor. These data indicate that 
tracheal invasion lowers long-term survival.
Presentation of Laryngotracheal Invasion
Symptoms underestimate the depth of airway invasion. The symptoms associated 
with mucosal penetration, bleeding and airway obstruction, define a small subset of 
patients with the most advanced degree of invasion. Even deep tumor invasion into 
the tracheal wall is often not identified before operation unless fixation of the gland is 
obvious on physical examination. Among 40 patients with gross airway invasion, 
McCarty reported hoarseness in 22%, hemoptysis in 11% and dyspnea in 5% 19 In 
surgical series of tracheal resection for patients with tumors invading the trachea, 
both airway obstruction and bleeding are more common.
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We noted dyspnea in 31% and hemoptysis in 24%, while 10% had no symptoms 32 
Tsumori and colleagues found hemoptysis in 39% and some degree of dyspnea in 
89% of 18 patients 18 Hemoptysis occurred in 19 of 24 patients (79%) in a study by 
Ishihara and associates 1.
Diagnosis of Laryngotracheal Invasion
The preoperative diagnosis of tracheal invasion is unusual. McCarty and associates 
identified laryngotracheal invasion in 83% of their patients during the operation 19
Ultrasonography
Ultrasound may identify patients with local invasion. In papillary carcinoma, the 
sensitivity of preoperative ultrasound for tracheal invasion was 42.9% and for 
esophageal invasion 28.6% 33. Ultrasound in 24 patients correctly predicted invasion 
of the tracheal adventitia in 2 of 4, the intercartilage space in 9 of 10, and the 
mucosa in 9 of 10 patients 34 Invasion was thus correctly identified before 
exploration in 83% (20/24), higher than in the earlier study and coincidentally the 
inverse of McCarty’s findings. Tomoda and colleagues found histologically 
confirmed ultrasonographic evidence of airway invasion in 11 of 13 tumors (85%) 
and false-positive findings in 32 of 496 patients (6.5%) 35. In experienced hands, 
cervical ultrasound may therefore allow accurate preoperative prediction of airway 
invasion.
Bronchoscopy
Bronchoscopic examination identifies luminal compression, erythema and edema, 
neovascular formation, and frank mucosal invasion (Shin stage IV). Flexible 
endoscopes have a lower optic resolution than rigid systems and observe the 
mucosa at an angle, not head-on. Rigid bronchoscopy conducted in the fully 
anesthetized patient affords undisturbed and unhurried inspection at telescope 
angles from 0 to 90 degrees. Koike and colleagues reported 16 patients with airway 
invasion who underwent preoperative flexible bronchoscopy 20 They graded a 
negative bronchoscopic examination as diagnostic of perichondrial invasion only 
(Shin stage I), treating 4 such patients with shaving of the tracheal wall alone, 
although Shin and associates specifically described normal bronchoscopic findings 
in stages 0 through III 28. Koike treated deeper invasion associated with at least one 
abnormal bronchoscopic characteristic with full thickness resection. Randolph and 
Kamani advocate, and we support, the use of pre-operative endoscopy in all patients 
undergoing thyroidectomy to diagnose vocal cord paralysis and invasive thyroid 
disease 23 The purpose of endoscopic examination is not to identify patients who 
may undergo shave resection, but to diagnose advanced invasion and estimate 
luminal extent and resectability.
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Staging of Laryngotracheal Invasion
A staging system for local laryngotracheal invasion evolved from investigating the 
lymphatic drainage of the laryngotracheal unit and the thyroid gland 28 Shin and 
associates found a relationship between the depth of invasion and intermediate-term 
(5-year) survival in 22 patients with papillary carcinoma and airway invasion 28. 
Table 2 details the five stages of this system. An important corollary of the Shin 
staging was the likelihood of positive resection margins and lymph node 
involvement, present in 54 and 91%, respectively, of patients with the most 
advanced stage IV, compared to 36 and 36%, respectively, in stages I to III. The 
Shin staging requires a full thickness specimen of tracheal or laryngeal wall to 
precisely determine depth of invasion. This system is therefore misinterpreted when 
applied to patients undergoing shave resection 6,20 The purpose of staging organ 
invasion in this manner lies in the clinical observation that tumor depth and prognosis 
are related.
Table 2. Staging for Differentiated Thyroid Carcinoma Based on the Extent of Tracheal Invasion
28According to Shin et al.
Stages Definition
Stage 0 Carcinoma confined to the substance of the thyroid
Stage I Extension through the capsule of the thyroid gland and 
abutting the external perichondrium
Stage II Invasion between the rings of cartilage or destroying the 
cartilage chapter
Stage III Extension through the cartilage or between the cartolaginous 
plates into the lamina propria of the tracheal mucosa 5 1
Stage IV Extension through the entire thickness of and expansion
into the tracheal mucosa
Other staging schemes for thyroid carcinoma may account for local invasion but not 
on the depth of airway disease. The AMES score identifies men older than 40 years 
and women older than 50 years with major involvement of the thyroid capsule as a 
high-risk group 36. The European Organization for Research and Treatment of 
Cancer (EORTC) system labels tumors with fixation or infiltration of adjacent 
structures as T3 and adds a weight factor for local invasion of any depth 37. The 
MACIS 38 and AGES 39 scores also add a weight factor, while the TNM system does 
not account for local invasion 40
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Surgical Management
Resection of the airway for laryngotracheal invasion may be considered in five 
different clinical settings, each with different prognostic implications and treatment 
goals.
1. Incidental, asymptomatic adherence of the gland to the airway at initial 
thyroidectomy.
2. Early referral after incomplete tangential excision of thyroid cancer.
3. Transmural invasion with airway obstruction or hemoptysis prior to surgical 
therapy.
4. Local recurrence with airway obstruction late after thyroidectomy.
5. Malignant airway obstruction in the presence of distant metastatic disease. 
Treatment with curative intent appears possible in categories 1 through 3, though 
recurrence in group 3 is common due to advanced disease. Palliation alone is 
realistic in categories 4 and 5. The controversy over the extent of resection is 
greatest in the treatment of thyroid cancer with seemingly superficial adherence to 
the airway. The role of standard en bloc resection, and of shave resection, in this 
group of patients remains unclear. The surgical alternatives will be discussed in 
ascending order of extent of resection.
Tangential Excisions of Tumor
Shaving. This technique consists of sharp separation of the gland from the 
wall of the airway with a knife. Often the surface of the trachea is scraped or 
tangentially cut to remove a further layer of airway tissue for microscopic analysis. 
Melliere and colleagues shaved off any tight adherence of the gland, occasionally 
cutting into tracheal rings; with evidence of deep tracheal invasion, electrocautery 
was applied on the tracheal wall or tracheal resection was selected 10 The lack of a 
clear margin constitutes the main concern regarding this technique. Frazell and 
Foote 9, also quoted in Djalilian 8, stated "one can be reasonably certain that such 
sharp dissection does not remove all tumor cells”. They warned of late reactivation 
of disease with penetration of the trachea, obstruction, and hemorrhage. The 
purpose of tangential excision is to achieve long-term control of thyroid carcinoma as 
long as no gross disease remains 29 Nishida and coauthors saw no indication for 
tracheal resection in those carcinomas that abutted the external perichondrium and 
performed a shave resection 6. Shin and coworkers 28, however, showed that there 
is no continuous plane underneath the "external perichondrium” since the 
peritracheal fascia is virtually continuous with dense fibrous tissue between the 
tracheal rings. Further, the perithyroidal adventitia and the lymphatics of the tracheal 
mucosa communicate in the intercartilaginous spaces, allowing tumor to spread into 
the trachea. Ozaki and colleagues performed circumferential tracheal resection and 
reconstruction in 21 patients and discovered that disease extended beyond the 
tracheal adventitia in 18 cases 41. While luminal disease in 6 of 18 patients might 
have been diagnosed by bronchoscopy, Ozaki notes that carcinoma between
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tracheal rings in 2 and submucosal disease in 10 patients would have remained 
undiagnosed, had the thyroid gland been shaved off the airway.
Complete resection, while possible in shave resection, is difficult to confirm. 
McCarty and coauthors found that all of 35 shave procedures left microscopic 
residual disease on the trachea 19. Six of the 35 patients developed locoregional 
recurrence for a rate of 17% after a mean follow-up of 81 months 19 Only 4 of 16 
patients with tracheal invasion reported by Park and colleagues remained disease- 
free during 70.7 month of follow-up after a cartilage-shaving procedure 5; trachea 
and paratracheal space were the site of failure in 10 of the 12 patients and 7 died of 
disease. These reports suggest therefore that shave resection is incomplete and a 
high rate of local failure must be expected. These observations translate into rates
of local recurrence after shave procedures that are higher by a factor of 8 relative to
22segmental airway resection . Residual disease may grow over time, may permeate 
the adjacent organs, may metastasize, or dedifferentiate in histology, even if overall 
survival rates 10 or 20 years after resection do not decline in younger patients 42
Window Resection. The creation of local defects in the wall of the airway 
probably originated from deep tangential excisions and represents an implicit 
recognition of transmural invasion. Window defects impose limits on the extent of 
resection in length and circumference and leave a reconstructive problem. To avoid 
an unstable tracheal lumen, no more than a fraction of the circumference, and 
approximately 35% of the cricoid cartilage, may be resected 43. Most resected 
patients require airway protection with a tracheostomy. The method of confirming 
the margin status is haphazard and positive margins are often left behind. Two 
patients so treated and referred to Massachusetts General Hospital for repair of the 
tracheal defect were found to have positive margins in all four quadrants of the 
windows 44 Primary reconstructive options for a window defect are limited and 
consist of local muscle or myoperichondrial flaps 43. Suture closure of a window 
defect is rarely possible. Given the safety of circumferential tracheal resection, there 
is no clinical role for window resection.
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Tracheal or Laryngotracheal Sleeve resection
Tracheal sleeve resection was initially applied to invasive thyroid carcinoma after 
successful reconstruction for postintubation strictures and primary tumors 45-47. The 
operation consists of en bloc resection of thyroid gland and attached trachea. 
Incidentally discovered invasion is often limited to two or three tracheal rings, 
allowing a short tracheal resection. Such an operation is not complex in experienced 
hands and adds little time to an unhurried thyroidectomy. Most reported surgical 
series originate from thoracic surgical centers with an interest in tracheal disease 
and contain predominantly patients with recurrent disease. The series of tracheal 
resection for thyroid cancer began with Ishihara and colleagues’ report on 11 
patients with papillary carcinoma, including a small number of patients treated with 
incomplete shave resection 48 Separate thyroidectomy preceded tracheal resection 
in 73% of their patients 48, 46 of 82 patients (56%) in our series 32, and 11 of 18
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patients (61%) in Tsumori and associates’ study 18. The advantages of this 
approach include a full thickness specimen of the trachea with precise determination 
of invasion depth and margin status, information on prognosis 28, immediate 
reconstruction of the airway, and rarely a need for tracheostomy. The operation is 
performed preferably as an en bloc resection, with attached thyroid gland, although a 
discontinuous resection, shortly after thyroidectomy, may also be done. This 
technique is suitable at the time of primary resection, with or without immediate 
histologic confirmation of invasion, or for treatment of a local recurrence. Tumor 
involving the lower larynx may be resected in continuity, reconstructing the subglottic 
airway with the trachea shaped to conform to the cricoid or thyroid cartilage defect 
44,49 Ishihara and associates performed anterior cricoid resection in 2 of 11 patients 
48, while laryngotracheal reconstruction was needed more commonly in our hands 
(58%, 40 of 69 patients) 32
Operative risk in centers experienced in tracheal surgery is low when patients with 
high-dose preoperative radiation or cervical exenteration for recurrent disease are 
excluded. Including such high-risk patients, Grillo and colleagues reported 3 
operative deaths (8.8%) of whom 1 occurred from anastomotic separation after 
cervical radiation with 7800 cGy and 1 after cervicomediastinal exenteration 44 
Excluding these high-risk patients in our most recent series, the mortality in patients 
undergoing airway reconstruction measures 1.4% (1/69) 32 The single death was 
due to anoxic brain injury from airway obstruction after laryngotracheal 
reconstruction. Temporary tracheostomy was required in 18.8% and a permanent 
airway tube in 4.3%. Ozaki and associates reported 21 tracheal sleeve resections 
without operative mortality, and only one patient required tracheostomy for bilateral 
vocal cord palsy 41. Tsumori and associates reported 13 patients with tracheal 
resection and end-to-end anastomosis without operative death 18. Ishihara and 
colleagues reported no operative death in 24 patients undergoing sleeve resection 
for invasion, a 28% rate of postoperative laryngeal stenosis in the entire group, and a 
8% rate of anastomotic stricture 1. Wada and co-workers experienced no critical 
operative complications in 13 cases of complete en bloc resection 50 Musholt and 
associates initiated tracheal and laryngotracheal resection in an endocrine surgical 
unit after gaining experience with shave and window techniques. They observed 1 
death after 6 laryngotracheal resections (17%) and none after 5 tracheal resections 
51. In 6 window resections, there was 1 death due to an innominate artery fistula; 
permanent or prolonged tracheostomy was necessary in 29% of shave resections 
and 3 of 6 window resections (50%). Thus segmental tracheal resection adds a very 
small risk of major complications or death to thyroidectomy, while voice, respiration, 
and deglutition are preserved.
Total Laryngectomy and Cervical Exenteration
Laryngectomy and cervical exenteration are salvage resections for patients with 
extensively invasive primary disease or locoregional recurrent disease following 
previous resection or radiation. Exenteration refers to the combined removal of
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larynx, pharynx, cervical esophagus, thyroid, and lymph nodes with intestinal 
reconstruction using stomach (gastric pull-up), jejunum or colon 52 The indications 
for total laryngectomy without reconstruction are laryngeal destruction or permanent 
glottic dysfunction due to bilateral vocal cord palsy. Exenteration encompasses 
resection of the esophagus with reconstruction of swallowing by either gastric, 
jejunal or colonic transposition. Depending on the length of resected trachea, a 
cervical or mediastinal tracheostomy is constructed 53. The operation should remove 
all gross tumor to provide meaningful palliation. Postoperative hypoparathyroidism 
may occur. In the report of Grillo and colleagues 44, seven patients underwent 
cervical exenteration. Three of these had no prior surgical therapy, and 4 previously 
underwent thyroidectomy. One patient (17%) died of perforated peptic ulcer and a 
leak of the esophageal closure; other complications included respiratory failure and 
transient hemiplegia after division of the right carotid and innominate artery in 1 
each, and stenosis of the tracheal stoma in 3. Of 6 operative survivors, 2 patients 
died of progressive disease, 3 died late of other causes, and 1 was alive less than 2 
years after surgery.
Other Palliative Resection
Resection of the airway in carefully selected patients with advanced locoregional or 
distant disease provides meaningful palliation of airway bleeding or obstruction. The 
aim is to reduce the risk of tracheal hemorrhage and the need for an airway tube 
without performing a complete regional resection. Segal and co-workers observed 
hemoptysis or airway obstruction in 7 of 15 patients after thyroidectomy with or 
without tracheostomy and lymph node dissection, but in none of 13 patients following 
laryngectomy or partial tracheal resection in addition to thyroidectomy 17 In the most 
recent update of the MGH experience, 5 patients with distant metastasis at operation 
did not have local recurrence after airway resection, and of 9 other patients with 
distant disease at operation who later developed local recurrence, only 2 required an 
airway tube 32.
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Radioactive Iodine
The indication for radioactive iodine (RAI) therapy alone is metastatic or locally 
advanced disease when surgical options are exhausted. The role of orally RAI has 
not been separately investigated in airway invasion. Postoperative adjuvant therapy 
for residual disease in the tracheal wall may have limited effectiveness for two 
reasons. As noted above, tumors invading the airway are less differentiated, may 
take up less RAI and therefore be resistant to therapy. When tracheal tumor burden 
is large, a larger proportion of RAI is taken up, sparing microscopic disease 
elsewhere. Despite these caveats, adjuvant RAI as postoperative treatment is 
commonly administered after all types of resection.
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External Beam Radiation Therapy (EBRT)
Adjuvant or palliative radiation is commonly proposed for locally advanced cancer 
after incomplete resection. The benefit of EBRT in thyroid cancer, however, is 
controversial. In patients with known residual disease in the neck, EBRT may 
improve local control 54,55 The use of adjuvant radiation in patients with resected 
locally advanced disease improved recurrence rates in one study 56 while another 
showed no benefit 57 EBRT is not a substitute for complete removal of the tumor. 
Further, prior radiation vastly increases the risks associated with future airway 
resection, even when vascularized tissue such as omentum protects the healing 
tracheal anastomosis.
Outcome Parameters
Reports of surgical treatment for airway invasion usually contain a mix of operations 
with curative and palliative intent. A summary of results is provided in Table 3 
6,18,19,22,26,32,50,51,58,59. Overall survival for well-differentiated tumors conveys little 
information regarding the success of resection. Local control and disease-free 
survival rates are more accurate, specifically when buttressed with follow-up 
examinations including thyroglobulin level, ultrasound, iodine scans, and 
bronchoscopy. A good example was provided by McCarty and colleagues who 
compared the rates of overall survival, disease-free survival, and local control in 40 
patients with laryngotracheal invasion (Table 4) 19 While the overall 10-year survival 
of patients with well-differentiated carcinoma and shave resection was 90.8%, the 
disease-free survival was only 50.9%. A 28.1% rate of overt local failure 10 years 
after thyroidectomy is unsatisfactory when life expectancy exceeds three decades.
19Table 4. Comparison of Outcome Measures by McCarty et al. in Patients with Differentiated 
Thyroid Carcinoma Invading the Trachea Treated with Cartilage Shaving
Outcome Measure 5-year (%) 10-year (%)
Overall survival 90.3 85.3
Local control rate 95.2 71.9
Disease-free survival 76.6 49.9
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Table 3. Management and Outcome in Patients with Thyroid Carcinoma Invading the Airway
First author
N+
Year (%)
M1
(%)
Recurrent
disease
(%)
WD
(%)
Mean
follow-up ' 
(years)
Survival data according to type of resection t
All cases Shave Radical Window Incomplete
No. 5-year % No. (%) 5-year % No. (%) 5-year % No. (%) No. (%) 5-year %
Tsumori18 1985 - - 38.9 78 2.9 28 46 64 60
McCaffrey58 1994 - - 0 100 13 126 79 (63) [54] - 90 (70) [60] - 95 (90) [70] 65 (45) [40]
McCarty 19 1997 62.5 0 0 88 6.8 40 89 (84) 88 90 (85) 12 68% FOD*
Nishida 6 1997 82.6 18.8 23.2 100 5.5 69 19 80 (68) 61 62 (43)
Musholt*51 1999 78.8 18.2 51.5 88 3.5ft 33 - 48 19 ms 33 8 & 37 ms 18 12 ms
Nakao 59 2001 19.4 9.7 - 100 7.5 31 77 (68) 100 77 (67)
Tsa i22 2005 61.8 5.9 8.8 100 5.8** 34 86 47 84 53 88
Segal26 2006 - - - 88 10.3ft 49 78 67 79 33 75
Wada**50 2006 - 37.5 - 100 7.7 64 52 92 (88) [81] 20 84 (63) 28 44(11)
Gaissert32 2007 42.7 20.7 56.1 75.6 6.1 82 52 (35) [22] 100 52 (35) [22]
f  Numbers in parenthesis: 10-year survival rate. Numbers in brackets: 15-year survival rate
* After 5 years of follow-up, 4 of 6 patients were free of disease
* Survival stated as median survival. Median survival 8 months in circumferential resection, 37 months in step resection 
f t  Follow-up duration in alive patients
** Median follow-up period
** Disease-specific survival stated. Conservative resection group consisted of 13 shave excisions and 20 partial resections such as window resection 
N1 = presence of lymph node metastases, M1 = presence of distant metastases, WD = well-differentiated, ms = months
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Outcome measures after resection performed with palliative intent focus on freedom 
from airway obstruction, hemoptysis, and airway tubes in the survival period. Of 7 
patients in the series of Grillo and colleagues who underwent airway resection in the 
presence of pulmonary metastasis, 2 with undifferentiated carcinoma survived less 
than one year, but during a mean survival of 4.2 years the remaining patients were 
free of airway events 44 Quality of life for patients with thyroid carcinoma invading 
the airway improves after tracheal resections with end-to-end anastomosis 21,51,60,61. 
Resection of the trachea invaded by tumor appears largely to accomplish the goals 
of preventing the dire late problems of airway obstruction and hemorrhage.
Discussion
Once thyroid carcinoma has transgressed the glandular capsule, invasion into the 
airway wall leads to a reduction in local control and survival. Four of the 5 staging 
systems for thyroid cancer acknowledge the negative prognostic impact of local 
invasion. The accelerated progression of disease in the years after diagnosis of 
luminal tracheal invasion is not controversial. A separation of these tumors into 
those with superficial and deep invasion is artificial and inadequate to guide 
treatment selection. There is now clear evidence of a higher rate of local recurrence 
and death after tangential shave resection for presumed superficial invasion. 
Conversely, immediate airway resection is associated with longer disease-free 
survival compared to later resection at the time of recurrence 32 No oncologic data 
exist to support an incomplete resection for curative intent. Partial thickness 
invasion of the tracheal wall should therefore be regarded as an earlier stage of 
transmural invasion and treated with sleeve resection of the airway.
The surgeon unfamiliar with the techniques of tracheal resection has three options 
when encountering tracheal invasion. Operative exploration without thyroidectomy, 
leaving complete, combined resection to the surgeon trained in thyroid and airway 
procedures. Alternatively, combined resection may be performed by a 
multidisciplinary team of thyroid and tracheal surgeons. If thyroidectomy has been 
completed with a shave resection, tracheal or laryngotracheal resection may then be 
performed after referral to a surgeon or center experienced in airway surgery. 
Observation alone of a potentially invaded trachea not proven to be tumor-free is 
less than ideal given the option of tracheal and laryngotracheal resection in centers 
with experience in airway surgery.
Long-term (> 10 to 20 years) follow-up studies with detailed clinical and pathologic 
data including serum thyroglobulin levels, ultrasound examination, thyroid scans, and 
bronchoscopy to measure local recurrence and survival are scant or non-existent. 
The burden of proof rests on surgeons continuing to use shave resection, and based 
on the literature and our experience, we advocate tracheal resection when indicated.
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ABSTRACT
Background: Laryngotracheal invasion worsens prognosis in patients 
with thyroid carcinoma. The extent of resection is controversial.
Methods: We performed a retrospective study of patients with thyroid 
carcinoma and invasion of larynx or trachea between 1964 and 2005.
Results: Eighty-two patients, mean age 64 years and 50% female, 
underwent segmental airway resection. Differentiated carcinoma was present in 
76% (62/82), prior tracheal "shave” procedures in 40% (33/82), transmural 
invasion in 58% (48/82), and preoperative vocal cord paralysis in 35% (29/82). 
There were 29 tracheal and 40 laryngotracheal resections (Reconstruction 
group, 69 patients); 5 had laryngectomy, 7 cervical exenteration and 1 tracheal 
resection after exenteration (Salvage group, 13 patients). Operative mortality 
was 1.2% (1/82) and anastomotic dehiscence 4.3% (3/69). Tracheostomy was 
permanent in 4.3% (3/69). Mean follow-up was 6.1 years. Following 
Reconstruction, mean survival was 9.4 years and 10-year survival 40%, after 
Salvage, 5.6 years and 15%. In differentiated carcinoma, thyroidectomy, 
immediate shave procedure and delayed (mean 67 months) resection of airway 
recurrence in 15 patients resulted in overall and disease-free survival of 13.1 
and 5.1 years, compared to 17.9 and 14.6 years after thyroidectomy and early 
airway resection in 11 patients. Airway symptoms, metastases at presentation, 
recurrent disease and salvage operation were associated with decreased 
survival; airway resection early after thyroidectomy, complete resection, and 
well-differentiated tumors with improved prognosis.
Conclusions: Segmental airway resection for invasive thyroid cancer is 
safe, preserves voice, and relieves airway obstruction. Complete resection of 
laryngeal and tracheal invasion during or early after thyroidectomy is 
associated with improved survival.
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Introduction
The prognosis of patients with well-differentiated thyroid carcinoma is excellent, with 
a 10-year survival rate close to 90% after surgical resection 1. Laryngeal or tracheal 
invasion, found in approximately 6% of thyroid carcinoma 2, is an independent 
predictor of death 3 Advanced invasion may produce hemoptysis, hoarseness and 
dyspnea and leads to life-threatening complications such as airway hemorrhage and 
suffocation. Indeed, airway obstruction is the cause of death in 50% of patients with 
thyroid carcinoma 4 These observations emphasize the importance of local control in 
both early and advanced airway invasion.
In thyroid carcinoma, complete resection of local disease provides the longest 
survival and the best palliation. In pursuit of this goal, segmental laryngotracheal and 
tracheal resection have been applied at Massachusetts General Hospital (MGH) to 
patients with superficial and transmural invasion of the airway. While segmental 
resection is widely accepted for transmural invasion 3,5-7 adherence to the trachea or 
larynx due to superficial invasion, in contrast, often is treated with tangential excision 
from the airway ("shaving”), even though this technique violates oncologic principle 
and falls short of complete resection 2 Long-term evidence supporting tangential 
excision is absent, and recurrence is common 8-10 Our approach was previously 
reported 11,12 and is now updated to analyze long-term results in a larger group of 
patients.
Patients and Methods
Patient Selection
Between 1964 and July 2005, 113 patients were seen with thyroid carcinoma 
invading larynx or trachea. Thirty-one patients (27.4%) were excluded from further 
analysis. Disease was not resected in 28 patients due to extensive local disease, 
advanced distant disease, or refusal of surgery. Three patients in the early 
experience of Grillo and colleagues 11,12 were excluded because their treatment is 
now obsolete: 2 had skin tube reconstruction of the trachea using cervical skin 
supported with plastic rings, a technique not used since and considered 
unnecessary; 1 who presented after high-dose (78 Gy) external beam radiation 
elsewhere experienced anastomotic dehiscence following tracheal reconstruction. 
Two of the 3 patients were operative deaths. The remaining 82 patients (72.6%) 
constitute the study population.
The 82 patients were classified according to clinical presentation and extent of 
disease. Twenty-eight patients presented with locoregional recurrent disease late 
after prior thyroidectomy (Delayed Presentation), while 11 patients were either 
referred for tracheal resection directly after thyroidectomy (8 patients) or underwent 
airway resection (3 patients) at the time of thyroidectomy (Early Presentation). There 
were 26 patients without previous thyroidectomy who had either airway obstruction
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or hemoptysis due to transmural disease (Symptomatic Presentation). Finally, 17 
patients had symptomatic airway disease and distant metastasis (Palliative 
Presentation). In the Early Presentation group, no patient had hemoptysis or 
dysphagia and only 1 who at first refused resection had dyspnea.
Pathology reports, operative reports, and hospital charts were reviewed. The survival 
period began on the day of operation at MGH, except where otherwise indicated. 
The MGH institutional review board approved previous retrospective studies and the 
most recent protocol in August 2005. Consent was received from patients before 
obtaining follow-up information.
Determination of Resectability
Patients underwent assessment of locoregional and distant metastatic disease 
before resection. Radiographic evaluation included conventional tracheal 
tomography in the early experience and computed tomography thereafter. Limited 
presumed or known pulmonary metastasis was not a contraindication to resection. 
Bronchoscopy was performed before resection to assess presence and extent of 
luminal invasion. Tracheal resection was considered when complete resection of 
gross airway disease appeared feasible. Symptomatic airway involvement was an 
indication for palliative resection even when grossly positive peritracheal margins or 
pulmonary metastasis were noted. A tumor was considered unresectable when 
advanced metastatic disease was present, the length of involved airway at 
bronchoscopy precluded primary anastomosis or mediastinal tracheostomy, or when 
invasion of vital adjacent organs was found during operative exploration.
Types of Resection
For tracheal resection, a segment of trachea was removed with end-to-end 
reconstruction. For laryngotracheal resection, the tumor was removed with a portion 
of infraglottic larynx, shaping the remaining trachea to reconstruct the laryngeal 
defect. These procedures belonged to the Reconstruction group and required at 
least one functioning recurrent laryngeal nerve not involved with tumor. When 
preoperative unilateral vocal cord paralysis was present, the contralateral thyroid 
lobe was often preserved. Invasion of esophageal muscle or mucosa was treated 
with tangential resection of full-thickness wall or muscle coat. The procedures in the 
Salvage group, cervicomediastinal exenteration or laryngectomy alone, were 
considered in patients who had airway compromise due to malignant airway stricture 
or aspiration with or without impaired swallowing. Exenteration and intestinal 
substitution was performed when the larynx could not be salvaged and consisted of 
laryngectomy, resection of trachea, esophagectomy, total thyroidectomy and usually 
parathyroid resection with creation of a cervical or mediastinal tracheal stoma. 
Locoregional lymph nodes were resected except for paratracheal nodes not 
immediately adjacent to tumor, which were preserved to protect tracheal blood 
supply. Absence of tumor at the airway margins was confirmed by frozen section 
unless the limits of resection had been reached and no additional trachea could be
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removed without sacrificing larynx. The resection was judged to be complete when 
airway margins were found to be free of disease, soft tissue margins were not 
grossly involved with tumor, and no statement in the operative note indicated that 
gross tumor remained.
Tumor Data
Tumor dimension in the airway axis, depth of invasion, and the presence of tumor at 
airway or radial margins were recorded from a review of pathology reports. Positive 
airway margins indicated true residual, most often microscopic, tumor. Tumor 
involvement of excised lymph nodes was noted. To analyze the extent of invasion, 
the Shin staging system was used for well- (papillary and follicular carcinoma) and 
poorly differentiated thyroid carcinoma 13
External Beam Radiotherapy and I-131 Therapy
Postoperative radiotherapy or oral radioactive iodine therapy were administered 
selectively when the resection was incomplete. After bronchoscopic assessment of 
anastomotic healing, a recommended dose of 54 Gy to the neck and superior 
mediastinum was administered 6 to 8 weeks after resection, following bronchoscopic 
check of the anastomosis. Most patients received treatment outside MGH, and the 
decision to administer adjuvant therapy was made elsewhere.
Follow-Up
Patients and their physicians were contacted for follow-up information. The social 
security death index was searched. Patients were determined to have died if name, 
date of birth, and social security number matched.
Statistical Analysis
Overall and disease-free survival after airway resection were calculated using the 
Kaplan-Meier procedure with the log rank test implemented in the SPSS 12.0 
statistical software program (SPSS Inc., Chicago, IL). In patients presenting with 
airway recurrence only, the date of tracheal resection concluded the disease-free 
survival after previous thyroidectomy. To compare overall and disease-free survival 
after thyroidectomy with shave excision of the airway to thyroidectomy with 
immediate or early tracheal resection, the survival period was calculated from the 
date of first thyroidectomy.
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Results
Patient Characteristics
The characteristics of 82 patients are listed in Table 1 according to the type of 
resection and airway reconstruction. Overall, well-differentiated tumors were found in 
62 patients (75.6%), in 72.5% of patients undergoing Reconstruction and in only 
38.5% of the Salvage group. Pathologic evaluation identified transluminal tumors 
(Shin stage IV) in 48 patients (58.5%).
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Table 1. Characteristics of 82 resected patients with thyroid carcinoma invading the airway. 
Reconstruction consisted of primary airway anastomosis; resection for salvage included
Reconstruction Salvage Overall p-value
n % n % n % (X2)
N 69 84.1 13 15.9 82 100.0
Mean age (median) in years 63.9 (66) 64.0 (67) 63.9 (66)
Sex 0.131
Male 32 46.4 9 69.2 41 50
Female 37 53.6 4 30.8 41 50
Prior thyroidectomy 39 56.5 7 53.8 46 56.1 0.858
Prior shaving 29 42.0 4 30.8 33 40.2 0.745
Previous I-131 29 42.0 5 38.5 34 41.5 0.811
Previous XRT 6 8.7 4 30.8 10 12.2 0.026
Transluminal disease 42 60.9 6 46.2 48 58.5 0.323
Laryngotracheal resection 40 58.0 40 58.0
Complete resection 36 52.2 8 61.5 44 53.7 0.535
Adjuvant RAI 28 40.6 3 23.1 31 37.8 0.233
Adjuvant XRT 24 34.8 4 30.8 28 34.1 0.780
Common symptoms
Hemoptysis 19 27.5 1 7.7 20 24.4 0.126
Dyspnea, wheezing 18 26.1 7 53.8 25 30.5 0.046
Mass 26 37.7 2 15.4 28 34.1 0.120
Vocal cord paralysis 25 36.2 4 30.8 29 35.4 0.706
Asymptomatic 8 11.6 0 0.0 8 9.8 0.196
Histologic type
Papillary 50 72.5 5 38.5 55 67.1 0.017
Follicular 6 8.7 1 7.7 7 8.5 0.905
Anaplastic 3 4.3 4 30.8 7 8.5 0.002
Huerthle cell 3 4.3 0 0.0 3 3.7 0.444
Oxyphillic 2 2.9 1 7.7 3 3.7 0.398
Squamous cell 1 1.4 1 7.7 2 2.4 0.181
Medullary 1 1.4 0 0.0 1 1.2 0.662
Undifferentiated giant cell 1 1.4 0 0.0 1 1.2 0.662
Carcinosarcoma 0 0.0 1 7.7 1 1.2 0.020
Poorly differentiated 2 2.9 0 0.0 2 2.4 0.534
Operative treatment
In the Reconstruction group, 40 patients underwent laryngotracheal resection (58%) 
and 29 tracheal resection (42%). One patient had a tracheal resection for primary 
tracheal neoplasm with skin tube reconstruction 31 years before presenting with a 
new papillary thyroid carcinoma invading her skin tube. She underwent resection of 
thyroid and skin tube with primary tracheal end-to-end anastomosis. A single patient 
had a wedge resection of the anterior tracheal wall early in the experience. Three 
patients (4.3%) underwent concomitant lateral excision of full-thickness esophageal 
wall with primary closure and 10 patients (14.5%) had excision of esophageal 
muscle for tumor invasion. The length of the resected airway measured 1.5 to 6.0 cm
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(mean 3.2 cm). Resection was complete in 36 patients (52.2%). In 33 patients with 
incomplete resection, 4 had residual gross disease. Microscopic positive resection 
margins in 29 patients consisted of 25 positive airway margins, 3 uncertain airway 
margins with positive soft tissue margins, and 1 positive soft tissue margin only. 
Residual gross disease was due to distant metastases in 3 and the single wedge 
resection in 1. Five patients with incomplete resection had prior total thyroidectomy; 
all others underwent thyroidectomy.
In the Salvage group, 7 of 13 patients underwent cervical exenteration, 4 patients 
laryngectomy without esophagectomy, 1 laryngectomy with partial lateral 
esophagectomy, and 1 underwent tracheal resection after exenteration and 
tracheostomy. In patients with exenteration, the larynx was spared in 1 patient and 
the esophagus was reconstructed with colon interposition in 3, gastric pull-up in 2, a 
pectoralis flap in 1 and primary reconstruction in 1. Esophageal muscle was partly 
excised in 3 of 4 patients undergoing laryngectomy without esophagectomy. Mean 
length of resected airway was 9.1 cm (range 3.0 to 15.5 cm, the latter length 
including larynx). Complete resection was accomplished in 8 patients (61.5%).
Complications
The single death resulted from airway obstruction due to glottic edema after 
laryngotracheal resection. Table 2 lists the complications after Reconstruction and 
Salvage. Anastomotic dehiscence occurred in 3 Reconstruction patients (4.3%). Two 
had laryngotracheal reconstruction and were treated with temporary tracheostomy 
for less than a month. The third patient, in whom 4.5 cm of trachea were resected 
with laryngeal release, died 7 months later from respiratory failure. After Salvage, 2 
patients with separation of tracheal stoma from skin were treated with a stomal stent. 
Hypoparathyroidism occurred in only 2 patients after Salvage (15.4%) and 3 after 
Reconstruction (4.3%). Four of 6 patients with postoperative aspiration developed 
pneumonia. Postoperative dysphagia was observed in 3 patients, of whom 2 had 
lateral esophageal resection.
Table 2. Complications after Reconstruction and Salvage (n). Percentages in parenthesis
Reconstruction Salvage Overall
N 69 13 82
Hypoparathyroidism 3 (4.3) 2 (15.4) 5 (6.1)
Aspiration 5 (7.2) 1 (7.7) 6 (7.7)
Dysphagia 3 (4.3) 0 3 (3.7)
Anastomotic dehiscence 3 (4.3) 2 (15.4) 5 (6.1)
Bilateral vocal cord paralysis 6 (8.7) 6 (8.7)
Temporary tracheostomy 13 (18.8) 13 (18.8)
Permanent tracheostomy 3 (4.3) 3 (4.3)
Other 7 (10.1) 7 (53.8) 14 (4.9)
Mortality 1 (1.4) 0 1 (1.2)
No complications 44 (63.8) 6 (46.2) 50 (61.0)
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Five of 6 patients in the Reconstruction group with postoperative bilateral vocal cord 
paralysis had preoperative unilateral paralysis, and the contralateral recurrent 
laryngeal nerve was preserved in 4. Four of 6 had temporary tracheostomy from 1 to
9 months: 3 required vocal cord lateralization and 1 had spontaneous vocal cord 
recovery less than 1 month after operation. The indications for temporary 
tracheostomy in 13 of 69 patients (18.8%; mean duration 2, range 0 to 9, months) 
were bilateral vocal cord paralysis in 4, anastomotic dehiscence in 2, aspiration 
pneumonia in 1 and dyspnea from subglottic edema in 1. Five were placed for 
protective reasons during operation. Three patients required permanent 
tracheostomy (4.3%): 1 patient with anastomotic dehiscence and respiratory failure 
described above, 1 who died 10 months after operation from metastatic disease, and
1 patient who died 2 months after resection from myocardial ischemia. The 
incidence of complications decreased over 4 decades to 25.8% from 1996 to 2005. 
Postoperative adjuvant therapy is detailed in Table 1.
Long-term Results
The mean follow-up period was 6.1 years (range 2 months to 24 years). Follow-up 
was complete in all patients. Of 65 patients surviving the operation without 
permanent tracheostomy, 11 patients had only local recurrence treated with an 
airway tube in 4, 7 patients had distant recurrence only, 6 patients had both distant 
and local recurrence treated with an airway tube in 2, 5 patients with distant 
metastasis at operation did not develop local recurrence, and of 9 other patients with 
distant disease at operation who later developed local recurrence, 2 required an 
airway tube. In total, 8 patients received an airway tube due to local recurrence. 
Table 3 shows overall and disease-free survival in the Reconstruction and Salvage 
groups. Figure 1 depicts the survival curves of Reconstruction and Salvage groups.
Table 3. Overall and disease-free survival (DFS) in Reconstruction and Salvage groups
Overall
(n=82)
Reconstruction
(n=69)
Salvage
(n=13)
Mean survival (years) 8.93 9.45 5.56
5-year survival (%) 52 55 38
10-year survival (%) 35 40 15
15-year survival (%) 22 23 15
Mean DFS (years) 5.35 6.07 2.67
5-year DFS (%) 33 34 23
10-year DFS (%) 16 21 0
15-year DFS (%) 14 18 0
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Figure 1.
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Survival in years
Patients at risk (n)
69 31 14 5 --------  Reconstruction
13 5 2 1 ..........Salvage
Figure 2.
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Survival in years
Patients at risk (n)
37 21 12 6 --------  Complete resection
25 9 3 0 - - - - -  Incomplete resection
Figure 3.
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Figures 1-3. Survival curves by 1. Reconstruction and Salvage groups; 2. Complete and incomplete 
resection in well-differentiated carcinomas (n=62); 3. Type of presentation
.25
Sixty-two patients with well-differentiated thyroid carcinoma were analyzed 
separately. Overall and disease-free survival is shown in Table 4. After complete 
resection, mean survival was 13.8 years and survival at 15 years 44%. As shown in 
Figure 2, after incomplete resection mean survival was only 5.3 years and none of
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the patients is alive at 15 years (p<0.0001). Disease-free survival was also 
significantly higher in patients with complete resection (p=0.0053).
As shown in Figure 3, there is a marked difference in survival between asymptomatic 
patients undergoing airway resection at the time of thyroidectomy or early thereafter 
in comparison with all other groups. The prognosis after Delayed, Symptomatic, or 
Palliative Presentation is worse compared to patients with Early Presentation 
(p=0.0417). Palliative resection, however, in some patients is compatible with long­
term survival. Three patients are presently alive 5, 11 and 21 years after palliative 
airway resection.
Table 4. Overall and disease-free survival (DFS) in well-differentiated thyroid carcinoma
Overall
(n=62)
Reconstruction
(n=56)
Salvage
(n=6)
Complete resection
Yes
(n=37)
No
(n=25)
Mean survival (years) 10.23 10.57 6.11 13.77 5.34
5-year survival (%) 60 63 33 74 39
10-year survival (%) 42 45 17 61 17
15-year survival (%) 25 26 17 44 0
Mean DFS (years) 6.45 7.02 1.67 8.53 2.94
5-year DFS (%) 37 41 0 50 18
10-year DFS (%) 22 25 0 28 14
15-year DFS (%) 19 22 0 28 7
Survival after Thyroidectomy
We identified 15 patients with well-differentiated histology and recurrent disease after 
shave procedure (Delayed Airway Resection group) among 28 with prior 
thyroidectomy and compared them to 11 patients who underwent early airway 
resection (Early Airway Resection group). Characteristics of these groups are 
described in Table 5. Three of the 15 patients belonged to a low-risk age group 14 at 
the time of thyroidectomy (2 women less than 50 years, 1 man less than 40 years of 
age) and 11 (73.3%) had received radioactive iodine therapy after thyroidectomy. 
One patient, counted as an early resection, was referred immediately following 
thyroidectomy and tracheostomy, but did not present for laryngotracheal resection 
until 14 months later.
Figure 4 compares the overall survival of patients with early shave procedure and 
late airway resection for recurrence after a mean delay of 67 months to those who 
underwent immediate or early airway resection. Mean survival calculated from the 
date of thyroidectomy in the Delayed group was 13.1 years and 20-year survival 
24%, lower than following early airway resection. Disease-free survival after early 
airway resection was significantly higher (p=0.0092) than after delayed resection 
(14.6 vs. 5.1 years; Figure 5), and disease-free survival at 20 years was also 
significantly higher (50 vs. 0%).
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Table 5. Characteristics of patients with delayed vs early airway resection after thyroidectomy
Delayed Airway Early Airway 
Resection Resection
n % n %
N 15 11
Mean age at thyroidectomy* 59.7 (34-79) 60.3 (17-79)
in years
Sex
Male 5 66.7 5 45.5
Female 10 33.3 6 54.5
Well-differentiated histology 15 100.0 11 100.0
Papillary carcinoma 12 80.0 10 90.9
Positive lymph nodes at thyroidectomy 4 26.7 4 36.4
Distant metastasis at thyroidectomy 0 0.0 0 0.0
Mean interval thyroidectomy - airway resection* 62 (13-202) 3 (0-14)
in months
Shin stage at airway resection
I 1 6.7 4 36.4
II 1 6.7 1 9.1
III 2 13.3 3 27.3
IV 11 73.3 3 27.3
* Numbers in parentheses: range
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Discussion
The present study confirms in a large group of patients the safety and effectiveness 
of segmental tracheal resection noted in the earlier reports from our unit. With 
increasing experience and when considering presently applied indications and 
procedures, the operative mortality has declined to 1.2% and the complication rate 
decreased from 44% to 26% over the last three decades. These results are 
substantiated by Ozaki 15, Tsumori 1, Ishihara 4, and their colleagues who saw no 
operative deaths in a combined 58 segmental tracheal resections. Operative risk 
should therefore not serve as the reason to forgo complete resection of thyroid 
cancer involving the airway, though operative risk remains a function of surgical 
experience 16,17
Shave or tangential excision appears to be common and preferred surgical 
management for airway invasion. More than half of all patients in our study treated 
with segmental laryngotracheal and tracheal resection (46/82) had prior resection of 
thyroid carcinoma, and 33 of these underwent so-called "shave” procedures. The 
proponents of shave procedures point to lack of data on the prognosis of airway 
invasion, to available adjuvant external beam radiotherapy (EBRT) and radioactive 
iodine (RAI), and to concerns about quality of life after tracheal resection. Czaja and 
associates compared 34 patients who underwent complete surgical resection of 
tumor with 75 patients who had shave excision and found no differences in survival 
between both groups 3. Nishida and colleagues agreed that survival in 40 patients 
with deep tracheal invasion treated with tracheal resection was no different than that 
in 13 patients with superficial invasion treated with a shave 6 Because a tracheal 
specimen does not accompany the thyroid after tangential excision, we do not know 
the presence or depth of invasion in the two studies above. There is now sufficient 
evidence to state that depth of invasion predicts outcome 1,13 In long-term studies, 
other authors emphasize the high risk of recurrence following excision of airway 
invasion by thyroid carcinoma. Six of 35 patients with superficial tracheal adherence 
treated with tracheal shaving in a study by McCarty et al. had local recurrence after 
10 years (17%) 5 Seven of 16 patients after shave procedures treated with RAI or 
EBRT after operation died of disease 3.6 years after surgery, and disease was 
controlled in only 25% of patients after 5.9 years 8 In contrast, local airway 
recurrence after segmental tracheal resection is infrequent. Following 31 patients for 
a mean of 10.6 years after resection, Nakao and colleagues 19 found only 2 local 
among 12 total recurrences (6.5%). The high recurrence rates reported above by 
Park and associates 8 occurred despite RAI or EBRT. In our group of 15 delayed 
airway resections for well-differentiated carcinoma, 11 patients had received RAI 
therapy after thyroidectomy (73.3%). We observed airway recurrence requiring 
tracheostomy in 12.3% (8/65). Since the surgical technique to achieve complete 
resection is well established, a reliance on RAI or EBRT following shave procedures 
is difficult to justify and may be futile. Finally, the quality of life after segmental airway
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resection in patients with thyroid carcinoma involving the airway is higher than before 
operation 17,18
Immediate or early complete resection of laryngotracheal invasion is followed by the 
longest overall and disease-free survival. We found complete resection a significant 
prognostic factor, and positive airway margins defined a majority of patients with 
incomplete resection (79%, 26/33). We also identified in this retrospective analysis a 
comparable set of patients mainly distinguished by the date of airway resection after 
thyroidectomy. When determining survival from the date of the first thyroidectomy as 
the start of follow-up, and after adding a mean survival period of more than 5 years 
to patients who presented after shave resection for delayed airway resection, we 
found a persistent benefit of early airway resection for differentiated thyroid 
carcinoma. The two groups had minor differences in the proportion of female 
patients, though not in age at first resection or absence of distant metastasis. Overall 
survival calculated from the date of first thyroidectomy was longer after early airway 
resection, though not significant due to sample size. Disease-free survival, however, 
was significantly higher after early resection, with 10- and 20-year disease-free 
survival rates of 67% and 50%, while after delayed resection disease-free survival at
10 years was only 7% and none of the patients was alive without disease after 20 
years. The purpose of such comparison, exposed as it may be to selection bias, is of 
course not to replace, but to provoke, an overdue prospective multi-institutional study 
of the surgical options in laryngotracheal invasion.
Palliative resection offers benefit in terms of survival or quality of life in few solid 
tumors. The patients presenting with distant metastasis had a mean survival of 6 
years after segmental airway resection. Even in the presence of distant metastasis, 
segmental airway resection may prolong survival, control disease and lead to long 
term survival in some patients 19. We therefore continue to apply palliative tracheal 
resection in carefully selected patients.
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General Discussion
This thesis describes two unusual types of cancer both localized in the trachea, 
namely primary tracheal carcinoma (Chapters 2, 3 and 4) and thyroid carcinoma 
invading the trachea (Chapter 5), focusing on the treatment of these cancers, and 
addressing existing controversies and shortcomings in the management of patients 
with these rare tumors.
Primary Tracheal Carcinoma
In Chapter 3.1, it is shown that in resected squamous cell carcinoma (SCC) of the 
trachea, irradical resection, involvement of the thyroid gland, and lymphatic invasion 
are histopathologic features with important negative prognostic value. Contrastingly, 
as described in Chapter 3.2, in adenoid cystic carcinoma (ACC) of the trachea, 
invasion of adjacent organs does not seem to affect survival. En bloc resection of 
invaded organs, such as the thyroid or the esophageal muscle coat, resulted in 
acceptable long-term survival, as long as negative radial margins could be obtained. 
Lymph node invasion and perineural invasion were also important negative 
predictors of survival. No statement on the absence or presence of perineural 
invasion was included in the pathology report in 55% of cases. Given its important 
impact on survival, we recommend to always include a statement regarding 
perineural growth in the pathology reports describing all specimens of tracheal 
tumors.
For both studies on tracheal SCC and ACC, it is important to realize that the 
conclusions are based on resected cases only. Tumors growing into vital organs 
such as the heart or the great vessels and tumors involving long segments of airway 
judged unresectable were not included in these studies.
In both tumors, one of the most important prognostic factors was completeness of 
resection. Gaissert previously described that survival in patients with unresectable 
tracheal cancer is dismal 1. In addition, long-term survival (> 10 years) is observed 
after tracheal resection of locally advanced ACC (Chapter 3.2). Thus tumor 
resectability, usually dictated by tumor length in the long axis of the airway and 
invasion of vital organs, is possibly the single most important prognostic factor in this 
very distinct type of cancer. In future research, the possible roles of HPV-infection, 
K-ras mutation, EGFR and possibly more mutations should be further investigated 
focusing on relation of prognosis and individual treatment planning.
Undertreatment of Primary Tracheal Carcinoma
Comparing population-based studies and surgical series in Chapter 2, there are 
several striking differences. First, the incidence of ACC proved to be lower in studies 
derived from epidemiologic data: 3-21% 2-7 compared to 30-60% in clinical series 18' 
14 Second, the rate of patients undergoing surgical resection in population-based 
studies is around 10% 2-6, while in series from clinics with experience in tracheal 
resections, around 70% of patients are treated with surgery 1,15 Third, a relatively
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high incidence of small cell carcinoma (6-7%) is found in population-based studies 
25, while this histologic type is virtually never reported in clinical series 9 
The study undertaken in the Netherlands described in Chapter 4.1 of this thesis 
confirms all the above mentioned findings that were previously reported in 
population-based studies from the United Kingdom 56, Finland 16, Japan 3, Denmark
2 and the United States 7 In the Netherlands, ACC accounted for only 7% of all 
tracheal malignancies, 12% of patients underwent resection and small cell 
carcinoma was found in 11 % (Chapter 4.1). Of 22 patients with ACC, 11 (50%) were 
treated with surgery, making up 32% of the group of surgically treated patients 
(Chapter 4.1). However, in series from Canada and China, around 80% of patients 
with ACC were resected 15,17.
As surgery is the best curative treatment modality currently available, it is important 
to determine what the reasons are for the discrepancy in treatment pattern between 
population-based studies and several large clinics. Part of this striking difference is 
likely based on the referral function that centers with experience in the management 
with tracheal tumors have, leading to a highly selected population in reports from 
these clinics. However, taking this factor into account, Gaissert and Hazama stated 
that at least half of all patients with tracheal carcinoma in the general population 
should be candidates for surgical resection 911. Gaissert also stated that due to the 
absence of radiologic and pathologic review of cases in population-based studies, 
some cases might be misclassified as primary tracheal tumors 9 The relatively high 
incidence of small cell carcinoma (6-11%) is an important sign of this contamination 
with metastatic, mainly bronchial, carcinoma 18
To determine the proportion of patients registered in the Netherlands Cancer 
Registry (NCR) with tracheal cancer whose radiographic findings are consistent with 
the diagnosis and who are candidates for surgical resection, a nationwide audit of 
cases was conducted as described in Chapter 4.2. Of 101 registered cases in the 
period 2000-2005, 34 (34%) were other primary tumors misclassified as tracheal 
cancer. This finding in combination with earlier results described in Chapter 4.1 
(0.142 per 100,000) leads to an estimated incidence of approximately 1 case of 
primary tracheal carcinoma per one million persons per year. Based on the results 
from the audit, one can assess that ACC makes up around one quarter of all tracheal 
carcinomas, while SCC accounts for around half of all cases. In the process of 
registration in the NCR, results of any biopsy of malignant cells from the trachea are 
reported to the NCR automatically as tracheal cancer by the national pathology 
database (PALGA). The final registration in the NCR database, however, involves a 
review of the complete medical file. Thus, reasons for this misclassification may be 
administrative in the NCR registration, incomplete disclosure of surgery reports, 
typing errors or misclassification by doctors.
Since population-based studies based on Finnish 4 and Danish 2 cancer registries 
found 27% and 12% misclassified tumors even without radiologic review of all cases, 
this is likely an internationally existing problem that should be addressed, at least
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partially by adapting the registration process. This could lead to a more correct 
registration of rare airway tumors in the future.
Fifty patients with primary tracheal carcinoma and sufficient data were available for 
the multidisciplinary panel of specialists and second reviewer to judge respectability. 
Of those, 12 patients had been treated with surgery, while both panel and second 
reviewer identified 16 additional surgical candidates, a total of 28 (56%). Of 13 
patients with ACC, 10 (77%) were judged to be candidates for surgical resection, 
while only 7 of these (54%) had actually undergone surgery. These findings indicate 
that there might be an undertreatment of this rare airway tumor in the Netherlands, 
and, in view of the similar results in other population-based studies, likely in more 
countries. The concept of unsolicited panel and radiographic review of all registered 
cases of a certain type of tumor in one country in a designated period by external 
auditing of blinded and abstracted data by a panel of experts is unique in its design. 
It approximates the concept of multidisciplinary oncologic review by local experts 
adopted for common tumors in everyday practice. However, the method itself is 
subject to limitations, the most important being that not all specialists have had 
personal contact with the patient. Treatment advice of our panel review was however 
highly reproducible: the inter-reviewer disagreement between panel and second 
reviewer was small (8%).
Potentially Too Conservative Treatment of Thyroid Carcinoma Invading the 
Airway
Controversy exists on the extent of resection needed to treat thyroid carcinoma 
appropriately if the tumor has invaded the airway. One of the most important issues 
that leads to this controversy is selection bias in clinical studies. In most studies 
comparing conservative "shave” excisions with segmental airway resection, shave 
excision is only applied to superficially invasive carcinomas, while segmental airway 
resection is reserved for, often recurrent, tumors extensively invading the larynx and 
or trachea 19,20  As discussed in Chapter 5.1, there is however clear evidence of a 
higher rate of local recurrence and death after shave resection even in patients with 
superficial invasion 21-23  Conversely, segmental airway resection is associated with 
longer disease-free survival compared to delayed resection when recurrent disease 
has been diagnosed (Chapter 5.2).
As reported in Chapter 5.2, the mortality and complication rates have dropped to 
1.2% and 26% in the last three decades. Although operative risk remains a function 
of surgical experience 24,25, it should not serve as a reason to forgo complete 
resection of thyroid cancer involving the airway. Moreover, the quality of life after 
segmental airway resection in patients with thyroid carcinoma involving the airway is
25,26higher than before the operation ,26. No data exist to support an incomplete 
resection for curative intent in oncology practice. Partial thickness invasion of the 
tracheal wall should probably be regarded as an earlier stage of transmural invasion 
and treated with sleeve resection of the airway. This implies that in the situation
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where airway invasion is diagnosed pre-operatively, consultation of an experienced 
airway surgeon is recommended for adequate planning of the operation including en 
bloc resection of thyroid and the diseased part of the airway. When, more commonly, 
involvement of the larynx or trachea is found unexpectedly during thyroidectomy, we 
advocate consulting with an airway surgeon intra-operative or directly post-operative 
to warrant immediate or early resection of the remaining part of the tumor in the 
airway wall by means of a segmental airway resection and reconstruction.
Although thyroid carcinoma invades the airway in 6% of cases, this scenario lacks in 
the Dutch guideline on thyroid carcinoma (Centraal Begeleidings Orgaan, CBO, 
2007) 27. However, the guideline emphasizes that any patient with thyroid carcinoma 
should be treated in a multidisciplinary team and that all patients with lymph node 
metastasis and / or recurrent disease should be treated in a multidisciplinary team in 
a highly specialized centre (level 1 hospital) 27 In this respect, airway-involvement 
should be regarded as the same serious stage of disease.
Centralization
In rare diseases such as tracheal tumors, the pool of experts is small and often not 
local. We believe that each patient diagnosed with a tracheal tumor should be 
referred to a tertiary oncology center with multidisciplinary experience in the 
treatment of tracheal tumors. Given the rarity of the disease, to warrant sufficient 
exposure to (malignant) tracheal pathology and to maintain experience, one center 
per each population of an estimated 10 to 20 million would be optimal. In such a 
centre, approximately 10 to 20 patients with primary tracheal cancer would be 
managed by a multidisciplinary team of specialists and an estimate of 5 to 10 
patients would eventually be operated on. In the Dutch situation with a population of 
16.5 million inhabitants (Centraal Bureau voor de Statistiek, CBS, 2009), this would 
mean one national center. By centralizing the care for patients with this rare airway 
tumor, more patients may be selected for surgical resection, thus potentially 
improving survival outcome and quality of care. Because this improvement is inferred 
but untested, close evaluation would be needed once a centralized system is 
implemented to assess the exact benefit of this new strategy. Similar centralization 
has been organized in the Netherlands for much more frequent malignant tumors like 
esophageal cancer and gynecological cancers. This process was driven by studies 
relating volume and outcome in these cancers 28-30, but also in other patients groups 
like lung cancer and head and neck cancer the evidence for centralization is 
increasing.
In the Netherlands, these insights ultimately led to a report from the Dutch Cancer 
Society in which is concluded that oncologic care in the Netherlands should be 
centralized in (high-volume) centres by 2012. As a rule, an oncologic surgeon should 
only perform a procedure when a volume criterion of at least 10 per year is met.
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Future developments
On a final note, one issue that should not be left unaddressed is the ongoing quest 
for a material with which large post-resection tracheal defects can be reconstructed, 
as primary reconstruction with end-to-end anastomosis can usually only be achieved 
under acceptable tension in defects less than 50% of tracheal length. Replacement 
of the trachea is difficult, because the material should be rigid laterally and flexible 
longitudinally and should have an epithelialized lumen. Attempts at creating a 
material that meets these requirements have been undertaken for decades. Despite 
efforts, there has not been much success in animal and clinical studies 31. However, 
some encouraging results have been achieved. The group of Carpentier 
transplanted aortic allografts in 20 sheep and found that the tubes were epithelialized 
with mucociliairy epithelium and contained newly formed cartilage rings 32. Wurtz and 
colleagues successfully used this technique in two patients as reported in the New 
England Journal of Medicine in 2006 33 Biopsy after one year showed respiratory 
epithelium, and the patients are breathing well after 18 months of follow-up with the 
silicone stent still in place. In 2008, the group of Macchiarini and Birchall published a 
case in The Lancet in which the left mainstem bronchus was replaced with a de- 
cellularized and de-antigenized donor tracheal transplant colonized by the recipients 
epithelial cells and chondrogenic mesenchymal cells 34 Although the follow-up in this 
case was only two months, these results are promising for the future of tracheal 
replacement, which is still the ‘holy grail’ of airway surgery. Very recently, Delaere 
from the Leuven University (Belgium), presented the first successful case of a 
vascularized tracheal allotransplantation at the European Respiratory Society 
meeting (Vienna, Austria, September 2009; no reference yet available).
Conclusion
In summary, complete segmental resection for primary tracheal carcinoma and 
thyroid carcinoma invading the airway, when feasible, is currently the best treatment 
modality available leading to good long-term outcome. The fact that, in general, only 
10-25% of patients are treated with surgery is likely based on undertreatment of this 
disease. Although currently still widely applied, conservative shave resection for 
invasive thyroid carcinoma leads to a marked increased risk of local recurrence 
compared to segmental airway resection.
To improve patient care and survival outcome, the management of these rare tumors 
in the airway should always involve a tertiary center with experience in the 
multidisciplinary treatment of tracheal tumors. For this reason the Dutch Centre for 
Central Airway Diseases as part of the Radboud University Nijmegen Medical Centre 
will be launched in 2010.
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Summary
In this thesis, several aspects of malignant tumors located in the trachea are 
expounded and issues concerning the treatment of patients with these rare types of 
cancer are discussed.
Chapter 2 describes the clinical aspects and treatment of primary tracheal 
malignancies by reviewing the available literature on this topic. New diagnostic, 
staging and treatment guidelines are proposed. One of the key elements in the 
workup of patients with tracheal cancer is selecting patients that are candidates for 
surgical treatment, as surgical resection and primary reconstruction is the best 
curative treatment modality available at present.
Chapter 3 focuses on the pathologic characteristics of the two most common types 
of tracheal cancer, squamous cell carcinoma and adenoid cystic carcinoma (ACC). 
These histopathologic features are correlated with clinical outcome, to investigate 
which of these characteristics can be used to help predicting survival in patients with 
these tumors.
In Chapter 3.1, the pathologic characteristics of 59 cases of resected squamous cell 
carcinoma (SCC) of the trachea are described. SCC is the most common primary 
tumor of the trachea. A classification for the manner and depth of invasion 
appropriate for tracheal resections is proposed. Three factors were very important 
predictors of outcome: incomplete resection, extension of the tumor into the thyroid 
gland and lymphatic invasion or lymph node metastases all lead to very unfavorable 
prognosis. It is thus very important for the surgeon to establish clean lines of 
resection, using as appropriate intraoperative frozen section. Keratinization, 
dyskeratosis, acantholysis, necrosis, and tumor thickness, had no discernible 
prognostic value.
Chapter 3.2 describes the prognostic value of pathologic characteristics and 
resection margins in 108 cases of tracheal adenoid cystic carcinoma (ACC). ACC is 
the second most common primary tracheal tumor, known for its tendency to exhibit 
extensive submucosal and perineural spread. A resection with tumor-free margins 
may therefore be difficult to achieve. This could also be appreciated in our study; 
airway margins were grossly positive in 8%, microscopically positive in 55% and 
negative in 37%. Adventitial margins of transmural sections were grossly positive in 
3%, microscopically positive in 88% and negative in only 9%. Overall survival and 
disease survival were highest in patients with negative resection margins, followed 
by microscopic positive resection margins, followed by a very poor (disease-free) 
survival in patients with gross positive margins. Absence of extramural disease was 
a positive prognostic factor, while invasion of adjacent organs did not significantly 
impact (disease-free) survival. Perineural growth was present in 34%, absent in 11% 
and not noted in the pathology report in 55%. Because the presence of perineural 
growth was a negative prognostic factor, it is emphasized that this feature should 
always be looked for by the pathologist and noted in the pathology report. A positive
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lymph node biopsy led to a decline in (disease-free) survival. These results show 
that even in patients with advanced disease, tracheal resection can lead to long-term 
survival (> 10 years).
Chapter 4 sheds light on the treatment of tracheal cancer in the Netherlands. Both 
studies incorporated in this chapter have been conducted in collaboration with the 
Netherlands Cancer Registry.
In Chapter 4.1, the incidence, characteristics, treatment and survival of patients with 
tracheal cancer in the Netherlands is mapped for a 14-year period from 1989 to 
2002. In total, 308 cases could be identified, an annual incidence of 0.142 per 
100,000 inhabitants. Of the 293 patients diagnosed while alive, only 12% underwent 
surgical resection, while 53% received radiotherapy, and 35% neither. Median 
survival was only 10 months, with 5-year and 10-year survival rates of 15% and 6%, 
respectively. Survival in patients who underwent surgical resection was much higher: 
51% after 5 years and 33% after 10 years. These results support the good outcome 
reported in the literature describing series of patients with tracheal cancer treated 
with surgery. Some authors have suggested that at least 50% of patients with 
tracheal cancer should be candidates for surgical resection. In other European 
countries, it was also found that that only 12% of tracheal cancer patients were 
treated with surgery. The question is raised what proportion of patients with primary 
tracheal carcinoma really are surgical candidates and why only little over 10% are 
currently treated with surgery.
To address these questions, the study described in Chapter 4.2 was undertaken. A 
medical audit based on national epidemiologic data was conducted. Blinded patient 
data and radiologic images were reviewed by a multidisciplinary panel and a second 
reviewer to assess diagnosis and resectability. One third of NCR-registered primary 
tracheal carcinomas were misclassified non-tracheal primaries involving the trachea. 
In 50 cases confirmed by panel and second reviewer, actual treatment consisted of 
surgery in 24%, radiotherapy in 58%, endobronchial treatment in 12%, and 
observation in 6%. Both panel and second reviewer identified 16 additional surgical 
candidates, a total of 56%. A majority of cases meeting audit criteria for diagnosis 
and surgical resection was treated with other modalities. This study suggested that 
incorrect diagnosis and undertreatment are common in rare airway tumors.
Chapter 5 deals with thyroid carcinoma growing into the larynx or trachea. A review 
of the literature on the management of thyroid carcinoma invading the larynx or 
trachea is given in Chapter 5.1. Controversy exists on the extent of resection 
needed in case of invasion of the larynx or trachea by thyroid carcinoma, usually 
found intra-operatively during thyroidectomy. The technique of shaving off the thyroid 
carcinoma from the airway evades resection of the airway but poses a marked risk of 
local recurrence. Circumferential sleeve resection of larynx and trachea are safe and 
lower the risk of local recurrence. In recurrent disease, laryngotracheal resection can 
provide effective palliation of airway obstruction and hemoptysis. In view of the slow
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growth of thyroid carcinoma, long-term (>10 to 20 years) prospective studies are 
required to compare the outcome after shave excision with segmental airway 
resection.
Chapter 5.2 describes the results of segmental laryngotracheal and tracheal 
resection for invasive thyroid carcinoma in 82 patients. There were 69 reconstructive 
operations and 13 salvage operations. Overall operative mortality was 1.2%. After 
reconstructive operations, anastomotic dehiscence occurred in 4.3% and 
tracheostomy was permanent in 4.3%. Airway symptoms, metastases at 
presentation, recurrent disease and salvage operation were associated with 
decreased survival. Airway resection early after thyroidectomy, complete resection, 
and well-differentiated tumors led to more favorable prognosis. Segmental airway 
resection for invasive thyroid cancer is safe, preserves voice, and relieves airway 
obstruction. When thyroid carcinoma is found to invade the larynx or trachea during 
thyroidectomy, complete resection including segmental airway resection and 
reconstruction should be performed during or early after thyroidectomy, as this 
management is associated with improved survival compared with shaving and 
delayed airway resection.
In conclusion, the treatment of patients with a rare tumor of the airway should always 
be situated in an experienced center with multidisciplinary experience in the 
management of these tumors. This will improve the quality of care and probably the 
outcome of disease as well, by attacking the current undertreatment. Also, further 
research would be facilitated that could unravel many remaining questions that could 
not be answered yet.
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“Maligne Tumoren van de Trachea”
Dutch Discussion and Summary
Primair tracheacarcinoom
Maligne aandoeningen van de bovenste luchtwegen en de longen komen relatief 
frequent voor, in Nederland is de incidentie meer dan 10.000 per jaar 1. 
Tracheatumoren vormen binnen deze groep een zeldzaamheid met een geschatte 
incidentie van ongeveer 1 op de miljoen inwoners per jaar 2 Dit leidt er toe dat er 
doorgaans weinig bekendheid bestaat over de vergaande mogelijkheden van 
behandeling. Een chirurgische behandeling met en bloc verwijdering van de tumor in 
de vorm van een segmentale trachearesectie met een directe end-to-end 
anastomose reconstructie al of niet gevolgd door radiotherapie is doorgaans de 
meest aangewezen therapie in geval van een tracheacarcinoom 3
De meeste tumoren in de trachea zijn
maligne 4  en bedreigen het leven van de
patiënt niet alleen door
luchtwegobstructie, maar ook door
locoregionale invasie en eventuele
metastasering op afstand. Omdat
klachten van dyspneu en stridor pas
ontstaan wanneer ongeveer 75% van het
oppervlak van het tracheale lumen
geobstrueerd is wordt de tumor vaak pas
in een laat stadium gediagnosticeerd
. _ . .............. .. (Fiquur 1). Od dat moment is de mate
Figuur 1. Endoscopisch zicht op een ernstige -------, , ,  , , ,
van luchtwegobstructie doorgaans 
trachea obstructie ten gevolge van een , , , . , 5
levensbedreigend 5.
adenoidcystischcarcinoom ten tijde van het 
stellen van de diagnose
Meestal zijn er bij de patiënt al geruime tijd (maanden tot jaren) een hoorbare 
ademhaling en niet verontrustende klachten zoals lichte dyspneu bij inspanning en 
hoesten aanwezig 6. Dit klachtenpatroon wordt nogal eens onterecht toegeschreven 
aan en behandeld als obstructieve longziekten zoals astma en COPD 7
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Onderbehandeling van primaire tracheatumoren
De meeste grote onderzoeken naar het voorkomen en het klinisch beloop van het
tracheacarcinoom zijn vanwege de lage incidentie gebaseerd op landelijke of
regionale gegevens van kankerregistraties van enkele decades. Er zijn wereldwijd
slechts enkele centra met een dusdanig grote verwijzingsfunctie dat het zinvol is de 
f f  6 8 12 resultaten van één kliniek te rapporteren als patiëntenserie 6’ Daarnaast zijn er
nog enkele multi-centrum studies van klinieken met ervaring in de behandeling van
13 14tracheatumoren, zoals uit Frankrijk 13 of Japan .
Registratiegebaseerde studies uit het Verenigd Koninkrijk 415, Finland 16, Japan 17,
7  "1 ftDenemarken 7 en de Verenigde Staten 18 laten geheel andere resultaten zien dan de 
genoemde klinieken met ervaring in de behandeling van luchtwegtumoren. Het 
belangrijkste verschil is dat uit kankerregistratie-gebaseerde rapportages is gebleken 
dat slechts ongeveer 10% van alle patiënten met een tracheacarcinoom chirurgisch 
behandeld wordt, terwijl dit percentage in gespecialiseerde klinieken tussen de 60­
80% ligt. Een deel van dit opmerkelijke verschil kan worden verklaard door een 
verschil van de onderzochte patiëntenpopulaties. Er valt bijvoorbeeld te verwachten 
dat patiënten met afstandsmetastasen niet, of zelden, verwezen worden naar een
"IQ i  Agespecialiseerde kliniek. Volgens Gaissert 19 en Hazama et al. 14 zou echter, na 
verdiscontering van deze factor, ongeveer de helft van de algehele populatie 
patiënten met een maligne tracheatumor een geschikte kandidaat voor chirurgische 
therapie zijn. Aangezien chirurgische behandeling de meest aangewezen curatieve 
behandeling vormt, is het belangrijk vast te stellen waarom slechts 10% van de 
patiënten in op populatie gebaseerde studies op deze wijze behandeld is. Licht et al. 
(Denemarken) stelden dat dit lage percentage mogelijk toe te schrijven is aan een 
nihilistische attitude gebaseerd op onvoldoende kennis van de chirurgische 
mogelijkheden bij tracheatumoren 7.
Nationale audit naar tracheatumoren in Nederland
Om de situatie in Nederland in kaart te 
brengen is in samenwerking met de 
Nederlandse Kankerregistratie (NKR) 
een landelijke studie uitgevoerd naar het 
voorkomen, de behandeling en de 
overleving van patiënten met een 
tracheacarcinoom 20. Uit dit onderzoek is 
gebleken dat in Nederland in de 14-jaar 
tellende periode van 1989 -  2003 van de 
293 patiënten slechts 12% werd 
behandeld met chirurgie, terwijl 53% 
primaire radiotherapie onderging. 35% 
heeft geen van beide, in potentie 
curatieve, behandelingen ondergaan.
Jaren
Figuur 2. Overleving van Nederlandse 
patiënten met een tracheacarcinoom naar 
behandeling 20
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In de gehele onderzoekspopulatie was de 5-jaars overleving 15%, terwijl deze voor 
chirurgisch behandelde patiënten 51% bedroeg (Figuur 2). Deze resultaten komen 
overeen met de eerder genoemde resultaten van de op kankerregistratie 
gebaseerde studies.
Naar aanleiding van deze resultaten rijst de vraag welk aandeel van alle patiënten 
met een primair tracheacarcinoom daadwerkelijk kandidaat is voor chirurgische 
behandeling. Om hier een antwoord op te kunnen geven werd een nationale audit 
gehouden 2 Via de NKR werden van de jaren 2000 -  2005 alle patiënten met 
tracheacarcinoom geïdentificeerd. Via het Integraal Kankercentrum Oost (IKO), een 
van de 8 integrale kankercentra in Nederland, werden alle hoofdbehandelaars 
benaderd om hen toestemming te vragen voor inclusie van de desbetreffende 
patiënt(en). Alle behandelaars gaven hun toestemming om de patiëntengegevens uit 
de status, de thoraxfoto’s en, indien van toepassing, CT- en MRI-scans van de 
afdelingen radiologie op te vragen. Al deze informatie werd verzameld, 
geanonimiseerd en gebundeld tot een samenvatting per patiënt. Een multidisciplinair 
team werd samengesteld bestaande uit een longarts, cardiothoracaal chirurg, 
radioloog, hoofd-hals oncologisch chirurg en twee radiotherapeuten. Op eenzelfde 
wijze als bij een tumorwerkgroep gebruikelijk is werd elke patiënt separaat 
besproken en naar aanleiding van de bovenbeschreven gegevens bepaald of het 
daadwerkelijk om een primair tracheacarcinoom ging. Daarnaast werd een advies 
uitgebracht over de te volgen behandeling. Vervolgens zijn alle casus opnieuw ter 
beoordeling voorgelegd aan een tweede beoordelaar, een thoraxchirurg van het 
Massachusetts General Hospital in Boston met een uitgebreide ervaring in de 
behandeling van patiënten met een tracheatumor. De gecombineerde mening van 
het multidisciplinaire panel en de tweede beoordelaar werd vergeleken met de 
werkelijke behandeling die de patiënt had ondergaan.
Zeven patiënten van de 108 NKR-geregistreerde patiënten werden uitgesloten: 2 
maal werd de diagnose vastgesteld bij autopsie, 2 maal betrof het kinderen en 3 
maal bleek de gemaakte CT-scan onvindbaar te zijn. Van de overgebleven 101 
patiënten werd in retrospect de diagnose primair tracheacarcinoom verworpen in 34 
gevallen (34%); in 20 gevallen was er sprake van een andere primaire tumor (long, 
slokdarm en larynx) en in 14 gevallen was er sprake van uitgebreide peribronchiale 
lymfadenopathie van een onbekende primaire tumor met doorgroei in de trachea. 
Daarnaast werden 17 patiënten geëxcludeerd omdat er onvoldoende klinische 
informatie beschikbaar was om een oordeel te vellen over de te volgen behandeling. 
Uiteindelijk bleven 50 patiënten over waarvoor het multidisciplinair panel en de 
tweede beoordelaar een behandeladvies hebben uitgebracht. Voor deze 50 
patiënten was de werkelijke behandeling chirurgie bij 12 patiënten (24%), 
radiotherapie bij 29 (58%), endobronchiale behandeling bij 6 (12%) en expectatief 
beleid bij 3 (6%). Een patiënt werd alléén als chirurgische kandidaat beschouwd 
wanneer zowel panel als tweede beoordelaar als advies chirurgie gaven. Dit leverde 
16 additionele chirurgische kandidaten op, een totaal van 28 (56%). Het panel en de 
tweede beoordelaar waren het in 4 gevallen oneens (8%).
147
appendix
Appendix I
Werkelijke
behandeling
r
(29)L J
Panel advies (28) (14)
Figuur 3. De tumor van een patiënt werd alleen als resectabel beschouwd indien resectie zowel 
door het panel als de tweede beoordelaar werd geadviseerd. De werkelijke behandeling 
(donkere ballonnen) wordt vergeleken met het oordeel van de audit (witte ballonnen) in 50 
patiënten met primair tracheacarcinoom (p = 0.005). De oppervlakte van de ballonnen komt 
overeen met het aantal patiënten per groep. NKR = Nederlandse Kankerregistratie
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Foutieve registratie en onderbehandeling van tracheatumoren in Nederland
Uit deze nationale audit blijkt dat ruim 1/3 van alle geregistreerde gevallen van 
tracheacarcinoom bij de NKR foutief geregistreerd zijn. De initiële (voorlopige) 
registratie in de NKR vindt plaats via een automatische koppeling met PALGA op 
basis van het aantonen van maligne cellen in de trachea. Deze cellen zouden 
evenwel afkomstig kunnen zijn van primaire long- of slokdarmtumoren met directe 
doorgroei in de trachea of lymfkliermetastasen in omliggende peribronchiale 
lymfklieren met invasie van de trachea. Definitieve registratie vindt echter pas plaats 
vanuit het volledige medisch dossier. Wellicht houden registratiemedewerkers te 
strikt vast aan de door PALGA opgegeven lokalisatie, maar een deel van de 
misclassificatie kan ook zijn ontstaan door een foutieve diagnose in het medisch 
dossier.
In eerdere studies uit Finland 21 en Denemarken 7 werden eveneens foutief 
geclassificeerde tumoren gevonden in respectievelijk 27% en 12% van het nationale 
cohort, terwijl in deze studies geen volledige beoordeling van de radiologische en 
klinische gegevens heeft plaatsgevonden. Misclassificatie van dit type tumor komt 
dus internationaal voor en dit geldt wellicht eveneens voor andere zeldzame vormen 
van kanker. Het is noodzakelijk dat het registratieproces van de NKR aangepast 
wordt om het aantal misclassificaties terug te dringen.
Meer dan de helft van de patiënten werd in de audit achteraf beoordeeld als 
chirurgisch kandidaat, terwijl slechts 24% deze behandeling had ondergaan. Dit 
suggereert een relatieve onderbehandeling van deze zeldzame tumor in Nederland. 
Gezien de overeenkomende getallen uit studies uit andere landen geldt dit 
waarschijnlijk zelfs internationaal. Hoewel het concept van een ongevraagde tweede 
mening op basis van beoordeling van klinische en radiologische gegevens van alle 
landelijk geregistreerde gevallen van een bepaald type tumor in een bepaalde 
periode uniek is, vertoont deze methode grote gelijkenis met de verschillende 
tumorwerkgroepen die in Nederland bestaan, waarbij patiëntencasus besproken 
worden door een vast team van specialisten van verschillende disciplines. Het 
grootste verschil is dat dit doorgaans geschiedt na verwijzing van de behandelend 
arts. Daarnaast was het verschil in de mening van het panel en de tweede 
beoordelaar klein (8%) en dus de reproduceerbaarheid groot.
Schildkliercarcinoom met invasie van de larynx of trachea
Schildkliercarcinoom is een relatief veel voorkomende tumor, die in Nederland 
jaarlijks bij ongeveer 3 per 100.000 inwoners voorkomt 1. In de Verenigde Staten is 
de incidentie 14 per 100.000 inwoners 22 en was schildkliercarcinoom de zesde op 
de lijst van meest voorkomende maligniteiten in 2008 22 Ondanks het feit dat sterfte 
als gevolg van schildklierkanker ongebruikelijk is, wordt meer dan de helft van alle 
sterfgevallen als gevolg van schildkliercarcinoom veroorzaakt door 
luchtwegobstructie en -bloeding 23 Invasie van de larynx of trachea komt voor bij 
ongeveer 5,8% van alle gevallen van schildkliercarcinoom 24 Dit wordt echter zelden
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gediagnosticeerd voorafgaand aan de gebruikelijke, waardoor de chirurgische 
planning niet gericht is op luchtwegchirurgie. In meer dan 80% van de gevallen van 
invasie van de luchtweg is dit onverwacht intra-operatief vastgesteld door de chirurg 
die de thyroïdectomie uitvoert 25
Mogelijk te conservatief beleid bij schildkliercarcinoom met invasie van de 
luchtweg
Er bestaat een controverse met betrekking tot welke behandelstrategie adequaat is 
voor invasie van de luchtweg door schildkliercarcinoom. De belangrijkste oorzaak 
voor deze controverse ligt in het feit dat er geen gerandomiseerde studies zijn naar 
de twee belangrijkste chirurgische opties: conservatieve (oppervlakkige, "shave”) 
verwijdering van de tumor versus en bloc segmentale resectie van het geïnvadeerde 
deel van de larynx of trachea. In de meeste studies waarin deze behandelingen 
vergeleken worden, wordt gekozen voor een conservatieve "shave” excisie indien de 
invasie van de luchtweg oppervlakkig is. Hierbij wordt tumorweefsel van de trachea 
afgeschraapt tijdens de thyroïdectomie. Een segmentale resectie van het betrokken 
deel van de trachea wordt met name toegepast bij tumoren die dieper of zelfs tot in 
het lumen van de luchtweg groeien, waarbij het vaak om recidieven gaat 26,27. 
Hierdoor ontstaat waarschijnlijk een selectie bias ten voordele van de "shave” 
excisie.
De conservatieve "shave” excisie wordt toegepast ondanks duidelijke aanwijzingen 
dat hierbij de kans op lokaal recidief en sterfte als gevolg hiervan groter is dan na 
segmentale resectie 25,28,29 Zo beschrijven McCarty et al. dat in alle 35 patiënten 
behandeld middels een "shave” excisie een microscopisch tumorresidu achterbleef 
op de larynx of trachea 25 Analoog hieraan leidt onmiddellijke resectie van het 
aangedane segment van de luchtweg tot een langere ziektevrije overleving dan 
latere resectie van een recidief. De mortaliteit en morbiditeit van een trachearesectie 
in combinatie met een thyroïdectomie voor een schildkliercarcinoom met invasie in 
de luchtweg zijn in de loop der jaren gezakt naar 1,2% en 26%, respectievelijk 30. 
Bovendien blijkt de kwaliteit van leven na segmentale trachearesectie in verband 
met een schildkliercarcinoom beter te zijn na de operatie dan voor de operatie 31,32. 
Het operatieve risico zou dus geen reden mogen zijn een volledige resectie van de 
tumor achterwege te laten en te kiezen voor een conservatieve "shave” excisie, 
waarbij wel aangetekend moet worden dat de uitkomsten van de operatie afhankelijk 
zijn van de ervaring die de chirurg heeft met luchtwegchirurgie 31,33 
Er bestaat geen oncologische data die het toepassen van een incomplete resectie 
rechtvaardigt als curatieve therapie. Gedeeltelijke of oppervlakkige invasie van de 
luchtweg zou daarom beschouwd moeten worden als een eerder stadium van 
transtracheale invasie en zou dus behandeld moeten worden middels segmentale 
trachearesectie. Dit houdt in dat indien pre-operatief invasie van de luchtweg is 
gediagnosticeerd, de thyroïdectomie gecombineerd zou moeten worden met een 
trachearesectie door een chirurg met ervaring in de luchtwegchirurgie. Meestal wordt 
invasie van de larynx of trachea echter onverwacht opgemerkt tijdens de
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thyroïdectomie. Wanneer dit het geval is, adviseren wij intra-operatief dan wel direct 
post-operatief een luchtwegchirurg te consulteren, zodat mogelijk direct tijdens de 
thyroïdectomie dan wel binnen enkele weken na de thyroïdectomie het residu van de 
tumor in de wand van de luchtweg verwijderd kan worden door middel van een 
segmentale luchtwegresectie.
Ondanks het feit dat schildkliercarcinoom in bijna 6% van de gevallen ingroei in de 
luchtweg vertoont, worden de consequenties voor de behandeling niet besproken in 
de Landelijke Richtlijn Schildkliercarcinoom van het Centraal BegeleidingsOrgaan 
(CBO, 2007) 34 Deze richtlijn benadrukt dat iedere patiënt met een 
schildkliercarcinoom in een multidisciplinair team behandeld zou moeten worden en 
dat alle patiënten met lymfekliermetastasen en / of recidief ziekte bij voorkeur 
behandeld zou moeten worden in een level 1 ziekenhuis 34
Centralisering van de zorg rondom patiënten met een zeldzame aandoening 
van de trachea
Bij zeldzame aandoeningen zoals tumoren van de trachea zijn er slechts weinig 
experts. Iedere patiënt waarbij de diagnose tracheatumor gesteld wordt, zou 
verwezen moeten worden naar een tertiair oncologiecentrum met multidisciplinaire 
ervaring in de behandeling van deze tumoren. Gezien de zeer lage incidentie, zou 
ongeveer 1 centrum per 10 a 20 miljoen inwoners een maximum zijn om te 
garanderen dat er voldoende expositie is aan (maligne) trachea pathologie. Hierdoor 
zou in een dergelijk centrum per jaar ongeveer 10 tot 20 patiënten gezien worden 
met een tracheacarcinoom. Van deze patiënten zou naar schatting 5 tot 10 patiënten 
een trachearesectie ondergaan. In de Nederlandse situatie met 16,5 miljoen 
inwoners (Centraal Bureau voor de Statistiek, 2009) betreft dit dus één nationaal 
centrum. Door deze hoge mate van centralisatie van zorg voor patiënten met deze 
zeldzame luchtwegtumor kunnen mogelijk meer patiënten geselecteerd worden voor 
chirurgische behandeling, hetgeen potentieel de overleving ten goede zou kunnen 
komen. Soortgelijke hoge mate van centralisatie is in Nederland al georganiseerd 
voor meer frequent voorkomende tumoren zoals slokdarm kanker en 
gynaecologische carcinomen. De drijvende kracht achter deze ontwikkelingen waren 
de studies waarin de relatie tussen volume van operaties per afdeling en resultaat 
werd aangetoond 35-37. Ook in andere groepen zoals patiënten met longkanker en 
hoofd-hals kanker ontstaat steeds meer bewijs voor deze relatie. In Nederland heeft 
dit inzicht geleid tot een rapport van het Koningin Wilhelmina Fonds (KWF) dat is 
opgesteld door experts van de verschillende medische beroepsgroepen in de 
oncologische zorg en leden van de Integrale Kankercentra met ruggespraak met 
patiëntenorganisaties, de overheid, verzekeraars en ziekenhuizen 38 Dit rapport 
wordt in 2010 gepubliceerd en zal er toe leiden dat de oncologische zorg in 
Nederland meer zal worden geconcentreerd 38 Dit zal met name vruchten afwerpen 
voor de "hoog-complexe, laag-volume zorg”.
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Conclusie
Samenvattend is een segmentale resectie van de luchtweg voor primair 
tracheacarcinoom en schildkliercarcinoom met invasie van de luchtweg veilig en leidt 
deze behandeling tot goede resultaten op langere termijn. Indien een chirurgische 
verwijdering technisch mogelijk is en de comorbiditeit van de patiënt het toelaat is dit 
momenteel de meest aangewezen behandelingsmogelijkheid, waarschijnlijk in 
minimaal de helft van de gevallen. Het feit dat over het algemeen slechts 10-25% 
van de patiënten met een primair tracheacarcinoom behandeld wordt met chirurgie 
komt minstens gedeeltelijk door onderbehandeling van deze aandoening.
Hoewel conservatieve "shave” excisie nog steeds veel wordt toegepast voor 
schildkliercarcinoom met invasie van de luchtweg, leidt dit tot een duidelijk verhoogd 
risico op lokaal recidief in vergelijking met segmentale resectie van de luchtweg.
Om de zorg voor en overleving van patiënten met een zeldzame tumor van de 
luchtweg te verbeteren zou de behandeling plaats moeten vinden in een tertiair 
kenniscentrum met ervaring in de multidisciplinaire behandeling van deze tumoren. 
Om deze reden zal het Radboud Centrum voor Centrale Luchtweg Ziekten als 
onderdeel van het Radboud Universitair Medisch Centrum te Nijmegen worden 
opgericht in 2010.
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